dextran sulfate - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	dextran sulfate	go back to main search page
Accession:	CHEBI:34674	browse the term
Definition:	A polymer composed of repeating (1->6)-alpha-linked anhydroglucose sulfate units.
Synonyms:	related_synonym:	Dextran polysulfate; Dextran sulfate 500; Dextran sulfuric acid; Dextran sulfuric acid ester; Dextran sulphate; Formula=(C12H20O29S6)n; Polydextran sulfate
	xref:	AGR:IND607703858; Beilstein:8187464; CAS:9042-14-2; KEGG:C13723
	xref_mesh:	MESH:D016264
	xref:	PMID:12885383; PMID:13225707; PMID:16002055; PMID:18606639; PMID:18722664; PMID:2478075; PMID:33476681; PMID:34683921; PMID:35119317; PMID:8018106; PMID:8713797
	cyclic_relationship:	is_conjugate_acid_of CHEBI:191931

show annotations for term's descendants Sort by:
Rat (1637) Mouse (1890) Human (1651) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (5) Green Monkey (0) Naked Mole-rat (0) All
Genes (1890)

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr16:8,331,293...8,439,432
Ensembl chr16:8,331,293...8,439,432

G

ATP-binding cassette, sub-family A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895

G

ATP-binding cassette, sub-family A member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA17 mRNA

NCBI chr17:24,483,231...24,570,079
Ensembl chr17:24,483,233...24,570,042

G

ATP-binding cassette, sub-family B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958

G

ATP-binding cassette, sub-family B member 1A

multiple interactions
increases response to substance
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate
Dextran Sulfate results in decreased expression of ABCB1A mRNA

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:29950665 PMID:30701287

NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315

G

ATP-binding cassette, sub-family B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 5:8,943,614...9,009,226
Ensembl chr 5:8,943,717...9,009,231

G

ATP-binding cassette, sub-family B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 1:75,148,284...75,157,066
Ensembl chr 1:75,148,361...75,157,036

G

ATP-binding cassette, sub-family C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr17:46,614,146...46,638,954
Ensembl chr17:46,614,147...46,639,278

G

ATP-binding cassette, sub-family member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179

G

ATP-binding cassette, sub-family C member 3

decreases expression
multiple interactions
affects response to substance

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCC3 protein affects the susceptibility to Dextran Sulfate

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr11:94,234,121...94,283,843
Ensembl chr11:94,234,121...94,283,823

G

ATP-binding cassette, sub-family C member 4

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631

G

ATP-binding cassette, sub-family C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr16:20,150,053...20,245,178
Ensembl chr16:20,150,053...20,245,144

G

ATP-binding cassette, sub-family C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 7:45,625,804...45,679,915
Ensembl chr 7:45,616,979...45,679,726

G

ATP-binding cassette, sub-family C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 6:142,533,592...142,648,472
Ensembl chr 6:142,533,588...142,648,041

G

ATP-binding cassette, sub-family F member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABCF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 5:24,770,339...24,782,465
Ensembl chr 5:24,770,343...24,782,465

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr17:31,276,668...31,336,958
Ensembl chr17:31,276,649...31,336,962

G

ATP binding cassette subfamily G member 2 (Junior blood group)

multiple interactions
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287

NCBI chr 6:58,561,476...58,669,436
Ensembl chr 6:58,561,508...58,672,661

G

abl interactor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABI1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253

G

acetyl-Coenzyme A acyltransferase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 9:119,170,113...119,179,361
Ensembl chr 9:119,168,742...119,179,365

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 9:118,977,111...118,986,149
Ensembl chr 9:118,977,091...118,986,161

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:74,912,283...74,939,278
Ensembl chr18:74,912,268...74,939,279

G

acetyl-Coenzyme A carboxylase alpha

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr11:84,020,461...84,292,477
Ensembl chr11:84,020,498...84,292,477

G

acyl-Coenzyme A dehydrogenase, short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr 5:115,248,358...115,257,405
Ensembl chr 5:115,248,358...115,257,405

G

acyl-Coenzyme A dehydrogenase, short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 7:131,012,330...131,047,940
Ensembl chr 7:131,012,330...131,050,673

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790

G

acetylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728

G

atypical chemokine receptor 1 (Duffy blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr 1:173,159,457...173,161,079
Ensembl chr 1:173,159,453...173,161,317

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 9:121,727,421...121,740,177
Ensembl chr 9:121,727,421...121,740,140

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 1:90,131,702...90,143,446
Ensembl chr 1:90,131,702...90,144,473

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 9:103,974,881...104,003,842
Ensembl chr 9:103,961,356...104,004,132

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr17:57,150,103...57,181,505
Ensembl chr17:57,150,103...57,181,447

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 7:119,217,035...119,261,738
Ensembl chr 7:119,206,249...119,261,738

G

acyl-CoA synthetase medium-chain family member 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ACSM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr 7:119,360,106...119,384,119
Ensembl chr 7:119,360,146...119,386,736

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 2:150,460,031...150,510,160
Ensembl chr 2:150,460,025...150,510,420

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr 2:155,359,963...155,404,663
Ensembl chr 2:155,359,868...155,427,644

G

actin-like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 3:32,762,695...32,781,122
Ensembl chr 3:32,760,447...32,781,122

G

actinin, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr12:80,214,316...80,307,165
Ensembl chr12:80,214,321...80,307,145

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr13:12,284,312...12,355,613
Ensembl chr13:12,284,312...12,355,641

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr11:20,012,304...20,062,951
Ensembl chr11:20,012,304...20,062,913

G

ARP3 actin-related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr 1:125,320,642...125,363,464
Ensembl chr 1:125,320,642...125,363,464

G

activin A receptor, type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 2:58,336,450...58,456,840
Ensembl chr 2:58,278,656...58,457,169

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 9:106,310,180...106,315,594
Ensembl chr 9:106,310,180...106,315,518

G

adenosine deaminase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159

G

a disintegrin and metallopeptidase domain 17

multiple interactions
affects response to substance
increases expression

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr12:21,373,510...21,423,633
Ensembl chr12:21,373,510...21,423,633

G

ADAM metallopeptidase with thrombospondin type 1 motif 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr16:85,590,715...85,600,001
Ensembl chr16:85,590,715...85,600,001

G

ADAM metallopeptidase with thrombospondin type 1 motif 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr10:61,032,886...61,109,447
Ensembl chr10:61,032,891...61,109,217

G

ADAM metallopeptidase with thrombospondin type 1 motif 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr11:50,492,912...50,698,400
Ensembl chr11:50,492,911...50,698,400

G

ADAM metallopeptidase with thrombospondin type 1 motif 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr 1:171,077,698...171,089,836
Ensembl chr 1:171,077,990...171,088,206

G

ADAM metallopeptidase with thrombospondin type 1 motif 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr16:85,655,045...85,698,013
Ensembl chr16:85,653,061...85,698,716

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr13:68,768,162...69,147,719
Ensembl chr13:68,768,162...69,147,660

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr14:56,006,513...56,021,552
Ensembl chr14:56,006,514...56,021,552

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr15:98,484,982...98,508,119
Ensembl chr15:98,487,854...98,507,957

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:88,998,818...89,056,593
Ensembl chr 8:88,999,031...89,056,590

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr17:93,506,448...93,513,967
Ensembl chr17:93,506,445...93,513,965

G

adenylate cyclase activating polypeptide 1 receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 6:55,428,486...55,478,440
Ensembl chr 6:55,428,963...55,478,436

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr 8:27,575,546...27,613,464
Ensembl chr 8:27,575,611...27,613,464

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr15:74,388,045...74,461,314
Ensembl chr15:74,388,044...74,461,314

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr 8:84,449,874...84,467,812
Ensembl chr 8:84,449,880...84,467,955

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr17:43,581,174...43,636,767
Ensembl chr17:43,581,220...43,635,628

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr17:43,671,225...43,770,448
Ensembl chr17:43,671,342...43,770,448

G

alcohol dehydrogenase 1 (class I)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 3:137,983,346...137,996,459
Ensembl chr 3:137,966,752...137,996,459

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 3:138,142,961...138,161,260
Ensembl chr 3:138,148,854...138,161,260

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr10:75,152,711...75,170,626
Ensembl chr10:75,152,711...75,170,618

G

adenosine A2b receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr11:62,139,810...62,157,278
Ensembl chr11:62,139,810...62,157,279

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 3:105,811,737...105,816,244
Ensembl chr 3:105,778,174...105,816,242

G

adrenergic receptor, alpha 2a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr19:54,033,690...54,037,413
Ensembl chr19:54,032,582...54,037,413

G

adrenergic receptor, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr18:62,310,784...62,313,052
Ensembl chr18:62,310,887...62,313,030

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr19:8,966,640...9,054,299
Ensembl chr19:8,966,648...9,054,278

G

aryl-hydrocarbon receptor

increases response to substance
multiple interactions

AHR gene mutant form results in increased susceptibility to Dextran Sulfate
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]

NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr 7:127,902,016...127,902,926
Ensembl chr 7:127,901,969...127,902,930

G

adenylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AK1 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein

NCBI chr 2:32,511,770...32,525,070
Ensembl chr 2:32,511,770...32,525,070

G

A kinase anchor protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr10:4,216,329...4,309,471
Ensembl chr10:4,216,380...4,309,470

G

A kinase anchor protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr12:76,371,652...76,380,925
Ensembl chr12:76,371,665...76,380,927

G

aldo-keto reductase family 1 member B

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of AKR1B1 protein
Dextran Sulfate results in increased expression of AKR1B1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413

G

aldo-keto reductase family 1, member C12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C12 mRNA

NCBI chr13:4,318,171...4,329,398
Ensembl chr13:4,318,175...4,329,432

G

aldo-keto reductase family 1, member C13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C13 mRNA

NCBI chr13:4,241,167...4,255,601
Ensembl chr13:4,241,149...4,255,595

G

aldo-keto reductase family 1, member C14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C14 mRNA

NCBI chr13:4,099,015...4,140,569
Ensembl chr13:4,099,011...4,140,688

G

aldo-keto reductase family 1, member C18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653

G

aldo-keto reductase family 1, member C19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C19 mRNA

NCBI chr13:4,283,499...4,298,360
Ensembl chr13:4,278,699...4,302,842

G

thymoma viral proto-oncogene 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461

G

aldehyde dehydrogenase family 1, subfamily A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr19:20,469,947...20,620,827
Ensembl chr19:20,470,079...20,620,829

G

aldehyde dehydrogenase family 1, subfamily A7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A7 mRNA
Dextran Sulfate results in decreased expression of ALDH1A7 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:20,670,318...20,704,920
Ensembl chr19:20,670,317...20,704,926

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 4:45,799,022...45,804,608
Ensembl chr 4:45,799,022...45,804,604

G

aldehyde dehydrogenase 2, mitochondrial

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr 5:121,704,090...121,731,887
Ensembl chr 5:121,704,090...121,731,887

G

aldehyde dehydrogenase family 3, subfamily A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr11:61,114,240...61,158,267
Ensembl chr11:61,114,243...61,158,290

G

aldehyde dehydrogenase family 7, member A1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr18:56,657,794...56,706,112
Ensembl chr18:56,642,759...56,706,023

G

aldolase C, fructose-bisphosphate

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr11:78,213,899...78,218,607
Ensembl chr11:78,213,794...78,218,607

G

arachidonate 12-lipoxygenase

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr11:69,047,898...69,060,617
Ensembl chr11:69,047,815...69,060,618

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 6:116,387,030...116,438,139
Ensembl chr 6:116,387,038...116,438,139

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr 5:149,201,814...149,224,963
Ensembl chr 5:149,201,577...149,224,963

G

alkaline phosphatase, liver/bone/kidney

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 4:137,469,042...137,523,695
Ensembl chr 4:137,469,044...137,523,695

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 2:151,753,127...151,787,257
Ensembl chr 2:151,753,130...151,787,257

G

angiopoietin-like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr17:33,993,874...34,000,549
Ensembl chr17:33,992,724...34,000,804

G

anoctamin 1, calcium activated chloride channel

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 7:144,142,286...144,305,762
Ensembl chr 7:144,142,286...144,305,711

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 9:122,004,958...122,123,440
Ensembl chr 9:122,004,940...122,123,489

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr15:95,688,724...95,873,353
Ensembl chr15:95,688,724...95,872,632

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 1:93,301,518...93,332,026
Ensembl chr 1:93,301,652...93,332,025

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 7:140,681,125...140,697,719
Ensembl chr 7:140,681,125...140,697,719

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr19:20,350,798...20,368,035
Ensembl chr19:20,350,792...20,368,308

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 6:86,713,822...86,770,616
Ensembl chr 6:86,713,822...86,770,566

G

adaptor-related protein complex AP-1, mu subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr 8:72,993,857...73,011,230
Ensembl chr 8:72,993,862...73,011,229

G

adaptor protein complex AP-1, sigma 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AP1S1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989

G

APC, WNT signaling pathway regulator

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr18:34,353,350...34,455,243
Ensembl chr18:34,353,977...34,455,605

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr 1:172,721,528...172,722,516
Ensembl chr 1:172,721,528...172,722,608

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:47,114,023...47,123,730
Ensembl chr X:47,114,023...47,123,730

G

apolipoprotein A-II

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr 1:171,049,133...171,053,948
Ensembl chr 1:171,052,623...171,053,948

G

apolipoprotein A-IV

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr 9:46,152,142...46,154,756
Ensembl chr 9:46,151,994...46,154,757

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr12:8,027,629...8,066,839
Ensembl chr12:8,027,648...8,066,835

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr 7:19,405,504...19,411,866
Ensembl chr 7:19,405,504...19,411,866

G

apolipoprotein E

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr 7:19,430,169...19,434,326
Ensembl chr 7:19,430,034...19,433,113

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654

G

aquaporin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 6:55,313,284...55,325,540
Ensembl chr 6:55,313,417...55,325,540

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 7:97,375,586...97,387,454
Ensembl chr 7:97,373,213...97,387,496

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr15:99,476,937...99,482,426
Ensembl chr15:99,476,936...99,482,428

G

aquaporin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 7:123,061,517...123,067,226
Ensembl chr 7:123,061,514...123,067,227

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 9:71,017,941...71,075,170
Ensembl chr 9:71,017,941...71,075,964

G

androgen receptor

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA
Dextran Sulfate results in increased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821

G

ADP-ribosylation factor 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr15:98,635,505...98,660,999
Ensembl chr15:98,634,515...98,661,095

G

arginase, liver

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]

NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 2:43,638,786...44,285,965
Ensembl chr 2:43,638,836...44,285,965

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 9:51,676,651...51,765,158
Ensembl chr 9:51,676,637...51,765,156

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 6:87,435,526...87,510,241
Ensembl chr 6:87,435,527...87,510,241

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 2:158,354,682...158,392,786
Ensembl chr 2:158,354,716...158,392,682

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450

G

Rho, GDP dissociation inhibitor beta

increases expression
multiple interactions
decreases expression

Dextran Sulfate results in increased expression of ARHGDIB mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr 6:136,900,653...136,918,895
Ensembl chr 6:136,900,653...136,918,897

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 7:24,601,762...24,626,019
Ensembl chr 7:24,602,337...24,626,019

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 9:42,875,138...43,017,069
Ensembl chr 9:42,875,138...43,018,534

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:56,276,845...56,384,119
Ensembl chr X:56,276,845...56,384,089

G

ADP-ribosylation factor-like 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr19:46,519,548...46,561,621
Ensembl chr19:46,519,535...46,561,637

G

ADP-ribosylation factor-like 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr 5:77,146,054...77,158,806
Ensembl chr 5:77,151,902...77,158,453

G

actin related protein 2/3 complex, subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 1:74,275,656...74,307,368
Ensembl chr 1:74,275,243...74,307,368

G

actin related protein 2/3 complex, subunit 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ARPC3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein

NCBI chr 5:122,529,941...122,544,244
Ensembl chr 5:122,529,941...122,552,247

G

actin related protein 2/3 complex, subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 6:113,355,074...113,367,408
Ensembl chr 6:113,355,076...113,367,409

G

arrestin, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr11:70,323,051...70,331,654
Ensembl chr11:70,323,461...70,331,654

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr13:93,908,187...94,079,524
Ensembl chr13:93,908,138...94,079,524

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr12:103,287,401...103,322,260
Ensembl chr12:103,287,401...103,322,260

G

acid-sensing ion channel family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 1:75,426,467...75,450,984
Ensembl chr 1:75,427,080...75,450,987

G

argininosuccinate synthetase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684

G

autophagy related 5

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287

G

autophagy related 7

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 6:114,620,075...114,837,565
Ensembl chr 6:114,620,058...114,837,575

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 1:71,596,315...71,618,562
Ensembl chr 1:71,596,309...71,618,790

G

ATPase, class V, type 10A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 7:58,305,896...58,479,783
Ensembl chr 7:58,305,914...58,479,168

G

ATPase, class VI, type 11B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 3:35,808,104...35,910,425
Ensembl chr 3:35,808,255...35,910,425

G

ATPase, H+/K+ transporting, nongastric, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr14:56,602,525...56,626,008
Ensembl chr14:56,602,525...56,626,007

G

ATPase, Na+/K+ transporting, alpha 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000

G

ATPase, Na+/K+ transporting, alpha 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383

G

ATPase, Na+/K+ transporting, alpha 4 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr 1:172,051,075...172,085,991
Ensembl chr 1:172,051,080...172,085,981

G

ATPase, Na+/K+ transporting, beta 1 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr 1:164,264,668...164,285,924
Ensembl chr 1:164,264,678...164,285,924

G

ATPase, Na+/K+ transporting, beta 3 polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 9:96,214,708...96,246,368
Ensembl chr 9:96,214,708...96,246,495

G

ATPase, Ca++ transporting, cardiac muscle, fast twitch 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280

G

ATPase, Ca++ transporting, ubiquitous

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr11:72,851,995...72,883,869
Ensembl chr11:72,851,995...72,883,870

G

ATPase, Ca++ transporting, plasma membrane 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr10:98,750,243...98,862,005
Ensembl chr10:98,750,268...98,862,005

G

ATPase, Ca++ transporting, type 2C, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr 8:120,426,748...120,484,457
Ensembl chr 8:120,426,748...120,484,456

G

ATPase, H+/K+ exchanging, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr 8:13,436,209...13,446,778
Ensembl chr 8:13,436,205...13,446,825

G

ATPase, H+ transporting, lysosomal V0 subunit A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr 5:124,767,117...124,801,519
Ensembl chr 5:124,766,641...124,801,519

G

ATPase, H+ transporting, lysosomal V0 subunit A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 6:38,025,418...38,101,521
Ensembl chr 6:38,025,418...38,101,521

G

ATPase, H+ transporting, lysosomal V0 subunit D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 4:19,876,838...19,922,566
Ensembl chr 4:19,876,841...19,922,605

G

ATPase, H+ transporting, lysosomal V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr17:87,251,537...87,255,315
Ensembl chr17:87,251,537...87,255,325

G

ATPase, H+ transporting, lysosomal V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 6:29,467,782...29,470,508
Ensembl chr 6:29,467,717...29,470,511

G

ATPase, H+ transporting, lysosomal V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr 1:138,201,476...138,217,200
Ensembl chr 1:138,201,476...138,217,200

G

ATPase, Cu++ transporting, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:105,070,830...105,171,766
Ensembl chr X:105,070,882...105,168,532

G

ATPase, class I, type 8B, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:64,662,050...64,794,342
Ensembl chr18:64,662,038...64,794,338

G

ATPase, class I, type 8B, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 3:89,846,795...89,870,645
Ensembl chr 3:89,846,788...89,870,815

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr10:122,284,404...122,289,358
Ensembl chr10:122,284,404...122,289,357

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr 1:131,526,908...131,539,740
Ensembl chr 1:131,526,977...131,539,738

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:72,935,371...72,938,034
Ensembl chr X:72,935,708...72,939,108

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr11:108,808,687...108,841,609
Ensembl chr11:108,811,175...108,841,609

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr 8:72,144,017...72,155,270
Ensembl chr 8:72,143,400...72,154,433

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of B3GNT7 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 1:86,230,943...86,235,027
Ensembl chr 1:86,230,554...86,235,027

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 7:25,327,025...25,328,917
Ensembl chr 7:25,326,079...25,334,525

G

bile acid-Coenzyme A: amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 4:49,489,416...49,507,915
Ensembl chr 4:49,489,422...49,506,557

G

BAF nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr19:5,414,661...5,416,904
Ensembl chr19:5,414,666...5,417,196

G

B cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 3:135,759,124...136,031,902
Ensembl chr 3:135,759,124...136,031,827

G

BCL2-associated X protein

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277

NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322

G

butyrylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein
Dextran Sulfate results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 3:73,543,138...73,615,767
Ensembl chr 3:73,543,141...73,615,748

G

B cell leukemia/lymphoma 2

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277

NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004

G

B cell CLL/lymphoma 7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr 7:127,260,626...127,307,938
Ensembl chr 7:127,260,628...127,308,105

G

bradykinin receptor, beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr12:105,570,350...105,571,770
Ensembl chr12:105,569,344...105,571,687

G

bradykinin receptor, beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr12:105,529,431...105,561,503
Ensembl chr12:105,529,485...105,561,496

G

beclin 1, autophagy related

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr19:9,962,536...9,978,997
Ensembl chr19:9,962,538...9,978,997

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:72,527,207...72,539,542
Ensembl chr X:72,527,208...72,539,539

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr15:100,538,963...100,567,384
Ensembl chr15:100,538,958...100,567,434

G

baculoviral IAP repeat-containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569

G

baculoviral IAP repeat-containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr17:74,835,247...75,010,351
Ensembl chr17:74,835,290...75,010,351

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr14:70,711,998...70,758,280
Ensembl chr14:70,711,998...70,757,674

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 6:87,405,976...87,411,494
Ensembl chr 6:87,405,976...87,414,659

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114

G

bone morphogenetic protein receptor, type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 3:141,540,230...141,875,335
Ensembl chr 3:141,542,897...141,875,186

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 1:59,802,721...59,917,240
Ensembl chr 1:59,802,559...59,918,173

G

BPI fold containing family A, member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr 2:153,984,800...153,991,137
Ensembl chr 2:153,984,800...153,991,139

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 4:62,398,248...62,415,537
Ensembl chr 4:62,398,290...62,415,535

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr 5:43,976,235...44,000,810
Ensembl chr 5:43,976,227...44,001,328

G

basic transcription factor 3-like 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BTF3L4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 4:108,671,489...108,691,445
Ensembl chr 4:108,671,492...108,690,811

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 6:7,845,224...7,872,042
Ensembl chr 6:7,844,842...7,875,687

G

C1GALT1-specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:37,719,660...37,724,020
Ensembl chr X:37,719,662...37,723,964

G

complement component 1, q subcomponent, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 4:136,623,227...136,626,155
Ensembl chr 4:136,623,228...136,626,114

G

complement component 1, q subcomponent, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 4:136,607,437...136,613,511
Ensembl chr 4:136,607,440...136,613,498

G

C1q and tumor necrosis factor related protein 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr15:78,407,546...78,416,370
Ensembl chr15:78,407,546...78,415,616

G

complement component 1, r subcomponent A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1RA mRNA

NCBI chr 6:124,489,580...124,500,399
Ensembl chr 6:124,489,364...124,500,402

G

complement component 1, s subcomponent 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 6:124,507,303...124,519,340
Ensembl chr 6:124,507,304...124,519,318

G

complement component 1, s subcomponent 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S2 mRNA

NCBI chr 6:124,601,584...124,613,044
Ensembl chr 6:124,601,584...124,613,044

G

complement component 3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr17:57,510,967...57,535,136
Ensembl chr17:57,510,970...57,535,136

G

complement component 3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 6:122,824,099...122,833,116
Ensembl chr 6:122,824,097...122,833,120

G

complement C4B (Chido blood group)

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr17:34,947,249...34,962,876
Ensembl chr17:34,947,354...34,962,856

G

complement component 4 binding protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C4BP mRNA

NCBI chr 1:130,562,510...130,589,365
Ensembl chr 1:130,562,510...130,589,369

G

complement component 5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 7:15,980,668...15,993,465
Ensembl chr 7:15,980,668...15,993,465

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 1:85,707,796...85,779,298
Ensembl chr 1:85,721,162...85,779,297

G

calcium channel, voltage-dependent, alpha 1F subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:7,473,342...7,501,435
Ensembl chr X:7,473,322...7,501,435

G

calcium channel, voltage-dependent, L type, alpha 1S subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr 1:135,980,549...136,047,268
Ensembl chr 1:135,980,488...136,047,560

G

calcitonin/calcitonin-related polypeptide, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 7:114,225,223...114,236,145
Ensembl chr 7:114,230,713...114,235,592

G

calcitonin-related polypeptide, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 7:114,315,790...114,322,603
Ensembl chr 7:114,317,878...114,322,600

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr12:100,165,694...100,176,083
Ensembl chr12:100,165,694...100,176,073

G

calmodulin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CALM2 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein

NCBI chr17:87,740,829...87,754,363
Ensembl chr17:87,740,840...87,754,363

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr14:20,784,943...20,844,225
Ensembl chr14:20,784,943...20,844,156

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:33,067,995...33,328,820
Ensembl chr18:33,067,984...33,324,281

G

calcium/calmodulin-dependent protein kinase kinase 1, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr11:72,906,869...72,932,899
Ensembl chr11:72,909,834...72,932,899

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 4:122,752,841...122,779,869
Ensembl chr 4:122,752,840...122,779,849

G

calpain 13

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr17:73,613,451...73,706,376
Ensembl chr17:73,613,459...73,707,861

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 4:138,920,210...139,019,131
Ensembl chr 4:138,920,210...139,019,129

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 3:14,951,329...14,965,830
Ensembl chr 3:14,951,333...14,965,830

G

carbonic anhydrase 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CA3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 3:14,928,598...14,937,441
Ensembl chr 3:14,928,572...14,937,583

G

carbonic anhydrase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CA4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr11:84,848,580...84,856,880
Ensembl chr11:84,848,612...84,856,870

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290

G

caspase 3

increases cleavage
multiple interactions
increases activity

Dextran Sulfate results in increased cleavage of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724

G

caspase 8

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CASP8 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662

G

catalase

decreases activity
multiple interactions
increases activity

Dextran Sulfate results in decreased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505

G

caveolae associated 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 1:51,328,285...51,342,119
Ensembl chr 1:51,328,285...51,342,119

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr16:93,404,752...93,407,226
Ensembl chr16:93,402,741...93,407,393

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 9:110,483,376...110,540,661
Ensembl chr 9:110,485,571...110,540,674

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr 8:71,320,870...71,326,134
Ensembl chr 8:71,320,871...71,326,579

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 9:121,626,690...121,668,581
Ensembl chr 9:121,626,693...121,668,527

G

coiled-coil domain containing 158

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr 5:92,756,096...92,823,327
Ensembl chr 5:92,755,813...92,823,130

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr19:6,821,991...6,835,586
Ensembl chr19:6,821,991...6,835,579

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr 7:16,005,938...16,020,713
Ensembl chr 7:16,007,967...16,020,720

G

coiled-coil domain containing 96

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr 5:36,641,932...36,645,515
Ensembl chr 5:36,641,932...36,645,516

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr17:35,827,914...35,841,912
Ensembl chr17:35,827,997...35,841,912

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 7:105,075,201...105,085,546
Ensembl chr 7:105,074,938...105,120,105

G

C-C motif chemokine ligand 11

increases secretion
multiple interactions
increases expression

Dextran Sulfate results in increased secretion of CCL11 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr11:81,948,658...81,953,781
Ensembl chr11:81,948,649...81,953,781

G

C-C motif chemokine ligand 2

increases secretion
multiple interactions
increases expression

Dextran Sulfate results in increased secretion of CCL2 protein
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]
Dextran Sulfate results in increased expression of CCL2 mRNA

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279

G

C-C motif chemokine ligand 21 (serine)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 4:42,772,860...42,773,991
Ensembl chr 4:42,772,860...42,773,993

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr 5:135,598,789...135,601,977
Ensembl chr 5:135,598,791...135,601,903

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr 8:4,375,207...4,410,020
Ensembl chr 8:4,375,210...4,410,020

G

C-C motif chemokine ligand 27A

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 4:41,769,467...41,774,251
Ensembl chr 4:41,769,467...41,774,247

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr13:120,085,355...120,115,895
Ensembl chr13:120,085,355...120,115,895

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
Dextran Sulfate results in increased expression of CCL3 protein
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr11:83,553,410...83,555,509
Ensembl chr11:83,553,410...83,555,509

G

C-C motif chemokine ligand 6

decreases expression
increases expression

Dextran Sulfate results in decreased expression of CCL6 mRNA
Dextran Sulfate results in increased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr11:83,478,712...83,483,913
Ensembl chr11:83,478,708...83,483,913

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr11:81,936,538...81,938,351
Ensembl chr11:81,936,538...81,938,351

G

C-C motif chemokine ligand 8

increases expression

Dextran Sulfate results in increased expression of CCL8 mRNA

PMID:19645018 PMID:23894361

NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625

G

C-C motif chemokine ligand 9

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL9 mRNA
Dextran Sulfate results in increased expression of CCL9 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:83,463,743...83,469,462
Ensembl chr11:83,463,745...83,469,462

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 9:123,901,954...123,913,594
Ensembl chr 9:123,901,987...123,913,594

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 9:114,319,384...114,334,544
Ensembl chr 9:114,319,384...114,333,984

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 9:123,921,557...123,934,153
Ensembl chr 9:123,921,580...123,947,736

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr11:99,035,025...99,045,903
Ensembl chr11:99,035,022...99,045,903

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 9:119,921,199...119,923,972
Ensembl chr 9:119,921,180...119,923,972

G

C-C motif chemokine receptor-like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 9:110,883,902...110,886,586
Ensembl chr 9:110,883,554...110,886,587

G

centriole, cilia and spindle associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr 8:124,566,712...124,586,948
Ensembl chr 8:124,567,570...124,586,948

G

CD14 antigen

multiple interactions
affects response to substance

[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr18:36,858,117...36,859,868
Ensembl chr18:36,858,120...36,859,851

G

CD163 antigen

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr 6:124,281,596...124,307,488
Ensembl chr 6:124,281,615...124,307,486

G

CD177 antigen

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr 7:24,443,408...24,459,759
Ensembl chr 7:24,443,408...24,459,736

G

CD180 antigen

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr13:102,830,055...102,843,139
Ensembl chr13:102,830,066...102,876,137

G

CD19 antigen

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr 7:126,007,620...126,016,401
Ensembl chr 7:126,007,622...126,014,061

G

CD200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr16:45,202,474...45,229,419
Ensembl chr16:45,202,498...45,229,416

G

CD209f antigen

decreases expression

Dextran Sulfate results in decreased expression of CD209F mRNA

NCBI chr 8:4,152,784...4,155,838
Ensembl chr 8:4,152,787...4,155,835

G

CD247 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr 1:165,607,514...165,698,722
Ensembl chr 1:165,616,250...165,704,846

G

CD274 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr19:29,339,428...29,365,495
Ensembl chr19:29,344,855...29,365,495

G

CD28 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518

G

CD34 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr 1:194,621,239...194,643,587
Ensembl chr 1:194,621,127...194,643,587

G

CD4 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 6:124,841,656...124,865,210
Ensembl chr 6:124,841,655...124,865,184

G

CD44 antigen

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr 2:102,641,486...102,732,014
Ensembl chr 2:102,641,486...102,732,010

G

CD52 antigen

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 4:133,820,849...133,822,384
Ensembl chr 4:133,809,759...133,822,393

G

CD53 antigen

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 3:106,666,177...106,697,465
Ensembl chr 3:106,667,237...106,697,465

G

CD55 molecule, decay accelerating factor for complement

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr 1:130,357,526...130,390,513
Ensembl chr 1:130,366,764...130,390,481

G

CD55 molecule, decay accelerating factor for complement B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55B mRNA

NCBI chr 1:130,316,263...130,350,831
Ensembl chr 1:130,316,274...130,350,746

G

CD68 antigen

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr11:69,555,039...69,556,996
Ensembl chr11:69,555,039...69,556,979

G

CD72 antigen

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 4:43,447,724...43,454,708
Ensembl chr 4:43,446,462...43,454,628

G

CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724

G

CD79A antigen (immunoglobulin-associated alpha)

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622

G

CD79B antigen

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr11:106,202,167...106,205,388
Ensembl chr11:106,202,167...106,205,588

G

CD81 antigen

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr 7:142,606,487...142,621,667
Ensembl chr 7:142,606,476...142,621,671

G

CD86 antigen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA

NCBI chr16:36,389,318...36,486,439
Ensembl chr16:36,424,231...36,486,443

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 4:138,065,839...138,095,623
Ensembl chr 4:138,065,735...138,095,303

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr 8:104,828,247...104,871,136
Ensembl chr 8:104,828,257...104,871,143

G

cadherin-related family member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDHR2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr13:54,849,276...54,884,475
Ensembl chr13:54,849,274...54,884,475

G

cyclin dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 4:155,709,303...155,734,392
Ensembl chr 4:155,709,311...155,734,395

G

cyclin dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787

G

caudal type homeobox 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]

NCBI chr 5:147,237,710...147,244,059
Ensembl chr 5:147,237,615...147,244,080

G

CEA cell adhesion molecule 12

increases expression

Dextran Sulfate results in increased expression of CEACAM12 mRNA

NCBI chr 7:17,799,854...17,811,911
Ensembl chr 7:17,799,854...17,811,911

G

CCAAT/enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr16:15,705,150...15,707,409
Ensembl chr16:15,705,150...15,708,895

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 2:28,445,831...28,453,415
Ensembl chr 2:28,445,807...28,453,415

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr11:119,955,247...119,977,684
Ensembl chr11:119,955,256...119,977,653

G

carboxylesterase 1D

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 8:93,892,700...93,924,432
Ensembl chr 8:93,892,696...93,924,466

G

carboxylesterase 1E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1E mRNA

NCBI chr 8:93,927,846...93,956,233
Ensembl chr 8:93,927,846...93,956,247

G

carboxylesterase 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2A mRNA

NCBI chr 8:105,460,635...105,468,266
Ensembl chr 8:105,460,635...105,468,266

G

carboxylesterase 2C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 8:105,573,700...105,581,115
Ensembl chr 8:105,573,700...105,581,115

G

carboxylesterase 2E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr 8:105,652,892...105,661,304
Ensembl chr 8:105,652,892...105,661,304

G

carboxylesterase 2G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CES2G mRNA

NCBI chr 8:105,688,350...105,696,169
Ensembl chr 8:105,688,350...105,696,169

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr 1:172,348,697...172,373,437
Ensembl chr 1:172,348,368...172,373,437

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr17:35,075,350...35,081,492
Ensembl chr17:35,075,350...35,081,494

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr10:79,726,687...79,728,489
Ensembl chr10:79,726,687...79,728,489

G

complement component factor h

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr 1:140,013,593...140,111,149
Ensembl chr 1:140,012,446...140,111,502

G

cofilin 1, non-muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr19:5,540,483...5,544,059
Ensembl chr19:5,540,483...5,545,229

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043

G

cystic fibrosis transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 6:18,170,686...18,322,769
Ensembl chr 6:18,170,686...18,322,767

G

cell growth regulator with EF hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935

G

chromatin assembly factor 1, subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289

G

calcium homeostasis endoplasmic reticulum protein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHERP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr 8:73,214,327...73,229,077
Ensembl chr 8:73,214,333...73,229,070

G

chitinase-like 3

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHIL3 mRNA]

NCBI chr 3:106,054,870...106,074,852
Ensembl chr 3:106,054,870...106,074,880

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr 7:12,765,933...12,768,704
Ensembl chr 7:12,765,937...12,768,734

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr 2:154,498,949...154,536,703
Ensembl chr 2:154,493,625...154,536,705

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 6:54,016,917...54,278,797
Ensembl chr 6:54,016,539...54,278,795

G

chordin-like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr 7:99,655,611...99,683,935
Ensembl chr 7:99,655,379...99,683,935

G

cholinergic receptor, muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 2:91,752,531...91,760,180
Ensembl chr 2:91,757,594...91,759,033

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr14:66,370,685...66,390,397
Ensembl chr14:66,372,488...66,390,397

G

cholinergic receptor, nicotinic, alpha polypeptide 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 7:62,748,440...62,862,274
Ensembl chr 7:62,748,440...62,862,317

G

cholinergic receptor, nicotinic, beta polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr 8:27,858,688...27,889,758
Ensembl chr 8:27,858,739...27,889,758

G

cholinergic receptor, nicotinic, epsilon polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr11:70,505,709...70,510,074
Ensembl chr11:70,505,709...70,510,042

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr10:82,820,274...83,031,738
Ensembl chr10:82,821,332...83,031,734

G

conserved helix-loop-helix ubiquitous kinase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919

G

creatine kinase, brain

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr12:111,635,789...111,638,772
Ensembl chr12:111,635,795...111,638,772

G

creatine kinase, muscle

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr 7:19,145,019...19,155,508
Ensembl chr 7:19,138,701...19,156,766

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 3:144,710,298...144,738,537
Ensembl chr 3:144,709,578...144,738,537

G

chloride channel accessory 4A

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 3:144,658,247...144,680,806
Ensembl chr 3:144,658,241...144,680,806

G

chloride channel, voltage-sensitive 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr16:20,521,185...20,536,496
Ensembl chr16:20,521,714...20,536,496

G

chloride channel, voltage-sensitive 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr 8:61,363,423...61,436,351
Ensembl chr 8:61,363,423...61,436,334

G

claudin 1

decreases expression
multiple interactions
increases expression

Dextran Sulfate results in decreased expression of CLDN1 protein
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609

NCBI chr16:26,175,395...26,190,589
Ensembl chr16:26,175,392...26,190,591

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 3:31,204,069...31,218,475
Ensembl chr 3:31,204,069...31,218,473

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:138,701,552...138,712,135
Ensembl chr X:138,701,577...138,712,135

G

C-type lectin domain family 10, member A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr11:70,057,449...70,061,662
Ensembl chr11:70,047,023...70,061,660

G

chloride intracellular channel 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLIC1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein

NCBI chr17:35,269,219...35,277,695
Ensembl chr17:35,268,942...35,277,725

G

chymase 1, mast cell

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr14:56,178,908...56,182,132
Ensembl chr14:56,178,908...56,182,132

G

cytidine monophospho-N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 6:142,702,468...142,721,440
Ensembl chr 6:142,702,412...142,721,440

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 4:114,817,810...114,844,425
Ensembl chr 4:114,816,533...114,844,438

G

cyclic nucleotide gated channel alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 7:105,049,247...105,057,981
Ensembl chr 7:105,053,775...105,057,949

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr10:79,824,434...79,831,234
Ensembl chr10:79,824,418...79,831,896

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 4:33,923,171...33,948,831
Ensembl chr 4:33,924,593...33,948,831

G

cannabinoid receptor 2

multiple interactions
increases expression
affects response to substance
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 protein affects the susceptibility to Dextran Sulfate
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 4:135,622,500...135,647,530
Ensembl chr 4:135,622,705...135,647,518

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 4:41,657,498...41,697,091
Ensembl chr 4:41,657,498...41,697,089

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr15:91,949,034...92,239,834
Ensembl chr15:91,949,046...92,239,848

G

component of oligomeric golgi complex 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COG1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr11:113,540,004...113,560,157
Ensembl chr11:113,539,995...113,557,880

G

collagen, type XI, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 3:113,823,933...114,014,405
Ensembl chr 3:113,824,189...114,014,367

G

collagen, type XIV, alpha 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr15:55,171,040...55,384,199
Ensembl chr15:55,171,146...55,384,199

G

collagen, type XVI, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 4:129,941,638...129,993,070
Ensembl chr 4:129,941,633...129,993,076

G

collagen, type XVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr10:76,888,013...77,002,351
Ensembl chr10:76,888,012...77,002,382

G

collagen, type I, alpha 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868

G

collagen, type I, alpha 2

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544

G

collagen, type XXII, alpha 1

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr15:71,667,644...71,906,087
Ensembl chr15:71,667,644...71,906,076

G

collagen, type XXIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr11:51,180,508...51,474,752
Ensembl chr11:51,180,747...51,474,745

G

collagen, type XXVIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 6:7,997,100...8,193,709
Ensembl chr 6:7,997,808...8,192,617

G

collagen, type III, alpha 1

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866

G

collagen, type IV, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr 8:11,248,423...11,362,889
Ensembl chr 8:11,248,423...11,362,826

G

collagen, type IV, alpha 2

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr 8:11,362,878...11,499,287
Ensembl chr 8:11,362,805...11,499,287

G

collagen, type V, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 2:27,776,393...27,929,522
Ensembl chr 2:27,776,437...27,929,526

G

collagen, type V, alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 1:45,413,491...45,542,442
Ensembl chr 1:45,413,481...45,542,442

G

collagen, type VI, alpha 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]

PMID:32272095 PMID:35093514

NCBI chr10:76,544,626...76,561,869
Ensembl chr10:76,544,626...76,562,002

G

collagen, type VI, alpha 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr10:76,431,590...76,459,464
Ensembl chr10:76,431,596...76,459,464

G

collagen, type VI, alpha 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A4 protein]

NCBI chr 9:105,867,284...105,975,729
Ensembl chr 9:105,866,653...105,973,982

G

collagen, type VIII, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr16:57,444,619...57,575,100
Ensembl chr16:57,444,621...57,575,100

G

coronin, actin binding protein 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr 7:126,298,946...126,303,925
Ensembl chr 7:126,298,945...126,306,959

G

coronin, actin binding protein 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr 5:113,980,500...114,046,767
Ensembl chr 5:113,980,497...114,046,819

G

coactosin like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr 8:120,535,953...120,567,318
Ensembl chr 8:120,535,961...120,567,283

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 1:36,730,568...36,732,469
Ensembl chr 1:36,730,530...36,732,762

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 3:20,011,097...20,063,914
Ensembl chr 3:20,011,218...20,063,309

G

carboxypeptidase A1, pancreatic

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 6:30,639,217...30,645,360
Ensembl chr 6:30,639,217...30,645,362

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr14:75,479,727...75,520,995
Ensembl chr14:75,479,727...75,520,995

G

complement receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr 1:194,819,120...194,859,096
Ensembl chr 1:194,819,119...194,859,024

G

capping protein inhibiting regulator of actin

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr 5:76,803,225...77,021,393
Ensembl chr 5:76,804,359...77,021,392

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr11:104,021,289...104,066,349
Ensembl chr11:104,023,681...104,066,349

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001

G

cysteine-rich secretory protein 4

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 1:18,185,113...18,216,126
Ensembl chr 1:18,185,415...18,216,126

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 9:114,204,204...114,219,743
Ensembl chr 9:114,204,202...114,219,743

G

colony stimulating factor 1 (macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 3:107,648,364...107,668,048
Ensembl chr 3:107,648,364...107,667,785

G

colony stimulating factor 2 (granulocyte-macrophage)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493

G

colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr15:78,166,707...78,189,921
Ensembl chr15:78,166,707...78,189,921

G

colony stimulating factor 3 (granulocyte)

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 4:125,917,241...125,938,233
Ensembl chr 4:125,918,343...125,938,233

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573

G

cytidine 5'-triphosphate synthase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTPS1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 4:120,397,065...120,427,473
Ensembl chr 4:120,397,065...120,427,473

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr 7:87,927,233...87,960,083
Ensembl chr 7:87,927,293...87,960,096

G

cathepsin D

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 3:95,406,521...95,416,698
Ensembl chr 3:95,406,567...95,416,673

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704

G

cathepsin S

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTSS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 3:95,434,097...95,463,716
Ensembl chr 3:95,434,097...95,463,714

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr 2:13,281,149...13,496,687
Ensembl chr 2:13,281,149...13,496,624

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 9:119,877,749...119,897,362
Ensembl chr 9:119,877,749...119,898,945

G

coxsackie virus and adenovirus receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr16:78,098,114...78,156,673
Ensembl chr16:78,098,377...78,156,662

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr 5:92,494,497...92,496,748
Ensembl chr 5:92,494,497...92,496,748

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr 6:117,145,496...117,158,329
Ensembl chr 6:117,145,496...117,158,328

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr 5:96,104,785...96,108,927
Ensembl chr 5:96,104,810...96,108,927

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr13:56,436,456...56,444,624
Ensembl chr13:56,436,456...56,444,364

G

C-X-C motif chemokine ligand 15

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CXCL15 protein; Dextran Sulfate results in increased expression of CXCL5 mRNA; Dextran Sulfate results in increased expression of CXCL8 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of CXCL8 protein]

PMID:19645018 PMID:20637373 PMID:29950665 PMID:32272095

NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression
increases secretion

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr 5:92,469,190...92,475,938
Ensembl chr 5:92,469,206...92,475,938

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 1:74,193,153...74,200,405
Ensembl chr 1:74,193,150...74,200,405

G

cytochrome b-245, alpha polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669

G

cytochrome b-245, beta polypeptide

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 7:55,491,556...55,582,381
Ensembl chr 7:55,491,493...55,582,350

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr11:46,084,676...46,203,686
Ensembl chr11:46,084,677...46,203,686

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 9:57,905,307...57,934,314
Ensembl chr 9:57,913,694...57,934,306

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP1A2 protein
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986

G

cytochrome P450, family 21, subfamily a, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP21A1 mRNA

NCBI chr17:35,020,322...35,023,400
Ensembl chr17:35,020,322...35,023,535

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 6:84,548,396...84,570,890
Ensembl chr 6:84,548,396...84,570,890

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA

NCBI chr10:126,884,115...126,891,897
Ensembl chr10:126,884,119...126,888,875

G

cytochrome P450, family 2, subfamily b, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049

G

cytochrome P450, family 2, subfamily b, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 7:25,760,813...25,795,622
Ensembl chr 7:25,760,922...25,795,622

G

cytochrome P450, family 2, subfamily c, polypeptide 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2C23 mRNA

NCBI chr19:43,993,461...44,017,695
Ensembl chr19:43,993,461...44,017,647

G

cytochrome P450, family 2, subfamily c, polypeptide 29

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr19:39,275,541...39,319,157
Ensembl chr19:39,257,849...39,319,157

G

cytochrome P450, family 2, subfamily c, polypeptide 38

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C38 mRNA

NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519

G

cytochrome P450, family 2, subfamily c, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C40 mRNA

NCBI chr19:39,755,517...39,801,258
Ensembl chr19:39,755,515...39,801,258

G

cytochrome P450, family 2, subfamily c, polypeptide 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C50 mRNA

NCBI chr19:40,078,123...40,102,399
Ensembl chr19:40,078,132...40,102,394

G

cytochrome P450, family 2, subfamily c, polypeptide 55

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr19:38,995,384...39,031,134
Ensembl chr19:38,995,463...39,031,137

G

cytochrome P450, family 2, subfamily c, polypeptide 65

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C65 mRNA

NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr19:39,102,342...39,175,200
Ensembl chr19:39,102,342...39,175,516

G

cytochrome P450, family 2, subfamily c, polypeptide 67

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C67 mRNA

NCBI chr19:39,597,288...39,637,497
Ensembl chr19:39,597,286...39,637,495

G

cytochrome P450, family 2, subfamily c, polypeptide 68

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C68 mRNA

NCBI chr19:39,677,280...39,729,545
Ensembl chr19:39,677,278...39,729,498

G

cytochrome P450, family 2, subfamily c, polypeptide 69

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C69 mRNA

NCBI chr19:39,831,104...39,875,213
Ensembl chr19:39,831,258...39,875,243

G

cytochrome P450, family 2, subfamily d, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D10 mRNA

NCBI chr15:82,287,046...82,291,449
Ensembl chr15:82,287,047...82,291,396

G

cytochrome P450, family 2, subfamily d, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D11 mRNA

NCBI chr15:82,273,355...82,278,223
Ensembl chr15:82,273,355...82,278,223

G

cytochrome P450, family 2, subfamily d, polypeptide 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D12 mRNA

NCBI chr15:82,439,244...82,443,614
Ensembl chr15:82,439,273...82,444,604

G

cytochrome P450, family 2, subfamily d, polypeptide 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D26 mRNA

NCBI chr15:82,674,308...82,678,653
Ensembl chr15:82,674,302...82,678,495

G

cytochrome P450, family 2, subfamily d, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2D9 mRNA

NCBI chr15:82,336,578...82,341,028
Ensembl chr15:82,317,638...82,341,046

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900

G

cytochrome P450, family 2, subfamily j, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J13 mRNA

NCBI chr 4:95,930,897...95,965,803
Ensembl chr 4:95,915,771...95,965,783

G

cytochrome P450, family 2, subfamily j, polypeptide 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J6 mRNA

NCBI chr 4:96,404,375...96,449,835
Ensembl chr 4:96,404,375...96,441,898

G

cytochrome P450, family 2, subfamily j, polypeptide 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J8 mRNA

NCBI chr 4:96,332,187...96,395,634
Ensembl chr 4:96,332,833...96,395,623

G

cytochrome P450, family 2, subfamily j, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 4:96,456,661...96,480,748
Ensembl chr 4:96,456,666...96,479,815

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA

NCBI chr 7:114,149,358...114,162,283
Ensembl chr 7:114,148,917...114,162,207

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 7:25,501,894...25,515,950
Ensembl chr 7:25,501,900...25,516,338

G

cytochrome P450, family 3, subfamily a, polypeptide 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A11 mRNA

NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774

G

cytochrome P450, family 3, subfamily a, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr 5:137,891,195...137,923,872
Ensembl chr 5:137,891,194...137,919,881

G

cytochrome P450, family 3, subfamily a, polypeptide 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A16 mRNA

NCBI chr 5:145,373,119...145,406,550
Ensembl chr 5:145,373,119...145,406,533

G

cytochrome P450, family 4, subfamily a, polypeptide 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A10 mRNA

NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846

G

cytochrome P450, family 4, subfamily a, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4A14 mRNA

NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 4:115,481,895...115,504,918
Ensembl chr 4:115,481,922...115,504,920

G

cytochrome P450, family 4, subfamily f, polypeptide 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F13 mRNA

NCBI chr17:33,143,662...33,166,389
Ensembl chr17:33,143,662...33,166,376

G

cytochrome P450, family 4, subfamily f, polypeptide 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr17:33,122,331...33,136,353
Ensembl chr17:33,124,044...33,136,316

G

cytochrome P450, family 4, subfamily f, polypeptide 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F17 mRNA

NCBI chr17:32,725,404...32,749,132
Ensembl chr17:32,725,024...32,749,117

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr17:32,671,670...32,712,294
Ensembl chr17:32,671,697...32,712,294

G

cytochrome P450, family 4, subfamily f, polypeptide 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F40 mRNA

NCBI chr17:32,877,860...32,895,893
Ensembl chr17:32,877,874...32,895,888

G

cytochrome P450, family 7, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 4:6,265,612...6,275,632
Ensembl chr 4:6,265,612...6,275,633

G

cytochrome P450, family 7, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 3:18,126,108...18,298,054
Ensembl chr 3:18,126,114...18,297,502

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 3:116,306,776...116,343,630
Ensembl chr 3:116,306,719...116,343,630

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr10:97,315,362...97,354,025
Ensembl chr10:97,315,471...97,354,005

G

discoidin domain receptor family, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr 1:169,799,874...169,938,525
Ensembl chr 1:169,799,876...169,938,331

G

DEPP1 autophagy regulator

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr 6:116,627,645...116,629,808
Ensembl chr 6:116,627,570...116,629,755

G

Der1-like domain family, member 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr10:75,729,232...75,731,775
Ensembl chr10:75,729,247...75,731,775

G

diacylglycerol kinase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr12:37,930,169...38,684,238
Ensembl chr12:37,867,725...38,684,238

G

diacylglycerol kinase, iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 6:36,814,316...37,281,034
Ensembl chr 6:36,822,957...37,277,119

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 4:106,418,279...106,446,310
Ensembl chr 4:106,418,235...106,446,310

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 2:69,210,806...69,233,430
Ensembl chr 2:69,210,789...69,234,877

G

dehydrogenase/reductase X linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr 4:156,390,105...156,410,432

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 3:131,791,027...131,886,065
Ensembl chr 3:131,791,053...131,886,065

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr12:109,418,411...109,429,262
Ensembl chr12:109,418,749...109,429,262

G

dystrophia myotonica-protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr 7:18,817,571...18,827,746
Ensembl chr 7:18,817,774...18,827,746

G

doublesex and mab-3 related transcription factor like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 4:89,576,435...89,583,003
Ensembl chr 4:89,567,673...89,583,009

G

dystrophia myotonica-containing WD repeat motif

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr 7:18,810,002...18,816,701
Ensembl chr 7:18,810,152...18,816,701

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 2:80,145,790...80,184,399
Ensembl chr 2:80,145,810...80,184,387

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 2:32,198,483...32,243,361
Ensembl chr 2:32,198,483...32,243,350

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr 1:161,810,022...162,305,890
Ensembl chr 1:161,810,022...162,305,603

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr14:71,003,336...71,015,934
Ensembl chr14:71,003,476...71,015,935

G

dipeptidase 1

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr 8:123,913,069...123,928,551
Ensembl chr 8:123,912,981...123,928,551

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr 8:106,711,577...106,732,658
Ensembl chr 8:106,711,576...106,718,391
Ensembl chr 8:106,711,576...106,718,391

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 3:118,355,758...119,226,573
Ensembl chr 3:118,355,778...119,226,573

G

DR1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr19:5,472,832...5,475,007
Ensembl chr19:5,472,833...5,475,007

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 7:140,871,931...140,874,868
Ensembl chr 7:140,871,919...140,876,377

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr 5:38,476,742...38,479,868
Ensembl chr 5:38,476,710...38,479,861

G

deltex 1, E3 ubiquitin ligase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr 5:120,818,268...120,850,879
Ensembl chr 5:120,818,267...120,849,992

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr 2:122,129,381...122,133,088
Ensembl chr 2:122,129,381...122,133,366

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102

G

enoyl-Coenzyme A delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr17:24,645,657...24,658,290
Ensembl chr17:24,645,615...24,658,322

G

Ecm29 proteasome adaptor and scaffold

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ECPAS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 4:58,797,234...58,917,748
Ensembl chr 4:58,798,911...58,912,749

G

ectodysplasin-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:99,019,212...99,444,366
Ensembl chr X:99,019,212...99,444,368

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:96,375,936...96,420,786
Ensembl chr X:96,377,446...96,420,822

G

endothelial differentiation-related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 2:25,447,838...25,452,096
Ensembl chr 2:25,447,859...25,452,094

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 4:120,018,403...120,024,557
Ensembl chr 4:120,018,403...120,024,557

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr 8:78,389,658...78,451,081
Ensembl chr 8:78,389,660...78,451,093

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr19:8,944,405...8,955,544
Ensembl chr19:8,944,405...8,955,843

G

epidermal growth factor-containing fibulin-like extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr19:5,523,974...5,532,548
Ensembl chr19:5,523,982...5,532,545

G

EF hand domain containing 2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 4:141,585,453...141,602,231
Ensembl chr 4:141,585,453...141,602,231

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 3:89,179,037...89,188,258
Ensembl chr 3:89,179,040...89,188,449

G

egl-9 family hypoxia-inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr 7:26,858,083...26,866,227
Ensembl chr 7:26,858,083...26,866,227

G

EH-domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr19:6,326,926...6,350,126
Ensembl chr19:6,326,755...6,350,126

G

EH-domain containing 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EHD4 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein

NCBI chr 2:119,919,958...119,985,028
Ensembl chr 2:119,919,656...119,985,087

G

enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr16:21,580,035...21,606,589
Ensembl chr16:21,580,037...21,606,557

G

euchromatic histone lysine N-methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028

G

eukaryotic translation initiation factor 2-alpha kinase 2

multiple interactions
increases phosphorylation

EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr17:79,157,933...79,190,001
Ensembl chr17:79,159,993...79,190,002

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr19:60,749,554...60,779,131
Ensembl chr19:60,749,555...60,779,096

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr11:69,807,538...69,812,784
Ensembl chr11:69,807,540...69,812,784

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 1:38,037,091...38,094,660
Ensembl chr 1:38,037,091...38,094,660

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr10:79,722,146...79,724,050
Ensembl chr10:79,722,081...79,724,049

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 2:165,129,951...165,168,421
Ensembl chr 2:165,129,951...165,168,399

G

ER membrane protein complex subunit 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of EMC2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr15:43,340,603...43,391,174
Ensembl chr15:43,340,625...43,391,159

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr16:10,099,613...10,131,832
Ensembl chr16:10,099,613...10,131,832

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 2:32,536,607...32,572,681
Ensembl chr 2:32,536,607...32,572,681

G

enolase 1, alpha non-neuron

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336

G

enolase 3, beta muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ENO3 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr11:70,543,973...70,553,339
Ensembl chr11:70,548,028...70,553,339

G

glutamyl aminopeptidase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ENPEP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 3:129,062,826...129,126,398
Ensembl chr 3:129,062,824...129,126,369

G

ectonucleoside triphosphate diphosphohydrolase 5

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr12:84,420,649...84,455,803
Ensembl chr12:84,420,631...84,455,803

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278

G

epoxide hydrolase 1, microsomal

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr 1:180,817,121...180,845,134
Ensembl chr 1:180,803,775...180,848,469

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr10:128,403,392...128,425,504
Ensembl chr10:128,403,392...128,425,521

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 1:68,071,063...69,147,756
Ensembl chr 1:68,071,345...69,147,218

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr 5:91,222,476...91,241,508
Ensembl chr 5:91,222,481...91,241,505

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 4:150,938,253...150,953,346
Ensembl chr 4:150,938,376...150,953,349

G

endothelial cell-specific adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 9:37,439,385...37,449,615
Ensembl chr 9:37,439,374...37,449,615

G

estrogen receptor 1 (alpha)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614

G

estrogen receptor 2 (beta)

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033

G

Ena-vasodilator stimulated phosphoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr12:108,520,942...108,654,775
Ensembl chr12:108,520,979...108,654,775

G

Ewing sarcoma breakpoint region 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr11:5,019,687...5,049,314
Ensembl chr11:5,019,689...5,049,266

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr 8:45,693,696...45,715,092
Ensembl chr 8:45,694,211...45,715,068

G

coagulation factor XIII, A1 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr13:37,051,150...37,234,220
Ensembl chr13:37,051,152...37,234,220

G

coagulation factor II thrombin receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr13:95,738,288...95,754,974
Ensembl chr13:95,738,311...95,754,995

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr 1:163,979,396...164,048,539
Ensembl chr 1:163,979,407...164,047,846

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 4:115,853,866...115,876,034
Ensembl chr 4:115,824,342...115,875,123

G

fatty acid binding protein 4, adipocyte

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr11:43,486,867...43,492,389
Ensembl chr11:43,486,876...43,492,367

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr19:10,160,245...10,174,238
Ensembl chr19:10,160,252...10,174,241

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110

G

family with sequence similarity 229, member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 4:129,384,983...129,385,749
Ensembl chr 4:129,384,983...129,385,749

G

family with sequence similarity 50, member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr13:34,918,833...34,931,605
Ensembl chr13:34,918,833...34,931,606

G

family with sequence similarity 98, member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr 2:117,080,150...117,102,021
Ensembl chr 2:117,080,220...117,102,021

G

FAU ubiquitin like and ribosomal protein S30 fusion

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FAU protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr19:6,107,977...6,109,554
Ensembl chr19:6,107,874...6,109,554

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 6:91,189,442...91,249,522
Ensembl chr 6:91,189,437...91,249,522

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr12:101,712,820...101,785,541
Ensembl chr12:101,712,824...101,785,314

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr 2:125,142,514...125,348,417
Ensembl chr 2:125,142,514...125,349,913

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 4:148,244,605...148,250,874
Ensembl chr 4:148,245,078...148,250,881

G

Fc receptor, IgE, high affinity I, gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr 1:171,057,141...171,061,918
Ensembl chr 1:171,057,141...171,061,934

G

Fc receptor, IgG, high affinity I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 3:96,190,225...96,201,285
Ensembl chr 3:96,190,225...96,201,285

G

Fc receptor, IgG, low affinity IIb

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr 1:170,786,186...170,804,141
Ensembl chr 1:170,786,186...170,804,116

G

Fc receptor, IgG, low affinity III

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr 1:170,878,738...170,893,477
Ensembl chr 1:170,878,743...170,892,504

G

Fc receptor, IgG, low affinity IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr 1:170,846,495...170,857,330
Ensembl chr 1:170,846,489...170,857,330

G

ferredoxin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr 9:51,854,323...51,874,902
Ensembl chr 9:51,854,606...51,874,856

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr11:115,158,850...115,167,925
Ensembl chr11:115,158,850...115,167,876

G

fermitin family member 3

multiple interactions
increases expression
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]
Dextran Sulfate results in decreased expression of FERMT3 protein

PMID:32272095 PMID:35999755

NCBI chr19:6,976,326...6,996,837
Ensembl chr19:6,976,326...6,996,837

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr 7:30,517,778...30,523,200
Ensembl chr 7:30,517,773...30,523,200

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr19:38,085,527...38,102,711
Ensembl chr19:38,085,519...38,102,711

G

fibroblast growth factor 15

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr 7:144,450,269...144,454,690
Ensembl chr 7:144,450,268...144,454,690

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr11:33,066,970...33,097,400
Ensembl chr11:33,067,430...33,097,400

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr 6:127,049,865...127,059,257
Ensembl chr 6:127,049,865...127,058,371

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr19:45,724,930...45,731,380
Ensembl chr19:45,725,237...45,731,354

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr14:58,308,543...58,350,311
Ensembl chr14:58,308,004...58,350,177

G

fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr 8:26,008,808...26,067,819
Ensembl chr 8:26,003,670...26,065,734

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr13:55,300,631...55,316,572
Ensembl chr13:55,300,453...55,316,572

G

fibrinogen-like protein 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr 8:41,644,471...41,671,015
Ensembl chr 8:41,644,471...41,668,193

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:55,776,569...55,838,704
Ensembl chr X:55,777,147...55,838,706

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 1:43,162,233...43,237,501
Ensembl chr 1:43,162,234...43,236,144

G

four and a half LIM domains 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 4:124,589,750...124,602,404
Ensembl chr 4:124,594,494...124,602,404

G

filamin, alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:73,267,067...73,293,787
Ensembl chr X:73,267,067...73,293,426

G

flotillin 2

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr11:77,928,757...77,951,260
Ensembl chr11:77,928,757...77,951,260

G

FMS-like tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr 5:147,498,414...147,663,419
Ensembl chr 5:147,498,414...147,662,821

G

FMS-like tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr11:49,500,506...49,543,566
Ensembl chr11:49,500,090...49,543,566

G

flavin containing monooxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr 1:162,657,130...162,694,170
Ensembl chr 1:162,657,130...162,694,179

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr 1:133,964,992...133,976,018
Ensembl chr 1:133,964,992...133,976,015

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359

G

FBJ osteosarcoma oncogene

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr12:85,520,664...85,524,048
Ensembl chr12:85,520,664...85,524,047

G

fos-like antigen 1

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr19:5,497,726...5,505,966
Ensembl chr19:5,497,575...5,505,974

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr 2:147,884,797...147,888,889
Ensembl chr 2:147,884,797...147,888,889

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr 7:18,747,208...18,757,464
Ensembl chr 7:18,747,209...18,757,463

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:100,297,855...100,304,479
Ensembl chr X:100,298,134...100,304,479

G

forkhead box P3

increases methylation
multiple interactions
increases expression

Dextran Sulfate results in increased methylation of FOXP3 gene
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:7,445,915...7,461,482
Ensembl chr X:7,439,883...7,461,484

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 3:154,790,552...154,799,024
Ensembl chr 3:154,790,555...154,799,040

G

formyl peptide receptor, related sequence 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of FPR-RS6 mRNA

NCBI chr17:20,402,340...20,403,359
Ensembl chr17:20,402,340...20,403,359

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr17:18,096,733...18,104,201
Ensembl chr17:18,096,733...18,104,202

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr17:18,108,086...18,114,214
Ensembl chr17:18,108,086...18,114,214

G

formyl peptide receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr17:18,190,720...18,191,939
Ensembl chr17:18,108,114...18,191,939

G

frequently rearranged in advanced T cell lymphomas 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr19:41,834,411...41,836,571
Ensembl chr19:41,834,411...41,836,571

G

follicle stimulating hormone beta

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of FSHB protein
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr 2:106,886,331...106,889,996
Ensembl chr 2:106,886,485...106,890,001

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr17:89,292,380...89,508,103
Ensembl chr17:89,292,380...89,508,103

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr13:114,588,798...114,595,522
Ensembl chr13:114,588,826...114,595,487

G

follistatin-like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr10:79,613,108...79,618,464
Ensembl chr10:79,613,106...79,618,464

G

fused in sarcoma

increases expression

Dextran Sulfate results in increased expression of FUS mRNA

NCBI chr 7:127,565,276...127,581,204
Ensembl chr 7:127,566,629...127,584,873

G

FXYD domain-containing ion transport regulator 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA
Dextran Sulfate results in decreased expression of FXYD1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:30,751,103...30,758,332
Ensembl chr 7:30,751,103...30,756,624

G

FXYD domain-containing ion transport regulator 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr 7:30,769,960...30,776,122
Ensembl chr 7:30,767,597...30,776,129

G

FXYD domain-containing ion transport regulator 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr 6:117,910,519...117,914,668
Ensembl chr 6:117,910,520...117,914,653

G

Fyn proto-oncogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr10:39,245,735...39,441,377
Ensembl chr10:39,244,851...39,441,377

G

frizzled class receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 5:4,803,839...4,808,216
Ensembl chr 5:4,803,839...4,808,035

G

frizzled class receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr 7:89,053,574...89,062,341
Ensembl chr 7:89,053,563...89,062,342

G

frizzled class receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 1:64,769,717...64,776,907
Ensembl chr 1:64,769,717...64,776,910

G

frizzled class receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr15:38,869,673...38,901,587
Ensembl chr15:38,869,429...38,901,583

G

frizzled class receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 1:59,521,306...59,526,114
Ensembl chr 1:59,521,583...59,526,114

G

frizzled class receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr18:9,212,856...9,216,201
Ensembl chr18:9,212,163...9,218,136

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr11:101,258,542...101,268,729
Ensembl chr11:101,258,387...101,268,729

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr17:37,356,888...37,385,197
Ensembl chr17:37,356,858...37,385,959

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr 5:71,115,735...71,253,192
Ensembl chr 5:71,114,940...71,253,192

G

gamma-aminobutyric acid type A receptor subunit alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr 7:57,057,417...57,240,808
Ensembl chr 7:57,057,420...57,159,807

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr11:42,310,342...42,523,418
Ensembl chr11:42,310,584...42,519,855

G

gamma-aminobutyric acid (GABA) A receptor, subunit delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 4:155,469,437...155,482,528
Ensembl chr 4:155,469,437...155,482,569

G

glutamate decarboxylase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 2:70,392,109...70,432,358
Ensembl chr 2:70,383,416...70,432,358

G

galactose-4-epimerase, UDP

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 4:135,690,550...135,695,489
Ensembl chr 4:135,691,038...135,695,489

G

galactokinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr 2:125,701,029...125,826,218
Ensembl chr 2:125,701,029...125,826,219

G

galactose mutarotase

increases expression

Dextran Sulfate results in increased expression of GALM mRNA

NCBI chr17:80,434,886...80,492,461
Ensembl chr17:80,434,900...80,492,530

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr11:57,536,268...57,678,327
Ensembl chr11:57,536,268...57,678,340

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 4:47,091,894...47,123,058
Ensembl chr 4:47,091,909...47,123,070

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr14:31,750,739...31,784,161
Ensembl chr14:31,750,946...31,784,154

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr12:80,565,245...80,650,672
Ensembl chr12:80,565,051...80,677,746

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr 7:111,070,863...111,379,274
Ensembl chr 7:111,070,868...111,379,184

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr 8:124,958,133...125,072,461
Ensembl chr 8:124,958,130...125,072,463

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr10:98,943,997...98,949,109
Ensembl chr10:98,944,021...98,949,109

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 2:57,887,832...57,931,039
Ensembl chr 2:57,887,896...57,935,872

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr15:100,587,796...100,627,257
Ensembl chr15:100,589,694...100,627,257

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr 8:57,976,859...58,106,089
Ensembl chr 8:57,976,862...58,106,066

G

UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr 8:58,225,523...59,366,213
Ensembl chr 8:58,227,086...59,365,674

G

GAR1 ribonucleoprotein

increases expression

Dextran Sulfate results in increased expression of GAR1 mRNA

NCBI chr 3:129,618,561...129,625,045
Ensembl chr 3:129,618,561...129,625,045

G

growth arrest specific 8

increases expression

Dextran Sulfate results in increased expression of GAS8 mRNA

NCBI chr 8:124,245,630...124,263,394
Ensembl chr 8:124,245,573...124,263,389

G

gastrin

decreases response to substance
multiple interactions

GAST protein modified form results in decreased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

PMID:16618411 PMID:29950665

NCBI chr11:100,225,233...100,227,823
Ensembl chr11:100,225,233...100,227,822

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA

NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014

G

guanylate-binding protein 9

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]

NCBI chr 5:105,224,331...105,258,255
Ensembl chr 5:105,225,496...105,287,405

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767

G

glutamate-cysteine ligase, modifier subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr 9:69,938,777...69,947,172
Ensembl chr 9:69,938,778...69,945,370

G

GDP dissociation inhibitor 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein

NCBI chr X:73,348,618...73,355,473
Ensembl chr X:73,348,604...73,355,468

G

glutamine fructose-6-phosphate transaminase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 6:87,019,828...87,069,189
Ensembl chr 6:87,019,828...87,069,179

G

glutamine fructose-6-phosphate transaminase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA

NCBI chr11:49,684,981...49,729,448
Ensembl chr11:49,685,005...49,729,440

G

GDP-L-fucose synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA

NCBI chr15:75,796,532...75,801,613
Ensembl chr15:75,796,525...75,801,681

G

golgi-associated olfactory signaling regulator

increases expression

Dextran Sulfate results in increased expression of GFY mRNA

NCBI chr 7:44,825,773...44,829,021
Ensembl chr 7:44,825,773...44,828,993

G

gamma-glutamyl cyclotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA

NCBI chr 6:54,962,080...54,969,947
Ensembl chr 6:54,959,565...54,969,935

G

gametogenetin binding protein 1

increases expression

Dextran Sulfate results in increased expression of GGNBP1 mRNA

NCBI chr17:27,237,009...27,255,352
Ensembl chr17:27,236,961...27,256,598

G

growth hormone

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA

NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691

G

ghrelin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA

NCBI chr 6:113,693,080...113,696,872
Ensembl chr 6:113,693,080...113,696,841

G

galactosidase, beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GLB1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein]

NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966

G

galactosidase, beta 1-like 2

decreases expression

Dextran Sulfate results in decreased expression of GLB1L2 mRNA

NCBI chr 9:26,674,338...26,717,769
Ensembl chr 9:26,674,340...26,717,764

G

GLI-Kruppel family member GLI1

decreases expression

Dextran Sulfate results in decreased expression of GLI1 mRNA

NCBI chr10:127,165,751...127,177,448
Ensembl chr10:127,165,751...127,177,843

G

GLI-Kruppel family member GLI3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA

NCBI chr13:15,638,308...15,904,611
Ensembl chr13:15,637,820...15,904,611

G

glucagon-like peptide 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA

NCBI chr17:31,120,841...31,155,484
Ensembl chr17:31,120,791...31,159,765

G

glutaminase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GLS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein]

NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391

G

GDP-mannose 4, 6-dehydratase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA

NCBI chr13:32,003,566...32,522,744
Ensembl chr13:32,003,562...32,522,723

G

guanine nucleotide binding protein, alpha 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA

NCBI chr10:81,364,558...81,380,996
Ensembl chr10:81,364,558...81,381,024

G

guanine nucleotide binding protein, alpha 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA

NCBI chr 5:140,745,699...140,816,186
Ensembl chr 5:140,744,163...140,816,186

G

guanine nucleotide binding protein, alpha 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA

NCBI chr19:16,413,031...16,590,706
Ensembl chr19:16,413,126...16,588,184

G

guanine nucleotide binding protein, alpha 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA

NCBI chr10:81,338,147...81,360,283
Ensembl chr10:81,338,140...81,360,059

G

guanine nucleotide binding protein, alpha z subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA

NCBI chr10:74,803,009...74,852,739
Ensembl chr10:74,803,009...74,852,739

G

guanine nucleotide binding protein (G protein), beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA

NCBI chr 6:124,811,203...124,817,238
Ensembl chr 6:124,811,203...124,817,238

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA

NCBI chr 4:44,034,075...44,084,177
Ensembl chr 4:44,034,075...44,084,177

G

guanine nucleotide binding protein (G protein), gamma 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA

NCBI chr13:13,958,644...14,002,480
Ensembl chr13:13,958,644...14,002,481

G

guanine nucleotide binding protein (G protein), gamma 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA

NCBI chr10:80,784,463...80,850,742
Ensembl chr10:80,784,458...80,850,779

G

guanine nucleotide binding protein (G protein), gamma 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA

NCBI chr 7:16,625,687...16,629,361
Ensembl chr 7:16,625,711...16,629,361

G

guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA

NCBI chr11:95,733,045...95,736,557
Ensembl chr11:95,728,042...95,736,560

G

guanine nucleotide binding protein-like 1

increases expression

Dextran Sulfate results in increased expression of GNL1 mRNA

NCBI chr17:36,290,847...36,300,354
Ensembl chr17:36,290,743...36,300,354

G

glucosamine-phosphate N-acetyltransferase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA

NCBI chr14:45,613,897...45,626,972
Ensembl chr14:45,613,791...45,642,370

G

glutamic-oxaloacetic transaminase 1, soluble

multiple interactions
increases activity

Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of GOT1 protein]

NCBI chr19:43,488,191...43,514,743
Ensembl chr19:43,488,191...43,513,044

G

glycoprotein Ib, beta polypeptide

increases expression

Dextran Sulfate results in increased expression of GP1BB mRNA

NCBI chr16:18,439,069...18,441,153
Ensembl chr16:18,439,067...18,441,153

G

glycoprotein 6 platelet

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GP6 protein

NCBI chr 7:4,365,852...4,400,849
Ensembl chr 7:4,366,964...4,400,743

G

G protein-coupled bile acid receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA

NCBI chr 1:74,316,269...74,318,868
Ensembl chr 1:74,317,709...74,318,783

G

glypican 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA

NCBI chr X:51,139,884...51,253,800
Ensembl chr X:51,141,898...51,254,129

G

glucose-6-phosphate isomerase 1

decreases expression

Dextran Sulfate results in decreased expression of GPI protein

NCBI chr 7:33,900,752...33,929,761
Ensembl chr 7:33,900,755...33,929,761

G

glycoprotein (transmembrane) nmb

increases expression

Dextran Sulfate results in increased expression of GPNMB mRNA

NCBI chr 6:49,013,449...49,044,413
Ensembl chr 6:49,013,480...49,047,863

G

G-protein coupled receptor 119

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA

NCBI chr X:47,756,856...47,763,355
Ensembl chr X:47,756,856...47,763,355

G

G protein-coupled receptor 137B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA

NCBI chr13:13,528,035...13,568,250
Ensembl chr13:13,532,205...13,568,599

G

G protein-coupled receptor 137B, pseudogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B-PS mRNA

NCBI chr13:12,628,954...12,665,284
Ensembl chr13:12,630,627...12,665,175

G

G protein-coupled receptor 149

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA

NCBI chr 3:62,436,851...62,512,861
Ensembl chr 3:62,436,498...62,512,561

G

G protein-coupled receptor 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA

NCBI chr16:58,537,006...58,539,235
Ensembl chr16:58,537,796...58,539,433

G

G protein-coupled receptor 152

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA

NCBI chr19:4,189,798...4,195,740
Ensembl chr19:4,189,786...4,195,739

G

G protein-coupled receptor 165

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR165 mRNA

NCBI chr X:95,757,074...95,762,994
Ensembl chr X:95,757,047...95,762,994

G

G protein-coupled receptor 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA

NCBI chr18:32,076,052...32,082,925
Ensembl chr18:32,076,050...32,082,689

G

G protein-coupled receptor 176

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA

NCBI chr 2:118,107,577...118,205,022
Ensembl chr 2:118,107,591...118,203,900

G

G protein-coupled receptor 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA

NCBI chr15:73,560,346...73,579,354
Ensembl chr15:73,566,453...73,579,354

G

G protein-coupled receptor 27

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA

NCBI chr 6:99,669,328...99,672,027
Ensembl chr 6:99,669,640...99,672,027

G

G protein-coupled receptor 37-like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA

NCBI chr 1:135,087,988...135,095,419
Ensembl chr 1:135,087,972...135,095,419

G

G protein-coupled receptor 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA

NCBI chr 1:125,604,725...125,804,132
Ensembl chr 1:125,604,732...125,801,599

G

G protein-coupled receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA

NCBI chr 7:18,946,463...18,958,101
Ensembl chr 7:18,946,463...18,958,099

G

G-protein-coupled receptor 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA

NCBI chr X:70,707,273...70,712,863
Ensembl chr X:70,707,273...70,712,863

G

G protein-coupled receptor 68

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA

NCBI chr12:100,842,941...100,874,457
Ensembl chr12:100,842,941...100,874,457

G

G protein-coupled receptor 83

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA

NCBI chr 9:14,771,038...14,782,085
Ensembl chr 9:14,771,506...14,782,085

G

G protein-coupled receptor 85

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA

NCBI chr 6:13,834,405...13,839,951
Ensembl chr 6:13,834,457...13,839,941

G

G-protein coupled receptor 88

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA

NCBI chr 3:116,043,304...116,047,123
Ensembl chr 3:116,043,303...116,047,152

G

G protein-coupled receptor, family C, group 5, member B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA

NCBI chr 7:118,571,263...118,594,434
Ensembl chr 7:118,571,270...118,594,434

G

G protein-coupled receptor, family C, group 5, member D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA

NCBI chr 6:135,082,989...135,095,281
Ensembl chr 6:135,082,989...135,095,281

G

glutamic pyruvic transaminase, soluble

decreases activity

Dextran Sulfate results in decreased activity of GPT protein

NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886

G

glutamic pyruvate transaminase (alanine aminotransferase) 2

decreases expression

Dextran Sulfate results in decreased expression of GPT2 mRNA

NCBI chr 8:86,219,090...86,255,531
Ensembl chr 8:86,219,205...86,254,189

G

glutathione peroxidase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA

NCBI chr11:54,793,680...54,801,213
Ensembl chr11:54,793,279...54,801,203

G

glutathione peroxidase 4

decreases activity
decreases expression
multiple interactions

Dextran Sulfate results in decreased activity of GPX4 protein
Dextran Sulfate results in decreased expression of GPX4 mRNA; Dextran Sulfate results in decreased expression of GPX4 protein
gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 mRNA]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of GPX4 protein]

NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273

G

glutathione peroxidase 6

decreases expression

Dextran Sulfate results in decreased expression of GPX6 mRNA

NCBI chr13:21,479,635...21,503,795
Ensembl chr13:21,496,295...21,503,794

G

glutathione peroxidase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA

NCBI chr 4:108,257,414...108,263,910
Ensembl chr 4:108,257,587...108,264,158

G

glutathione peroxidase 8 (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA

NCBI chr13:113,179,287...113,182,944
Ensembl chr13:113,179,287...113,182,944

G

growth factor receptor bound protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA

NCBI chr11:115,534,871...115,599,423
Ensembl chr11:115,534,871...115,599,423

G

growth factor receptor bound protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA

NCBI chr11:98,337,660...98,346,199
Ensembl chr11:98,337,220...98,346,199

G

gremlin 1, DAN family BMP antagonist

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GREM1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GREM1 protein]

NCBI chr 2:113,579,020...113,588,993
Ensembl chr 2:113,576,509...113,588,991

G

glutamate receptor, ionotropic, kainate 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA

NCBI chr 9:42,431,708...42,856,296
Ensembl chr 9:42,429,431...42,855,789

G

glutamate receptor, ionotropic, NMDA2B (epsilon 2)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA

NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509

G

glutamate receptor, ionotropic, NMDA2D (epsilon 4)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA

NCBI chr 7:45,481,307...45,520,708
Ensembl chr 7:45,481,307...45,527,802

G

G protein-coupled receptor kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA

NCBI chr 5:113,058,344...113,163,518
Ensembl chr 5:113,058,348...113,163,657

G

G protein-coupled receptor kinase 6

multiple interactions
decreases response to substance

GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
GRK6 results in decreased susceptibility to Dextran Sulfate

NCBI chr13:55,592,865...55,608,740
Ensembl chr13:55,592,885...55,608,740

G

glutamate receptor, metabotropic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA

NCBI chr17:27,641,361...27,732,800
Ensembl chr17:27,641,361...27,740,377

G

gastrin releasing peptide receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA

NCBI chr X:162,296,900...162,332,732
Ensembl chr X:162,296,900...162,332,673

G

gasdermin D

multiple interactions
increases cleavage

hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of GSDMD protein]

NCBI chr15:75,733,990...75,739,257
Ensembl chr15:75,734,176...75,739,257

G

gelsolin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA

NCBI chr 2:35,146,371...35,197,914
Ensembl chr 2:35,146,392...35,197,904

G

glutathione reductase

multiple interactions
decreases activity

Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of GSR protein]

NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191

G

glutathione synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA

NCBI chr 2:155,405,101...155,434,730
Ensembl chr 2:155,405,101...155,434,730

G

glutathione S-transferase kappa 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA

NCBI chr 6:42,222,869...42,227,375
Ensembl chr 6:42,222,869...42,227,381

G

glutathione S-transferase, mu 1

decreases expression

Dextran Sulfate results in decreased expression of GSTM1 mRNA

NCBI chr 3:107,919,566...107,925,289
Ensembl chr 3:107,919,571...107,925,289

G

glutathione S-transferase, mu 2

decreases expression

Dextran Sulfate results in decreased expression of GSTM2 mRNA

NCBI chr 3:107,889,018...107,893,736
Ensembl chr 3:107,889,018...107,893,769

G

glutathione S-transferase, mu 5

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GSTM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GSTM3 protein]

NCBI chr 3:107,803,240...107,806,002
Ensembl chr 3:107,803,137...107,806,002

G

glutathione S-transferase omega 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO1 mRNA

NCBI chr19:47,843,412...47,853,229
Ensembl chr19:47,843,409...47,853,229

G

glutathione S-transferase omega 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO2 mRNA

NCBI chr19:47,853,879...47,874,747
Ensembl chr19:47,853,973...47,874,763

G

glutathione S-transferase, theta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTT3 mRNA

NCBI chr10:75,609,951...75,617,256
Ensembl chr10:75,609,949...75,617,248

G

general transcription factor IIF, polypeptide 1

increases expression

Dextran Sulfate results in increased expression of GTF2F1 mRNA

NCBI chr17:57,310,402...57,318,398
Ensembl chr17:57,310,405...57,318,288

G

guanylate cyclase activator 1a (retina)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GUCA1A mRNA

NCBI chr17:47,705,482...47,724,439
Ensembl chr17:47,705,483...47,711,509

G

guanylate cyclase activator 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCA1B mRNA

NCBI chr17:47,692,526...47,703,892
Ensembl chr17:47,696,318...47,703,892

G

guanylate cyclase activator 2b (retina)

increases expression

Dextran Sulfate results in increased expression of GUCA2B protein

NCBI chr 4:119,513,798...119,516,142
Ensembl chr 4:119,513,804...119,516,151

G

guanylate cyclase 2f

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCY2F mRNA

NCBI chr X:140,862,282...140,980,399
Ensembl chr X:140,864,156...140,979,927

G

guanylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GUK1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GUK1 protein]

NCBI chr11:59,074,696...59,083,068
Ensembl chr11:59,074,701...59,083,069

G

gulonolactone (L-) oxidase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GULO mRNA

NCBI chr14:66,224,235...66,246,703
Ensembl chr14:66,224,235...66,246,656

G

granzyme A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GZMA mRNA

NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515

G

H1.10 linker histone

increases expression

Dextran Sulfate results in increased expression of H1F10 mRNA

NCBI chr 6:87,957,403...87,958,464
Ensembl chr 6:87,957,403...87,958,619

G

histocompatibility 2, class II antigen A, alpha

increases expression

Dextran Sulfate results in increased expression of H2-AA mRNA

NCBI chr17:34,501,718...34,506,797
Ensembl chr17:34,501,718...34,506,797

G

histocompatibility 2, class II antigen A, beta 1

increases expression

Dextran Sulfate results in increased expression of H2-AB1 mRNA

NCBI chr17:34,482,201...34,488,392
Ensembl chr17:34,476,663...34,488,393

G

histocompatibility 2, class II, locus DMa

increases expression

Dextran Sulfate results in increased expression of H2-DMA mRNA

NCBI chr17:34,338,667...34,358,075
Ensembl chr17:34,338,515...34,358,075

G

histocompatibility 2, class II, locus Mb2

increases expression

Dextran Sulfate results in increased expression of H2-DMB2 mRNA

NCBI chr17:34,362,203...34,370,527
Ensembl chr17:34,362,281...34,370,529

G

histocompatibility 2, class II antigen E beta

increases expression

Dextran Sulfate results in increased expression of H2-EB1 mRNA

NCBI chr17:34,524,841...34,535,648
Ensembl chr17:34,524,841...34,535,648

G

histocompatibility 2, class II antigen E beta2

increases expression

Dextran Sulfate results in increased expression of H2-EB2 mRNA

NCBI chr17:34,544,477...34,560,384
Ensembl chr17:34,544,639...34,560,386

G

histocompatibility 2, M region locus 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-M11 mRNA

NCBI chr17:36,857,967...36,861,165
Ensembl chr17:36,857,967...36,860,142

G

histocompatibility 2, M region locus 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-M3 mRNA

NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375

G

histocompatibility 2, O region beta locus

increases expression

Dextran Sulfate results in increased expression of H2-OB mRNA

NCBI chr17:34,457,879...34,464,882
Ensembl chr17:34,457,877...34,473,388

G

histocompatibility 2, Q region locus 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-Q8 mRNA

NCBI chr17:35,737,710...35,742,945

G

histocompatibility 2, T region locus 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-T24 mRNA

NCBI chr17:36,314,363...36,331,689
Ensembl chr17:36,316,587...36,331,452

G

hydroxyacyl-Coenzyme A dehydrogenase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of HADH protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of HADH protein]

NCBI chr 3:131,027,068...131,065,750
Ensembl chr 3:131,027,068...131,065,750

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HADHB mRNA

NCBI chr 5:30,360,251...30,389,591
Ensembl chr 5:30,360,246...30,389,591

G

hemoglobin alpha, adult chain 1

increases expression

Dextran Sulfate results in increased expression of HBA-A1 mRNA

NCBI chr11:32,233,672...32,234,486
Ensembl chr11:32,233,511...32,234,465

G

hemoglobin, beta adult major chain

increases expression

Dextran Sulfate results in increased expression of HBB-B1 mRNA

G

hemoglobin, beta adult minor chain

increases expression

Dextran Sulfate results in increased expression of HBB-B2 mRNA

G

hemoglobin, beta adult s chain

increases expression

Dextran Sulfate results in increased expression of HBB-BS mRNA

NCBI chr 7:103,475,730...103,477,135
Ensembl chr 7:103,475,741...103,477,303

G

hemoglobin, beta adult t chain

increases expression

Dextran Sulfate results in increased expression of HBB-BT mRNA

NCBI chr 7:103,461,731...103,463,130
Ensembl chr 7:103,461,731...103,463,203

G

hydroxycarboxylic acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCAR2 mRNA

NCBI chr 5:124,001,633...124,003,579
Ensembl chr 5:124,001,633...124,003,562

G

hyperpolarization-activated, cyclic nucleotide-gated K+ 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN2 mRNA

NCBI chr10:79,552,468...79,571,942
Ensembl chr10:79,552,468...79,571,942

G

hyperpolarization-activated, cyclic nucleotide-gated K+ 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN3 mRNA

NCBI chr 3:89,054,082...89,067,538
Ensembl chr 3:89,053,381...89,067,503

G

hyperpolarization-activated, cyclic nucleotide-gated K+ 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN4 mRNA

NCBI chr 9:58,730,232...58,770,458
Ensembl chr 9:58,730,695...58,770,458

G

HDGF like 2

increases expression

Dextran Sulfate results in increased expression of HDGFL2 mRNA

NCBI chr17:56,386,661...56,407,605
Ensembl chr17:56,386,634...56,407,607

G

hephaestin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HEPH mRNA

NCBI chr X:95,499,042...95,618,091
Ensembl chr X:95,498,965...95,618,091

G

hes family bHLH transcription factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HES1 mRNA

NCBI chr16:29,883,259...29,886,614
Ensembl chr16:29,883,202...29,886,614

G

hypoxia inducible factor 1, alpha subunit

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HIF1A protein
resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of HIF1A protein]

NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304

G

HIRA interacting protein 3

increases expression

Dextran Sulfate results in increased expression of HIRIP3 mRNA

NCBI chr 7:126,461,155...126,464,549
Ensembl chr 7:126,461,144...126,464,549

G

hexokinase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HK1 protein
hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of HK1 protein]

NCBI chr10:62,104,634...62,215,699
Ensembl chr10:62,104,634...62,215,687

G

hexokinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HK3 mRNA

NCBI chr13:55,153,798...55,169,233
Ensembl chr13:55,153,798...55,169,198

G

high mobility group box 1

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of HMGB1 protein]

NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299

G

heme oxygenase 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HMOX1 mRNA; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of HMOX1 protein]
Dextran Sulfate results in decreased expression of HMOX1 mRNA; Dextran Sulfate results in decreased expression of HMOX1 protein

PMID:29950665 PMID:30142311 PMID:33974900 PMID:36135333

NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217

G

HNF1 homeobox A

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of HNF1A protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1A mRNA

PMID:29680209 PMID:29950665

NCBI chr 5:115,087,039...115,109,121
Ensembl chr 5:115,087,039...115,109,153

G

HNF1 homeobox B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1B mRNA

NCBI chr11:83,741,035...83,796,743
Ensembl chr11:83,740,889...83,796,645

G

hepatic nuclear factor 4, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4A mRNA

NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830

G

hepatocyte nuclear factor 4, gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4G mRNA

NCBI chr 3:3,573,090...3,724,863
Ensembl chr 3:3,573,084...3,724,860

G

heterogeneous nuclear ribonucleoprotein A0

increases expression

Dextran Sulfate results in increased expression of HNRNPA0 mRNA

NCBI chr13:58,273,693...58,276,370
Ensembl chr13:58,273,693...58,276,370

G

hook microtubule tethering protein 2

increases expression

Dextran Sulfate results in increased expression of HOOK2 mRNA

NCBI chr 8:85,715,402...85,729,981
Ensembl chr 8:85,717,232...85,729,978

G

haptoglobin

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of HP protein; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of HP protein]

PMID:31807802 PMID:35999755

NCBI chr 8:110,301,760...110,305,804
Ensembl chr 8:110,301,760...110,305,804

G

hydroxyprostaglandin dehydrogenase 15 (NAD)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HPGD mRNA

NCBI chr 8:56,747,587...56,774,081
Ensembl chr 8:56,747,620...56,774,078

G

heparanase

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of HPSE protein

NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582

G

histamine receptor H3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HRH3 mRNA

NCBI chr 2:179,741,258...179,746,264
Ensembl chr 2:179,741,258...179,746,281

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD11B1 mRNA
Dextran Sulfate results in increased expression of HSD11B1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:192,903,917...192,946,345
Ensembl chr 1:192,903,942...192,946,383

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD11B2 mRNA

NCBI chr 8:106,245,378...106,250,620
Ensembl chr 8:106,245,387...106,250,620

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD17B1 mRNA

NCBI chr11:100,968,792...100,972,014
Ensembl chr11:100,969,237...100,971,353

G

hydroxysteroid (17-beta) dehydrogenase 3

decreases expression

Dextran Sulfate results in decreased expression of HSD17B3 mRNA

NCBI chr13:64,206,088...64,237,076
Ensembl chr13:64,206,080...64,237,044

G

hydroxysteroid (17-beta) dehydrogenase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD17B6 mRNA

NCBI chr10:127,826,800...127,843,517
Ensembl chr10:127,826,805...127,843,480

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

decreases expression

Dextran Sulfate results in decreased expression of HSD3B1 mRNA

NCBI chr 3:98,749,672...98,767,110
Ensembl chr 3:98,759,510...98,767,110

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD3B4 mRNA

NCBI chr 3:98,406,387...98,417,895
Ensembl chr 3:98,406,387...98,417,830

G

heat shock protein 90, alpha (cytosolic), class A member 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSP90AA1 mRNA
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AA1 mRNA]

NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162

G

heat shock protein 90 alpha (cytosolic), class B member 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSP90AB1 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of HSP90AB1 protein]

NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197

G

heat shock protein 1A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1A mRNA

NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132

G

heat shock protein 1B

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of HSPA1B mRNA

NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214

G

heat shock protein 8

decreases expression

Dextran Sulfate results in decreased expression of HSPA8 protein

NCBI chr 9:40,712,572...40,716,498
Ensembl chr 9:40,712,280...40,721,383

G

heat shock protein 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of HSPB1 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of HSPB1 mRNA]

NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417

G

perlecan (heparan sulfate proteoglycan 2)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSPG2 mRNA

NCBI chr 4:137,196,062...137,297,941
Ensembl chr 4:137,196,080...137,297,941

G

5-hydroxytryptamine (serotonin) receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR1B mRNA

NCBI chr 9:81,510,344...81,515,885
Ensembl chr 9:81,510,344...81,515,881

G

5-hydroxytryptamine (serotonin) receptor 1D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HTR1D mRNA

NCBI chr 4:136,150,835...136,171,716
Ensembl chr 4:136,150,835...136,171,709

G

5 hydroxytryptamine (serotonin) receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HTR4 mRNA

NCBI chr18:62,456,618...62,636,098
Ensembl chr18:62,457,275...62,629,648

G

5-hydroxytryptamine (serotonin) receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR7 mRNA

NCBI chr19:35,935,815...36,035,533
Ensembl chr19:35,936,134...36,034,907

G

HtrA serine peptidase 1

decreases expression

Dextran Sulfate results in decreased expression of HTRA1 mRNA

NCBI chr 7:130,537,933...130,587,388
Ensembl chr 7:130,537,841...130,587,390

G

intercellular adhesion molecule 1

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM1 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA]

PMID:21724996 PMID:24038091 PMID:25448682 PMID:25472953 PMID:29950665

NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113

G

intercellular adhesion molecule 4, Landsteiner-Wiener blood group

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM4 mRNA

NCBI chr 9:20,940,728...20,941,892
Ensembl chr 9:20,940,669...20,941,891

G

icos ligand

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICOSL mRNA

NCBI chr10:77,904,921...77,915,359
Ensembl chr10:77,905,136...77,919,747

G

isocitrate dehydrogenase 1 (NADP+), soluble

decreases expression

Dextran Sulfate results in decreased expression of IDH1 mRNA

NCBI chr 1:65,197,775...65,225,638
Ensembl chr 1:65,197,775...65,225,659

G

indoleamine 2,3-dioxygenase 1

increases expression

Dextran Sulfate results in increased expression of IDO1 mRNA

NCBI chr 8:25,074,148...25,086,987
Ensembl chr 8:25,074,152...25,087,025

G

immediate early response 3

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IER3 mRNA]

NCBI chr17:36,132,605...36,133,803
Ensembl chr17:36,132,576...36,133,815

G

interferon activated gene 204

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFI204 mRNA

NCBI chr 1:173,574,859...173,594,606
Ensembl chr 1:173,574,859...173,594,509

G

interferon activated gene 205

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IFI205 mRNA; Dextran Sulfate results in increased expression of IFI205 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFI205 protein]

PMID:32272095 PMID:35093514

NCBI chr 1:173,839,549...173,859,617
Ensembl chr 1:173,839,564...173,859,376

G

interferon activated gene 211

increases expression

Dextran Sulfate results in increased expression of PYHIN1 mRNA

NCBI chr 1:173,723,907...173,740,650
Ensembl chr 1:173,723,911...173,740,612

G

interferon induced transmembrane protein 3

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of IFITM3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFITM3 protein]

PMID:26271895 PMID:32272095

NCBI chr 7:140,589,503...140,590,657
Ensembl chr 7:140,589,499...140,590,683

G

interferon alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNA5 mRNA

NCBI chr 4:88,753,762...88,754,331
Ensembl chr 4:88,753,762...88,754,331

G

interferon (alpha and beta) receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNAR2 mRNA

NCBI chr16:91,166,517...91,202,477
Ensembl chr16:91,169,671...91,202,477

G

interferon gamma

multiple interactions
increases secretion
increases expression

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNG protein; [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IFNG protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of IFNG protein]
Dextran Sulfate results in increased expression of IFNG mRNA; Dextran Sulfate results in increased expression of IFNG protein

PMID:12105854 PMID:19940103 PMID:20637373 PMID:21068411 PMID:21359540 More...

NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797

G

interferon kappa

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNK mRNA

NCBI chr 4:35,152,055...35,154,019
Ensembl chr 4:35,152,056...35,154,005

G

insulin-like growth factor 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IGF1 protein

NCBI chr10:87,694,127...87,772,909
Ensembl chr10:87,694,127...87,772,904

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions

[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein; Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein]

NCBI chr 6:49,062,152...49,200,225
Ensembl chr 6:49,062,157...49,191,891

G

insulin-like growth factor binding protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP2 mRNA

NCBI chr 1:72,863,650...72,891,633
Ensembl chr 1:72,863,662...72,891,633

G

insulin-like growth factor binding protein 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA

NCBI chr11:98,930,820...98,943,481
Ensembl chr11:98,932,070...98,945,218

G

insulin-like growth factor binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP6 mRNA

NCBI chr15:102,052,621...102,057,947
Ensembl chr15:102,052,797...102,057,946

G

interferon gamma induced GTPase

increases expression

Dextran Sulfate results in increased expression of IGTP mRNA

NCBI chr11:58,090,382...58,098,418
Ensembl chr11:58,090,382...58,098,417

G

Indian hedgehog

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IHH mRNA

NCBI chr 1:74,984,474...74,990,831
Ensembl chr 1:74,984,474...74,990,831

G

interferon inducible GTPase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IIGP1 mRNA; Dextran Sulfate results in increased expression of IIGP1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IIGP1 protein]

PMID:23894361 PMID:32272095

NCBI chr18:60,506,688...60,525,706
Ensembl chr18:60,509,099...60,525,706

G

inhibitor of kappaB kinase beta

multiple interactions
increases activity
increases expression

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IKBKB mRNA; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IKBKB protein modified form]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of IKBKB protein]

PMID:20155626 PMID:25472953 PMID:29950665

NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605

G

inhibitor of kappaB kinase epsilon

multiple interactions
increases phosphorylation

GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of IKBKE protein]

NCBI chr 1:131,182,337...131,207,339
Ensembl chr 1:131,182,080...131,207,344

G

IKAROS family zinc finger 3

increases expression

Dextran Sulfate results in increased expression of IKZF3 mRNA

NCBI chr11:98,355,436...98,437,157
Ensembl chr11:98,355,728...98,436,857

G

interleukin 10

multiple interactions
increases expression
decreases expression

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester promotes the reaction [Dextran Sulfate results in increased expression of IL10 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; asperuloside inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; celastrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL10 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL10 protein]
Dextran Sulfate results in increased expression of IL10 mRNA; Dextran Sulfate results in increased expression of IL10 protein
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL10 mRNA]

PMID:20132809 PMID:20881082 PMID:21068411 PMID:21359540 PMID:21724996 More...

NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711

G

interleukin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11 mRNA; Melatonin inhibits the reaction [Dextran Sulfate results in decreased expression of IL11 protein]

PMID:29950665 PMID:36265525

NCBI chr 7:4,775,372...4,785,877
Ensembl chr 7:4,775,372...4,785,858

G

interleukin 11 receptor subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11RA1 mRNA

NCBI chr 4:41,760,443...41,769,473
Ensembl chr 4:41,699,989...41,769,474

G

interleukin 12a

affects response to substance

IL12A protein affects the susceptibility to Dextran Sulfate

NCBI chr 3:68,597,977...68,605,881
Ensembl chr 3:68,597,977...68,605,880

G

interleukin 12b

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL12B mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL12B mRNA]

NCBI chr11:44,290,890...44,305,504
Ensembl chr11:44,290,890...44,304,860

G

interleukin 15

increases response to substance
decreases expression
multiple interactions

IL15 protein results in increased susceptibility to Dextran Sulfate
Dextran Sulfate results in decreased expression of IL15 mRNA
Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of IL15 mRNA]
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL15 mRNA

PMID:16162679 PMID:16375993 PMID:29950665

NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851

G

interleukin 17A

multiple interactions
increases expression
affects response to substance

2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IFNG protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL17A mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]
Dextran Sulfate results in increased expression of IL17A mRNA; Dextran Sulfate results in increased expression of IL17A protein

PMID:20881082 PMID:21068411 PMID:24384223 PMID:24548422 PMID:26074695 More...

NCBI chr 1:20,801,129...20,804,720
Ensembl chr 1:20,801,129...20,804,720

G

interleukin 18

affects response to substance
increases expression
multiple interactions
increases secretion

IL18 protein affects the susceptibility to Dextran Sulfate
Dextran Sulfate results in increased expression of IL18 mRNA; Dextran Sulfate results in increased expression of IL18 protein
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL18 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL18 mRNA; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased secretion of IL18 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL18 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL18 protein]]

PMID:12940437 PMID:25448682 PMID:29950665 PMID:30270565 PMID:32470352 More...

NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140

G

interleukin 18 receptor 1

affects response to substance

IL18R1 protein affects the susceptibility to Dextran Sulfate

NCBI chr 1:40,504,712...40,540,014
Ensembl chr 1:40,504,712...40,540,014

G

interleukin 18 receptor accessory protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL18RAP mRNA

NCBI chr 1:40,554,548...40,590,867
Ensembl chr 1:40,554,522...40,590,865

G

interleukin 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL19 mRNA

NCBI chr 1:130,860,393...130,873,194
Ensembl chr 1:130,860,393...130,867,852

G

interleukin 1 alpha

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL1A mRNA; Dextran Sulfate results in increased expression of IL1A protein
2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1A protein; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1A protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1A mRNA]

PMID:23894361 PMID:25472953 PMID:29672155 PMID:34273909 PMID:36265525

NCBI chr 2:129,141,530...129,151,892
Ensembl chr 2:129,141,530...129,151,892

G

interleukin 1 beta

multiple interactions
increases expression
increases secretion
increases cleavage

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of IL1B protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1B mRNA; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased cleavage of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; phenethyl isothiocyanate inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Quercetin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of IL1B protein]
Dextran Sulfate results in increased expression of IL1B mRNA; Dextran Sulfate results in increased expression of IL1B protein

PMID:15652231 PMID:16774945 PMID:19028472 PMID:19285099 PMID:19645018 More...

NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059

G

interleukin 1 receptor, type I

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL1R1 mRNA]

PMID:29950665 PMID:32033881

NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417

G

interleukin 1 receptor, type II

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R2 mRNA

NCBI chr 1:40,123,872...40,164,390
Ensembl chr 1:40,113,239...40,164,391

G

interleukin 1 receptor antagonist

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein]

NCBI chr 2:24,226,872...24,241,503
Ensembl chr 2:24,226,865...24,241,506

G

interleukin 2

increases expression
multiple interactions
decreases expression

Dextran Sulfate results in increased expression of IL2 mRNA
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of IL2 protein]

PMID:21068411 PMID:25472953 PMID:32272095

NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108

G

interleukin 20 receptor, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RA mRNA

NCBI chr10:19,587,421...19,635,801
Ensembl chr10:19,588,318...19,635,801

G

interleukin 20 receptor beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RB mRNA

NCBI chr 9:100,339,772...100,368,526
Ensembl chr 9:100,339,772...100,368,841

G

interleukin 22B

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL22 mRNA
[Azoxymethane co-treated with Dextran Sulfate] results in increased secretion of IL22 protein; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL22 mRNA]; Dronabinol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased secretion of IL22 protein]

PMID:27920257 PMID:32942172 PMID:34998820 PMID:37385329

NCBI chr10:118,125,534...118,130,943
Ensembl chr10:118,125,534...118,130,943

G

interleukin 22 receptor, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL22RA1 mRNA

NCBI chr 4:135,455,470...135,482,694
Ensembl chr 4:135,455,483...135,479,451

G

interleukin 22 receptor, alpha 2

decreases expression

Dextran Sulfate results in decreased expression of IL22RA2 mRNA

NCBI chr10:19,497,776...19,510,429
Ensembl chr10:19,497,746...19,510,429

G

interleukin 23, alpha subunit p19

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IL23A protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL23A protein]
Dextran Sulfate results in increased expression of IL23A mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL23A mRNA]

PMID:20881082 PMID:24384223 PMID:36265525

NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621

G

interleukin 27 receptor, alpha

decreases response to substance

IL27RA protein results in decreased susceptibility to Dextran Sulfate

NCBI chr 8:84,756,915...84,769,250
Ensembl chr 8:84,756,923...84,769,218

G

interleukin 2 receptor, gamma chain

increases expression

Dextran Sulfate results in increased expression of IL2RG mRNA

NCBI chr X:100,307,991...100,311,861
Ensembl chr X:100,307,984...100,311,861

G

interleukin 3 receptor, alpha chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL3RA mRNA

NCBI chr14:8,114,270...8,123,851
Ensembl chr14:8,113,752...8,123,488

G

interleukin 4

decreases expression
multiple interactions
increases expression

Dextran Sulfate results in decreased expression of IL4 mRNA
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein; MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA]
Dextran Sulfate results in increased expression of IL4 protein

PMID:12105854 PMID:21068411 PMID:25777935 PMID:28438436

NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496

G

interleukin 4 receptor, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL4RA mRNA

NCBI chr 7:125,151,443...125,178,646
Ensembl chr 7:125,151,292...125,178,646

G

interleukin 6

multiple interactions
increases expression
affects expression
increases secretion

(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of IL6 protein]; Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Lipopolysaccharides affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; oxymatrine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of IL6 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]
Dextran Sulfate results in increased expression of IL6 mRNA; Dextran Sulfate results in increased expression of IL6 protein

PMID:15652231 PMID:16774945 PMID:19285099 PMID:19940103 PMID:20079348 More...

NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979

G

interleukin 6 signal transducer

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL6ST mRNA

NCBI chr13:112,600,604...112,643,394
Ensembl chr13:112,600,604...112,646,620

G

interleukin 7 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL7R mRNA

NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262

G

integrin linked kinase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ILK protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ILK protein

NCBI chr 7:105,385,797...105,392,132
Ensembl chr 7:105,385,799...105,392,132

G

inhibin beta-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA

NCBI chr13:16,178,841...16,206,194
Ensembl chr13:16,186,436...16,206,206

G

inhibin beta-B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBB mRNA

NCBI chr 1:119,343,193...119,349,978
Ensembl chr 1:119,343,195...119,349,978

G

INO80 complex subunit B

increases expression

Dextran Sulfate results in increased expression of INO80B mRNA

NCBI chr 6:83,098,746...83,102,100
Ensembl chr 6:83,098,746...83,102,412

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INPP5D mRNA

NCBI chr 1:87,548,034...87,648,232
Ensembl chr 1:87,548,034...87,648,229

G

insulin-like 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INSL5 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of INSL5 protein]

PMID:29950665 PMID:32272095

NCBI chr 4:102,875,069...102,884,468
Ensembl chr 4:102,875,069...102,884,039

G

IQ motif and ankyrin repeat containing 1

increases expression

Dextran Sulfate results in increased expression of IQANK1 mRNA

NCBI chr15:75,881,320...75,918,830
Ensembl chr15:75,881,737...75,918,830

G

IQ motif containing D

increases expression

Dextran Sulfate results in increased expression of IQCD mRNA

NCBI chr 5:120,724,829...120,745,185
Ensembl chr 5:120,727,081...120,745,183

G

inositol 1,4,5-triphosphate receptor associated 1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IRAG1 protein]

NCBI chr 7:110,467,464...110,582,116
Ensembl chr 7:110,467,473...110,581,668

G

interleukin-1 receptor-associated kinase 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK1 protein

NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524

G

interleukin-1 receptor-associated kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRAK2 mRNA

NCBI chr 6:113,615,428...113,671,987
Ensembl chr 6:113,615,428...113,671,987

G

interleukin-1 receptor-associated kinase 4

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK4 protein

NCBI chr15:94,441,495...94,466,198
Ensembl chr15:94,441,524...94,479,696

G

immunity-related GTPase family M member 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of IRGM2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of IRGM2 protein]

NCBI chr11:58,105,803...58,113,609
Ensembl chr11:58,090,444...58,113,608

G

insulin receptor substrate 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRS1 mRNA

NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137

G

Iroquois homeobox 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRX6 mRNA

NCBI chr 8:93,400,917...93,407,584
Ensembl chr 8:93,400,916...93,407,584

G

integrin, alpha 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGA10 mRNA

NCBI chr 3:96,552,900...96,571,835
Ensembl chr 3:96,552,900...96,571,835

G

integrin alpha 2b

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA2B mRNA

NCBI chr11:102,344,134...102,360,570
Ensembl chr11:102,344,123...102,360,948

G

integrin alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA4 mRNA

NCBI chr 2:79,084,767...79,163,458
Ensembl chr 2:79,085,770...79,163,467

G

integrin alpha 5 (fibronectin receptor alpha)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA5 mRNA

NCBI chr15:103,252,713...103,275,218
Ensembl chr15:103,252,713...103,275,190

G

integrin alpha 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA6 mRNA

NCBI chr 2:71,617,236...71,688,761
Ensembl chr 2:71,575,960...71,688,760

G

integrin alpha L

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA]

NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310

G

integrin beta 1 (fibronectin receptor beta)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB1 mRNA

NCBI chr 8:129,412,135...129,460,060
Ensembl chr 8:129,412,135...129,459,681

G

integrin beta 2

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITGB2 protein]

PMID:29950665 PMID:32272095

NCBI chr10:77,366,164...77,401,542
Ensembl chr10:77,366,086...77,401,542

G

integrin beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB3 mRNA

NCBI chr11:104,498,826...104,561,302
Ensembl chr11:104,498,826...104,561,302

G

integrin beta 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGB6 mRNA

NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987

G

integrin beta 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB8 mRNA

NCBI chr12:119,121,757...119,202,891
Ensembl chr12:119,121,757...119,202,537

G

inter-alpha trypsin inhibitor, heavy chain 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ITIH1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH1 protein]

NCBI chr14:30,651,137...30,665,246
Ensembl chr14:30,651,137...30,665,246

G

inter-alpha trypsin inhibitor, heavy chain 3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH3 protein

NCBI chr14:30,630,529...30,645,748
Ensembl chr14:30,630,529...30,645,717

G

inter alpha-trypsin inhibitor, heavy chain 4

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ITIH4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ITIH4 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ITIH4 protein]

PMID:32272095 PMID:35999755

NCBI chr14:30,608,433...30,623,943
Ensembl chr14:30,608,433...30,624,310

G

inter-alpha-trypsin inhibitor, heavy chain 5

decreases expression

Dextran Sulfate results in decreased expression of ITIH5 mRNA

NCBI chr 2:10,158,354...10,261,340
Ensembl chr 2:10,158,382...10,261,340

G

inositol 1,4,5-trisphosphate 3-kinase A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPKA mRNA

NCBI chr 2:119,572,818...119,581,734
Ensembl chr 2:119,572,818...119,581,744

G

inositol 1,4,5-triphosphate receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPR3 mRNA

NCBI chr17:27,275,976...27,341,197
Ensembl chr17:27,276,278...27,341,197

G

Janus kinase 2

multiple interactions
increases phosphorylation

Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]

NCBI chr19:29,229,006...29,290,495
Ensembl chr19:29,229,228...29,290,480

G

junction adhesion molecule 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM2 mRNA

NCBI chr16:84,571,011...84,623,268
Ensembl chr16:84,571,011...84,622,816

G

junction adhesion molecule 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM3 mRNA

NCBI chr 9:27,008,680...27,066,739
Ensembl chr 9:27,008,680...27,066,717

G

junction adhesion molecule like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAML mRNA

NCBI chr 9:44,990,451...45,019,829
Ensembl chr 9:44,990,481...45,019,832

G

immunoglobulin joining chain

decreases expression

Dextran Sulfate results in decreased expression of JCHAIN mRNA

NCBI chr 5:88,667,663...88,675,667
Ensembl chr 5:88,667,668...88,675,750

G

Josephin domain containing 2

increases expression

Dextran Sulfate results in increased expression of JOSD2 mRNA

NCBI chr 7:44,117,404...44,121,082
Ensembl chr 7:44,117,404...44,121,086

G

jun proto-oncogene

multiple interactions

Dextran Sulfate results in increased expression of and affects the localization of JUN protein; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of JUN protein]

NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459

G

kalirin, RhoGEF kinase

decreases expression

Dextran Sulfate results in decreased expression of KALRN protein

NCBI chr16:33,789,443...34,393,647
Ensembl chr16:33,789,443...34,393,902

G

KASH domain containing 5

increases expression

Dextran Sulfate results in increased expression of KASH5 mRNA

NCBI chr 7:44,833,043...44,854,344
Ensembl chr 7:44,833,048...44,854,316

G

potassium voltage-gated channel, shaker-related subfamily, beta member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNAB1 mRNA

NCBI chr 3:64,856,636...65,285,643
Ensembl chr 3:64,856,617...65,285,644

G

potassium voltage-gated channel, Isk-related subfamily, gene 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNE3 mRNA

NCBI chr 7:99,825,714...99,834,076
Ensembl chr 7:99,825,709...99,834,076

G

potassium voltage-gated channel, subfamily H (eag-related), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNH2 mRNA

NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602

G

potassium inwardly-rectifying channel, subfamily J, member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNJ9 mRNA

NCBI chr 1:172,148,075...172,156,889
Ensembl chr 1:172,148,068...172,156,885

G

potassium channel, subfamily K, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNK4 mRNA

NCBI chr19:6,903,030...6,912,261
Ensembl chr19:6,901,334...6,911,883

G

potassium channel, subfamily K, member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNK5 mRNA

NCBI chr14:20,190,125...20,231,850
Ensembl chr14:20,190,125...20,231,877

G

KH domain containing 1A

increases expression

Dextran Sulfate results in increased expression of KHDC1A mRNA

NCBI chr 1:21,419,901...21,422,423
Ensembl chr 1:21,419,865...21,422,424

G

KiSS-1 metastasis-suppressor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KISS1 mRNA

NCBI chr 1:133,249,625...133,257,460
Ensembl chr 1:133,237,565...133,257,460
Ensembl chr 1:133,237,565...133,257,460

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KIT mRNA
Dextran Sulfate results in decreased expression of KIT mRNA

PMID:29950665 PMID:35093514

NCBI chr 5:75,735,647...75,817,382
Ensembl chr 5:75,735,576...75,817,382

G

kit ligand

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KITL mRNA

NCBI chr10:99,851,477...99,936,278
Ensembl chr10:99,851,492...99,936,278

G

klotho beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KLB mRNA

NCBI chr 5:65,505,754...65,544,300
Ensembl chr 5:65,505,657...65,541,350

G

kinesin light chain 3

increases expression

Dextran Sulfate results in increased expression of KLC3 mRNA

NCBI chr 7:19,128,365...19,138,101
Ensembl chr 7:19,128,362...19,138,029

G

kallikrein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1 mRNA

NCBI chr 7:43,874,784...43,879,046
Ensembl chr 7:43,874,784...43,879,042

G

kallikrein 1-related peptidase b21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B21 mRNA

NCBI chr 7:43,654,040...43,756,007
Ensembl chr 7:43,751,752...43,756,007

G

kallikrein 1-related peptidase b22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B22 mRNA

NCBI chr 7:43,762,097...43,766,346
Ensembl chr 7:43,762,097...43,766,346

G

kallikrein 1-related peptidase b24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B24 mRNA

NCBI chr 7:43,837,658...43,841,879
Ensembl chr 7:43,837,660...43,841,879

G

kallikrein 1-related petidase b26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B26 mRNA

NCBI chr 7:43,662,102...43,666,393
Ensembl chr 7:43,661,592...43,666,392

G

kallikrein 1-related peptidase b27

decreases expression

Dextran Sulfate results in decreased expression of KLK1B27 mRNA

NCBI chr 7:43,701,714...43,706,136
Ensembl chr 7:43,701,714...43,706,136

G

kallikrein 1-related peptidase b3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B3 mRNA

NCBI chr 7:43,847,615...43,851,775
Ensembl chr 7:43,847,615...43,851,776

G

kallikrein 1-related pepidase b4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B4 mRNA

NCBI chr 7:43,856,857...43,861,178
Ensembl chr 7:43,856,859...43,861,178

G

kallikrein 1-related peptidase b5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B5 mRNA

NCBI chr 7:43,865,898...43,870,127
Ensembl chr 7:43,865,369...43,870,127

G

kallikrein 1-related peptidase b8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B8 mRNA

NCBI chr 7:43,600,090...43,604,368
Ensembl chr 7:43,600,088...43,604,365

G

killer cell lectin-like receptor, subfamily A, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KLRA4 mRNA

NCBI chr 6:130,020,693...130,044,242
Ensembl chr 6:130,020,694...130,044,234

G

karyopherin subunit alpha 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of KPNA1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of KPNA1 protein]

NCBI chr16:35,803,693...35,859,479
Ensembl chr16:35,799,120...35,857,501

G

Kirsten rat sarcoma viral oncogene homolog

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of KRAS protein]

PMID:29950665 PMID:32272095

NCBI chr 6:145,162,425...145,197,631
Ensembl chr 6:145,162,425...145,195,965

G

keratin 16

decreases expression

Dextran Sulfate results in decreased expression of KRT16 protein

NCBI chr11:100,136,917...100,139,728
Ensembl chr11:100,136,917...100,139,728

G

L1 cell adhesion molecule

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of L1CAM mRNA
Dextran Sulfate results in decreased expression of L1CAM protein

PMID:29950665 PMID:35999755

NCBI chr X:72,897,384...72,924,843
Ensembl chr X:72,897,384...72,939,711

G

laminin, alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMA5 mRNA

NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652

G

laminin, beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMB2 mRNA

NCBI chr 9:108,357,080...108,367,729
Ensembl chr 9:108,356,935...108,367,729

G

laminin, beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LAMB3 mRNA

NCBI chr 1:192,976,661...193,026,186
Ensembl chr 1:192,890,007...193,026,186

G

laminin, gamma 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMC1 mRNA

NCBI chr 1:153,094,668...153,208,532
Ensembl chr 1:153,094,668...153,208,532

G

laminin gamma 3

decreases expression

Dextran Sulfate results in decreased expression of LAMC3 mRNA

NCBI chr 2:31,777,293...31,839,095
Ensembl chr 2:31,777,303...31,836,551

G

lysosomal-associated protein transmembrane 5

increases expression

Dextran Sulfate results in increased expression of LAPTM5 mRNA

NCBI chr 4:130,640,627...130,663,459
Ensembl chr 4:130,640,436...130,663,452

G

La ribonucleoprotein 1, translational regulator

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LARP1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of LARP1 protein]

NCBI chr11:57,899,711...57,952,860
Ensembl chr11:57,899,890...57,952,860

G

LIM and SH3 protein 1

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LASP1 protein
Dextran Sulfate results in decreased expression of LASP1 protein

NCBI chr11:97,689,748...97,729,591
Ensembl chr11:97,689,826...97,729,590

G

linker for activation of T cells family, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAT2 mRNA

NCBI chr 5:134,628,957...134,648,637
Ensembl chr 5:134,628,876...134,643,879

G

layilin

decreases expression

Dextran Sulfate results in decreased expression of LAYN protein

NCBI chr 9:50,966,323...50,988,501
Ensembl chr 9:50,965,940...50,988,394

G

lipocalin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of LCN2 mRNA
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]

PMID:23894361 PMID:36519841

NCBI chr 2:32,274,649...32,277,751
Ensembl chr 2:32,274,645...32,278,264

G

lactase

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of LCT protein
Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in decreased activity of LCT protein]

NCBI chr 1:128,212,493...128,256,055
Ensembl chr 1:128,212,493...128,256,055

G

lactate dehydrogenase A

decreases expression

Dextran Sulfate results in decreased expression of LDHA protein

NCBI chr 7:46,491,698...46,505,051
Ensembl chr 7:46,490,899...46,505,051

G

lactate dehydrogenase A-like 6B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LDHAL6B mRNA

NCBI chr17:5,467,598...5,469,042
Ensembl chr17:5,467,598...5,469,042

G

lactate dehydrogenase B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LDHB mRNA

NCBI chr 6:142,435,975...142,453,683
Ensembl chr 6:142,435,975...142,453,683

G

lactate dehydrogenase C

increases activity
multiple interactions

Dextran Sulfate results in increased activity of LDHC protein
gingerol inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of LDHC protein]

NCBI chr 7:46,510,687...46,527,571
Ensembl chr 7:46,510,627...46,527,566

G

lymphoid enhancer binding factor 1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein]

NCBI chr 3:130,903,972...131,018,006
Ensembl chr 3:130,904,120...131,018,005

G

leukocyte receptor cluster (LRC) member 1

increases expression

Dextran Sulfate results in increased expression of LENG1 mRNA

NCBI chr 7:3,663,106...3,668,839
Ensembl chr 7:3,663,097...3,668,839

G

leptin

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP protein

NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LGR4 mRNA

NCBI chr 2:109,747,919...109,844,602
Ensembl chr 2:109,747,992...109,844,602

G

leucine-rich repeat-containing G protein-coupled receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LGR6 mRNA

NCBI chr 1:134,911,038...135,033,112
Ensembl chr 1:134,911,039...135,033,014

G

luteinizing hormone beta

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LHB protein
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of LHB protein]

NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of LHCGR mRNA
Dextran Sulfate results in decreased expression of LHCGR mRNA

PMID:29950665 PMID:35093514

NCBI chr17:89,023,812...89,099,487
Ensembl chr17:89,023,909...89,099,418

G

LIM domain kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LIMK1 mRNA

NCBI chr 5:134,684,893...134,718,713
Ensembl chr 5:134,684,893...134,717,452

G

LIM and senescent cell antigen-like domains 1

decreases expression

Dextran Sulfate results in decreased expression of LIMS1 protein

NCBI chr10:58,159,164...58,260,513
Ensembl chr10:58,159,288...58,260,513

G

lamin B2

increases expression

Dextran Sulfate results in increased expression of LMNB2 mRNA

NCBI chr10:80,737,197...80,754,079
Ensembl chr10:80,737,037...80,754,079

G

lysyl oxidase

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOX mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of LOX mRNA]

PMID:29950665 PMID:32033881 PMID:35093514

NCBI chr18:52,649,132...52,662,939
Ensembl chr18:52,649,139...52,662,939

G

lysyl oxidase-like 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOXL1 mRNA

NCBI chr 9:58,195,006...58,220,495
Ensembl chr 9:58,195,021...58,220,469

G

lysophosphatidic acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR2 mRNA

NCBI chr 8:70,275,215...70,283,752
Ensembl chr 8:70,275,079...70,283,752

G

lysophosphatidic acid receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LPAR3 mRNA

NCBI chr 3:145,926,716...145,991,969
Ensembl chr 3:145,926,718...145,991,941

G

lysophosphatidic acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR4 mRNA

NCBI chr X:105,964,231...105,977,505
Ensembl chr X:105,964,231...105,977,506

G

leucine-rich alpha-2-glycoprotein 1

increases expression

Dextran Sulfate results in increased expression of LRG1 mRNA

PMID:23894361 PMID:35093514

NCBI chr17:56,426,678...56,428,946
Ensembl chr17:56,426,678...56,429,001

G

low density lipoprotein receptor-related protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LRP1 mRNA

NCBI chr10:127,374,026...127,457,158
Ensembl chr10:127,374,030...127,457,017

G

low density lipoprotein receptor-related protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LRP2 mRNA

NCBI chr 2:69,254,679...69,416,373
Ensembl chr 2:69,254,684...69,416,409

G

low density lipoprotein receptor-related protein 5

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA]

NCBI chr19:3,634,825...3,736,574
Ensembl chr19:3,634,828...3,736,564

G

leucine rich repeat containing 61

increases expression

Dextran Sulfate results in increased expression of LRRC61 mRNA

NCBI chr 6:48,531,732...48,547,656
Ensembl chr 6:48,531,730...48,547,656

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

Dextran Sulfate results in increased expression of LSM4 mRNA

NCBI chr 8:71,124,663...71,131,402
Ensembl chr 8:71,125,898...71,131,402

G

lymphotoxin A

increases expression

Dextran Sulfate results in increased expression of LTA mRNA

NCBI chr17:35,422,141...35,424,568
Ensembl chr17:35,422,141...35,424,327

G

leukotriene A4 hydrolase

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of LTA4H protein

NCBI chr10:93,289,258...93,320,758
Ensembl chr10:93,289,273...93,320,737

G

leukotriene B4 receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTB4R1 mRNA

NCBI chr14:56,002,154...56,005,951
Ensembl chr14:56,003,419...56,005,951

G

latent transforming growth factor beta binding protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP3 mRNA

NCBI chr19:5,790,928...5,808,564
Ensembl chr19:5,790,932...5,808,560

G

latent transforming growth factor beta binding protein 4

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP4 mRNA
Dextran Sulfate results in decreased expression of LTBP4 mRNA

PMID:29950665 PMID:35093514

NCBI chr 7:27,004,566...27,039,142
Ensembl chr 7:27,004,561...27,037,117

G

lactotransferrin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of LTF protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of LTF protein

NCBI chr 9:110,848,360...110,871,834
Ensembl chr 9:110,848,339...110,871,835

G

lymphocyte antigen 6 family member D

decreases expression

Dextran Sulfate results in decreased expression of LY6D mRNA

NCBI chr15:74,633,905...74,635,416
Ensembl chr15:74,633,905...74,635,469

G

lymphocyte antigen 6 family member E

decreases expression

Dextran Sulfate results in decreased expression of LY6E mRNA

NCBI chr15:74,826,874...74,831,753
Ensembl chr15:74,826,900...74,831,752

G

lymphocyte antigen 86

increases expression

Dextran Sulfate results in increased expression of LY86 mRNA

NCBI chr13:37,529,276...37,603,012
Ensembl chr13:37,529,184...37,603,012

G

lysozyme 2

increases expression

Dextran Sulfate results in increased expression of LYZ2 mRNA

NCBI chr10:117,113,446...117,118,177
Ensembl chr10:117,113,236...117,118,226

G

v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)

increases expression

Dextran Sulfate results in increased expression of MAFF mRNA

NCBI chr15:79,230,813...79,243,278
Ensembl chr15:79,230,821...79,243,276

G

myelin-associated glycoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAG mRNA

NCBI chr 7:30,598,600...30,614,347
Ensembl chr 7:30,598,601...30,614,298

G

mesencephalic astrocyte-derived neurotrophic factor

decreases expression

Dextran Sulfate results in decreased expression of MANF protein

NCBI chr 9:106,765,952...106,769,137
Ensembl chr 9:106,715,511...106,769,178

G

monoamine oxidase A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MAOA mRNA

NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of and results in increased lipidation of MAP1LC3B protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of and results in increased lipidation of MAP1LC3B protein]

NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499

G

mitogen-activated protein kinase 1

multiple interactions
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK1 protein; resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK1 protein]

PMID:19931517 PMID:20155626

NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317

G

mitogen-activated protein kinase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAPK10 mRNA

NCBI chr 5:103,056,413...103,359,200
Ensembl chr 5:103,055,814...103,359,200

G

mitogen-activated protein kinase 3

multiple interactions
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK3 protein; resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MAPK3 protein]

PMID:19931517 PMID:20155626

NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991

G

microtubule-associated protein, RP/EB family, member 1

decreases expression

Dextran Sulfate results in decreased expression of MAPRE1 protein

NCBI chr 2:153,583,131...153,615,237
Ensembl chr 2:153,583,194...153,615,230

G

MBL associated serine protease 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MASP1 mRNA

NCBI chr16:23,261,778...23,340,127
Ensembl chr16:23,268,167...23,339,565

G

matrilin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MATN4 mRNA

NCBI chr 2:164,231,313...164,247,080
Ensembl chr 2:164,231,313...164,247,080

G

mitochondrial antiviral signaling protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MAVS protein]

NCBI chr 2:131,075,445...131,089,945
Ensembl chr 2:131,075,983...131,089,945

G

methyl-CpG binding domain protein 3

increases expression

Dextran Sulfate results in increased expression of MBD3 mRNA

NCBI chr10:80,228,373...80,235,365
Ensembl chr10:80,228,373...80,235,384

G

melanocortin 4 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MC4R mRNA

NCBI chr18:66,990,776...66,993,558
Ensembl chr18:66,990,775...66,993,577

G

minichromosome maintenance complex component 3

increases expression

Dextran Sulfate results in increased expression of MCM3 protein

NCBI chr 1:20,873,188...20,890,536
Ensembl chr 1:20,873,192...20,890,536

G

mast cell protease 1

increases expression

Dextran Sulfate results in increased expression of MCPT1 mRNA

NCBI chr14:56,255,421...56,257,848
Ensembl chr14:56,255,428...56,257,841

G

mast cell protease 2

increases expression

Dextran Sulfate results in increased expression of MCPT2 mRNA

NCBI chr14:56,259,041...56,282,092
Ensembl chr14:56,279,498...56,282,099

G

malate dehydrogenase 1, NAD (soluble)

decreases expression

Dextran Sulfate results in decreased expression of MDH1 protein

NCBI chr11:21,506,692...21,521,934
Ensembl chr11:21,506,692...21,522,367

G

midkine

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MDK mRNA

NCBI chr 2:91,760,149...91,762,348
Ensembl chr 2:91,760,150...91,762,642

G

malic enzyme 1, NADP(+)-dependent, cytosolic

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ME1 protein

NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006

G

meprin 1 alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1A mRNA

NCBI chr17:43,785,215...43,815,034
Ensembl chr17:43,785,215...43,813,703

G

meprin 1 beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1B mRNA

NCBI chr18:21,205,401...21,233,256
Ensembl chr18:21,194,980...21,233,256

G

mesoderm posterior 1

increases expression

Dextran Sulfate results in increased expression of MESP1 mRNA

NCBI chr 7:79,441,989...79,443,338
Ensembl chr 7:79,441,989...79,443,536

G

microfibrillar-associated protein 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP4 mRNA

NCBI chr11:61,376,257...61,379,536
Ensembl chr11:61,376,257...61,379,726

G

microfibrillar associated protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP5 mRNA

NCBI chr 6:122,490,543...122,506,249
Ensembl chr 6:122,482,804...122,506,249

G

milk fat globule EGF and factor V/VIII domain containing

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of MFGE8 mRNA

NCBI chr 7:78,783,516...78,798,808
Ensembl chr 7:78,783,516...78,798,808

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression
decreases expression

Dextran Sulfate results in increased expression of MFSD2A mRNA
Dextran Sulfate results in decreased expression of MFSD2A mRNA

PMID:23894361 PMID:35093514

NCBI chr 4:122,840,643...122,855,844
Ensembl chr 4:122,840,643...122,854,981

G

matrix Gla protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MGP mRNA

NCBI chr 6:136,849,433...136,852,821
Ensembl chr 6:136,849,433...136,852,821

G

microsomal glutathione S-transferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST2 mRNA

NCBI chr 3:51,544,179...51,590,096
Ensembl chr 3:51,567,781...51,590,098

G

microsomal glutathione S-transferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST3 mRNA

NCBI chr 1:167,199,535...167,221,410
Ensembl chr 1:167,199,535...167,221,410

G

macrophage migration inhibitory factor (glycosylation-inhibiting factor)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MIF mRNA
MIF protein affects the reaction [Dextran Sulfate results in decreased expression of IL4 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of IFNG mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr10:75,695,187...75,696,111
Ensembl chr10:75,695,187...75,696,074

G

myo-inositol oxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MIOX mRNA

NCBI chr15:89,218,676...89,221,210
Ensembl chr15:89,218,601...89,221,218

G

antigen identified by monoclonal antibody Ki 67

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein; berberrubine inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein]

PMID:19028472 PMID:34273909 PMID:37871880

NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090

G

mixed lineage kinase domain-like

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MLKL protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MLKL protein]

NCBI chr 8:112,037,879...112,065,081
Ensembl chr 8:112,038,429...112,064,809

G

membrane metallo endopeptidase

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MME mRNA
Dextran Sulfate results in decreased expression of MME mRNA

PMID:29950665 PMID:35093514

NCBI chr 3:63,202,632...63,291,134
Ensembl chr 3:63,148,958...63,293,451

G

matrix metallopeptidase 10

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MMP10 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP10 mRNA

PMID:20824662 PMID:29950665

NCBI chr 9:7,502,343...7,510,243
Ensembl chr 9:7,502,353...7,510,241

G

matrix metallopeptidase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP12 mRNA

NCBI chr 9:7,344,397...7,360,461
Ensembl chr 9:7,344,381...7,369,499

G

matrix metallopeptidase 13

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP13 mRNA; MIF protein affects the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP13 mRNA]

PMID:12105854 PMID:19285099 PMID:20824662 PMID:23894361 PMID:29950665

NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331

G

matrix metallopeptidase 14 (membrane-inserted)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP14 mRNA

NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821

G

matrix metallopeptidase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMP15 mRNA

NCBI chr 8:96,078,924...96,100,921
Ensembl chr 8:96,078,896...96,101,708

G

matrix metallopeptidase 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP19 mRNA

NCBI chr10:128,626,779...128,636,696
Ensembl chr10:128,626,779...128,636,693

G

matrix metallopeptidase 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MMP2 mRNA; Dextran Sulfate results in increased expression of MMP2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP2 mRNA; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP2 protein]

PMID:19285099 PMID:29950665

NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048

G

matrix metallopeptidase 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP23 mRNA

NCBI chr 4:155,735,111...155,738,982
Ensembl chr 4:155,735,112...155,737,841

G

matrix metallopeptidase 3

multiple interactions
increases expression

Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP3 mRNA]

PMID:19285099 PMID:20824662 PMID:32033881

NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975

G

matrix metallopeptidase 7

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA]

NCBI chr 9:7,692,095...7,699,587
Ensembl chr 9:7,692,091...7,699,587

G

matrix metallopeptidase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP8 mRNA

NCBI chr 9:7,558,430...7,568,487
Ensembl chr 9:7,558,457...7,568,486

G

matrix metallopeptidase 9

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP9 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of MMP9 protein]
Dextran Sulfate results in increased expression of MMP9 mRNA; Dextran Sulfate results in increased expression of MMP9 protein

PMID:19285099 PMID:27125760 PMID:29950665 PMID:30972795 PMID:32033881

NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770

G

methylmalonyl-Coenzyme A mutase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMUT mRNA

NCBI chr17:41,245,576...41,272,880
Ensembl chr17:41,245,576...41,272,879

G

myeloid nuclear differentiation antigen like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MNDAL mRNA

NCBI chr 1:173,684,786...173,708,038
Ensembl chr 1:173,676,692...173,708,447

G

meiosis-specific nuclear structural protein 1

increases expression

Dextran Sulfate results in increased expression of MNS1 mRNA

NCBI chr 9:72,345,276...72,366,036
Ensembl chr 9:72,345,293...72,369,307

G

MORN repeat containing 2

increases expression

Dextran Sulfate results in increased expression of MORN2 mRNA

NCBI chr17:80,597,626...80,613,130
Ensembl chr17:80,597,632...80,604,905

G

macrophage expressed gene 1

increases expression

Dextran Sulfate results in increased expression of MPEG1 mRNA

NCBI chr19:12,438,134...12,442,649
Ensembl chr19:12,438,143...12,442,649

G

mannose phosphate isomerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MPI mRNA

NCBI chr 9:57,448,744...57,460,095
Ensembl chr 9:57,451,539...57,460,046

G

megakaryocyte and platelet inhibitory receptor G6b

decreases expression

Dextran Sulfate results in decreased expression of MPIG6B protein

NCBI chr17:35,281,669...35,285,761
Ensembl chr17:35,281,669...35,285,160

G

myeloperoxidase

multiple interactions
increases expression
increases activity
increases secretion

Capsaicin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; lafutidine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Oligosaccharides inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; zileuton inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; 4-methylesculetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [Dextran Sulfate co-treated with Zearalenone] results in increased secretion of MPO protein; [Probenecid binds to Dextrans] inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [Streptozocin co-treated with Dextran Sulfate] results in increased activity of MPO protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; celastrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]]; HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; icilin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; morphiceptin analog inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; PNU-282987 inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; Tropisetron inhibits the reaction [Dextran Sulfate results in increased expression of MPO protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased secretion of MPO protein]

PMID:11766996 PMID:15339030 PMID:15573930 PMID:16375993 PMID:20637373 More...

NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239

G

mannose receptor, C type 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein]

NCBI chr 2:14,234,225...14,336,834
Ensembl chr 2:14,234,203...14,336,868

G

MAS-related GPR, member B4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRGPRB4 mRNA

NCBI chr 7:47,847,961...47,848,926
Ensembl chr 7:47,847,818...47,849,036

G

mitochondrial ribosomal protein L20

increases expression

Dextran Sulfate results in increased expression of MRPL20 mRNA

NCBI chr 4:155,887,335...155,893,288
Ensembl chr 4:155,887,335...155,894,432

G

membrane-spanning 4-domains, subfamily A, member 1

increases expression

Dextran Sulfate results in increased expression of MS4A1 mRNA

NCBI chr19:11,227,043...11,243,513
Ensembl chr19:11,227,039...11,243,605

G

methylsterol monoxygenase 1

decreases expression

Dextran Sulfate results in decreased expression of MSMO1 mRNA

NCBI chr 8:65,171,157...65,186,822
Ensembl chr 8:65,171,173...65,186,826

G

moesin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MSN mRNA

NCBI chr X:95,139,651...95,212,159
Ensembl chr X:95,139,648...95,212,158

G

NADH dehydrogenase 6, mitochondrial

increases expression

Dextran Sulfate results in increased expression of ND6 mRNA

NCBI chr MT:13,552...14,070
Ensembl chr MT:13,552...14,070

G

metallothionein 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MT1 mRNA
Dextran Sulfate results in increased expression of MT1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955

G

metallothionein 2

increases expression

Dextran Sulfate results in increased expression of MT2 mRNA

NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196

G

melatonin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1A mRNA

NCBI chr 8:45,522,144...45,542,270
Ensembl chr 8:45,522,174...45,541,543

G

melatonin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1B mRNA

NCBI chr 9:15,773,910...15,785,852
Ensembl chr 9:15,735,824...15,785,852

G

mechanistic target of rapamycin kinase

increases expression
multiple interactions
decreases phosphorylation

Dextran Sulfate results in increased expression of MTOR protein
CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]
Dextran Sulfate results in increased expression of MTOR protein modified form
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of MTOR protein modified form]

PMID:26074695 PMID:27611972 PMID:31926917 PMID:32470352

NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140

G

myotrophin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MTPN protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MTPN protein]

NCBI chr 6:35,485,759...35,516,823
Ensembl chr 6:35,485,841...35,516,823

G

mucin 13, epithelial transmembrane

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC13 mRNA

NCBI chr16:33,614,407...33,640,299
Ensembl chr16:33,614,407...33,640,304

G

mucin 2

decreases expression

Dextran Sulfate results in decreased expression of MUC2 mRNA

NCBI chr 7:141,276,583...141,308,428
Ensembl chr 7:141,276,583...141,308,430

G

mucin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC4 mRNA

NCBI chr16:32,555,089...32,602,786
Ensembl chr16:32,555,015...32,602,754

G

muscle, skeletal, receptor tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MUSK mRNA

NCBI chr 4:58,285,742...58,377,848
Ensembl chr 4:58,285,962...58,374,303

G

myosin binding protein C, slow-type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC1 mRNA

NCBI chr10:88,354,141...88,441,051
Ensembl chr10:88,354,141...88,441,014

G

myosin binding protein C, fast-type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC2 mRNA

NCBI chr 7:44,151,123...44,174,093
Ensembl chr 7:44,151,123...44,174,080

G

myosin binding protein C, cardiac

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC3 mRNA

NCBI chr 2:90,948,459...90,966,862
Ensembl chr 2:90,948,489...90,966,861

G

myelocytomatosis oncogene

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein]

NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223

G

myosin, heavy polypeptide 8, skeletal muscle, perinatal

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYH8 mRNA

NCBI chr11:67,167,950...67,199,460
Ensembl chr11:67,167,950...67,199,460

G

myosin, heavy polypeptide 9, non-muscle

decreases expression

Dextran Sulfate results in decreased expression of MYH9 protein

NCBI chr15:77,644,788...77,726,315
Ensembl chr15:77,644,787...77,726,375

G

myosin, light polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL1 mRNA

NCBI chr 1:66,963,454...66,987,091
Ensembl chr 1:66,963,454...66,984,563

G

myosin, light polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL3 mRNA

NCBI chr 9:110,592,746...110,598,870
Ensembl chr 9:110,570,929...110,598,866

G

myosin, light polypeptide 4

increases expression
multiple interactions

Dextran Sulfate results in increased expression of MYL4 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of MYL4 protein]

NCBI chr11:104,427,604...104,478,041
Ensembl chr11:104,441,489...104,486,579

G

myosin, light polypeptide 6, alkali, smooth muscle and non-muscle

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MYL6 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL6 protein

NCBI chr10:128,326,728...128,329,755
Ensembl chr10:128,326,729...128,330,014

G

myosin, light polypeptide 7, regulatory

increases expression

Dextran Sulfate results in increased expression of MYL7 mRNA

NCBI chr11:5,846,637...5,848,782
Ensembl chr11:5,846,637...5,848,782

G

myosin, light polypeptide 9, regulatory

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of MYL9 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of MYL9 protein

NCBI chr 2:156,617,373...156,623,578
Ensembl chr 2:156,617,340...156,623,578

G

myosin, light polypeptide kinase 2, skeletal muscle

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYLK2 mRNA

NCBI chr 2:152,753,265...152,764,985
Ensembl chr 2:152,753,272...152,764,988

G

myosin IB

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of MYO1B protein]

NCBI chr 1:51,788,915...51,955,143
Ensembl chr 1:51,788,924...51,955,230

G

myosin VB

decreases expression

Dextran Sulfate results in decreased expression of MYO5B mRNA

NCBI chr18:74,575,435...74,905,769
Ensembl chr18:74,574,007...74,904,564

G

myosin VIIA

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYO7A mRNA

NCBI chr 7:97,700,261...97,768,730
Ensembl chr 7:97,700,267...97,768,731

G

NEDD4 binding protein 3

increases expression

Dextran Sulfate results in increased expression of N4BP3 mRNA

NCBI chr11:51,533,908...51,541,664
Ensembl chr11:51,533,890...51,541,669

G

sodium leak channel, non-selective

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of NALCN mRNA

NCBI chr14:123,514,046...123,864,846
Ensembl chr14:123,514,046...123,864,556

G

N-acetylneuraminic acid synthase (sialic acid synthase)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NANS mRNA

NCBI chr 4:46,489,319...46,503,439
Ensembl chr 4:46,489,248...46,503,632

G

N-acyl phosphatidylethanolamine phospholipase D

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NAPEPLD protein
GR 113808 inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Granisetron inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]]; Serotonin promotes the reaction [Dextran Sulfate results in decreased expression of NAPEPLD protein]

NCBI chr 5:21,867,899...21,906,620
Ensembl chr 5:21,867,899...21,906,394

G

N-acetyltransferase 2 (arylamine N-acetyltransferase)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA

NCBI chr 8:67,947,527...67,955,296
Ensembl chr 8:67,947,510...67,955,236

G

N-acetyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of NAT3 mRNA

NCBI chr 8:67,976,506...68,001,279
Ensembl chr 8:67,976,506...68,001,279

G

neurocan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCAN mRNA

NCBI chr 8:70,545,735...70,573,494
Ensembl chr 8:70,545,735...70,573,523

G

neutral cholesterol ester hydrolase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCEH1 mRNA

NCBI chr 3:27,237,153...27,299,112
Ensembl chr 3:27,237,114...27,338,757

G

NCK interacting protein with SH3 domain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCKIPSD mRNA

NCBI chr 9:108,685,515...108,696,044
Ensembl chr 9:108,685,567...108,696,043

G

nuclear receptor co-repressor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCOR2 mRNA

NCBI chr 5:125,094,217...125,256,302
Ensembl chr 5:125,094,217...125,256,283

G

N-myc downstream regulated gene 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NDRG2 protein]

NCBI chr14:52,142,738...52,151,463
Ensembl chr14:52,142,728...52,151,615

G

NADH:ubiquinone oxidoreductase complex assembly factor 3

increases expression

Dextran Sulfate results in increased expression of NDUFAF3 mRNA

NCBI chr 9:108,442,786...108,444,635
Ensembl chr 9:108,442,736...108,444,633

G

nebulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NEB mRNA

NCBI chr 2:52,026,652...52,228,810
Ensembl chr 2:52,026,659...52,268,486

G

neural precursor cell expressed, developmentally down-regulated 4

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NEDD4 mRNA

NCBI chr 9:72,569,613...72,657,133
Ensembl chr 9:72,569,628...72,657,134

G

neurogenic differentiation 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NEUROD1 mRNA

NCBI chr 2:79,282,981...79,286,980
Ensembl chr 2:79,282,865...79,287,095

G

nuclear factor of activated T cells 5

increases activity
decreases expression

Dextran Sulfate results in increased activity of NFAT5 protein
Dextran Sulfate results in decreased expression of NFAT5 mRNA

PMID:27920257 PMID:35093514

NCBI chr 8:108,020,072...108,106,149
Ensembl chr 8:108,020,102...108,106,149

G

nuclear factor, erythroid derived 2, like 2

affects response to substance
decreases expression
multiple interactions

NFE2L2 affects the susceptibility to Dextran Sulfate
Dextran Sulfate results in decreased expression of NFE2L2 mRNA; Dextran Sulfate results in decreased expression of NFE2L2 protein
[asperuloside co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; [Cholecalciferol co-treated with Dextran Sulfate] results in increased expression of NFE2L2 protein; gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; NFE2L2 results in decreased susceptibility to [Dextran Sulfate co-treated with Azoxymethane]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in decreased expression of NFE2L2 protein]

PMID:20404090 PMID:23056183 PMID:23261717 PMID:30142311 PMID:30844440 More...

NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985

G

nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105

multiple interactions
affects localization

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein]
monotropein inhibits the reaction [Dextran Sulfate affects the localization of NFKB1 protein]

PMID:19028472 PMID:23261679

NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha

multiple interactions
increases expression
increases phosphorylation

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Dextran Sulfate results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of NFKBIA protein]

PMID:19940103 PMID:21724996 PMID:23261679 PMID:25472953 PMID:26190278 More...

NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432

G

nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor like 1

increases expression

Dextran Sulfate results in increased expression of NFKBIL1 mRNA

NCBI chr17:35,439,151...35,455,457
Ensembl chr17:35,439,151...35,454,768

G

neutrophilic granule protein

increases expression
multiple interactions
decreases expression

Dextran Sulfate results in increased expression of NGP protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NGP protein]
Dextran Sulfate results in decreased expression of NGP protein

PMID:32272095 PMID:35999755

NCBI chr 9:110,248,876...110,252,080
Ensembl chr 9:110,248,815...110,252,080

G

niban apoptosis regulator 1

decreases expression

Dextran Sulfate results in decreased expression of NIBAN1 mRNA

NCBI chr 1:151,447,215...151,597,690
Ensembl chr 1:151,446,937...151,597,690

G

nidogen 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NID2 mRNA

NCBI chr14:19,801,325...19,861,855
Ensembl chr14:19,801,333...19,861,855

G

naked cuticle 1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA]

NCBI chr 8:89,247,961...89,321,515
Ensembl chr 8:89,247,982...89,321,512

G

NK2 homeobox 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NKX2-2 mRNA

NCBI chr 2:146,967,909...147,037,270
Ensembl chr 2:147,019,466...147,036,163

G

neuroligin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN1 mRNA

NCBI chr 3:25,475,972...26,387,504
Ensembl chr 3:25,480,379...26,386,609

G

neuroligin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN3 mRNA

NCBI chr X:100,342,785...100,364,956
Ensembl chr X:100,342,774...100,369,569

G

neurolysin (metallopeptidase M3 family)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NLN protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NLN protein]

NCBI chr13:104,159,558...104,246,170
Ensembl chr13:104,159,565...104,246,122

G

NLR family, CARD domain containing 5

increases expression

Dextran Sulfate results in increased expression of NLRC5 mRNA

NCBI chr 8:95,160,963...95,253,900
Ensembl chr 8:95,160,984...95,253,900

G

NLR family, pyrin domain containing 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLRP1A mRNA

NCBI chr11:70,982,023...71,035,780
Ensembl chr11:70,983,062...71,035,530

G

NLR family, pyrin domain containing 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein
[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of NLRP3 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]]

PMID:27611972 PMID:30270565 PMID:32470352 PMID:37001609

NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782

G

neuromedin B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NMB mRNA

NCBI chr 7:80,551,975...80,554,810
Ensembl chr 7:80,551,975...80,554,824

G

NME/NM23 nucleoside diphosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of NME1 protein

NCBI chr11:93,849,751...93,859,341
Ensembl chr11:93,847,805...93,859,347

G

NME/NM23 nucleoside diphosphate kinase 2

decreases expression

Dextran Sulfate results in decreased expression of NME2 protein

NCBI chr11:93,840,640...93,847,082
Ensembl chr11:93,840,640...93,847,085

G

neuromedin U receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NMUR2 mRNA

NCBI chr11:55,915,816...55,931,813
Ensembl chr11:55,915,813...55,931,836

G

nitric oxide synthase 2, inducible

multiple interactions
affects response to substance
increases expression
increases activity

3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of NOS2 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA]
NOS2 protein affects the susceptibility to Dextran Sulfate
Dextran Sulfate results in increased expression of NOS2 mRNA; Dextran Sulfate results in increased expression of NOS2 protein

PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:17449036 More...

NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080

G

nitric oxide synthase 3, endothelial cell

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS3 mRNA

NCBI chr 5:24,569,772...24,589,472
Ensembl chr 5:24,569,808...24,589,472

G

notum palmitoleoyl-protein carboxylesterase

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA]

NCBI chr11:120,544,614...120,552,019
Ensembl chr11:120,544,614...120,552,001

G

NADPH oxidase 4

increases expression

Dextran Sulfate results in increased expression of NOX4 mRNA; Dextran Sulfate results in increased expression of NOX4 protein

NCBI chr 7:86,893,638...87,047,918
Ensembl chr 7:86,895,304...87,047,918

G

N-acetylneuraminate pyruvate lyase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of NPL protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NPL protein]

NCBI chr 1:153,378,762...153,425,460
Ensembl chr 1:153,378,761...153,425,791

G

neuronal pentraxin 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of NPTX1 mRNA

NCBI chr11:119,429,545...119,438,646
Ensembl chr11:119,429,545...119,438,579

G

neuropeptide Y

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY mRNA

NCBI chr 6:49,799,690...49,806,487
Ensembl chr 6:49,799,690...49,806,487

G

neuropeptide Y receptor Y1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY1R mRNA

NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444

G

neuropeptide Y receptor Y2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NPY2R mRNA

NCBI chr 3:82,445,688...82,455,404
Ensembl chr 3:82,445,690...82,455,391

G

NAD(P)H dehydrogenase, quinone 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NQO1 mRNA; Dextran Sulfate results in decreased expression of NQO1 protein
gingerenone A inhibits the reaction [Dextran Sulfate results in decreased expression of NQO1 protein]

NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1H4 mRNA

NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1I2 mRNA

NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR5A2 mRNA

NCBI chr 1:136,770,300...136,888,186
Ensembl chr 1:136,770,309...136,888,186

G

Nik related kinase

decreases expression

Dextran Sulfate results in decreased expression of NRK mRNA

NCBI chr X:137,814,980...137,911,281
Ensembl chr X:137,815,179...137,911,281

G

neuropilin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NRP1 mRNA

NCBI chr 8:129,085,553...129,231,957
Ensembl chr 8:129,085,085...129,229,844

G

netrin G1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NTNG1 mRNA

NCBI chr 3:109,687,366...110,057,291
Ensembl chr 3:109,687,356...110,051,327

G

neurotensin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NTS mRNA

NCBI chr10:102,317,617...102,326,294
Ensembl chr10:102,317,617...102,326,347

G

nucleobindin 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of NUCB1 protein

NCBI chr 7:45,142,300...45,159,813
Ensembl chr 7:45,139,882...45,159,830

G

nudC nuclear distribution protein

increases expression

Dextran Sulfate results in increased expression of NUDC mRNA

NCBI chr 4:133,259,853...133,273,338
Ensembl chr 4:133,259,853...133,273,307

G

nudix hydrolase 16

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of NUDT16 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of NUDT16 protein]

NCBI chr 9:105,006,531...105,010,332
Ensembl chr 9:105,006,102...105,009,023

G

nucleoporin 205

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of NUP205 protein]

NCBI chr 6:35,154,551...35,224,534
Ensembl chr 6:35,154,356...35,224,531

G

nuclear protein transcriptional regulator 2

increases expression

Dextran Sulfate results in increased expression of NUPR2 mRNA

NCBI chr 5:129,937,381...129,942,629
Ensembl chr 5:129,937,381...129,942,630

G

odorant binding protein IA

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of OBP1A protein

NCBI chr X:77,129,111...77,134,980
Ensembl chr X:77,129,111...77,134,980

G

occludin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of OCLN mRNA; Dextran Sulfate results in decreased expression of OCLN protein
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN mRNA]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of OCLN protein]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of OCLN protein]

PMID:23261717 PMID:27995407 PMID:35439472 PMID:35670535 PMID:36281492 More...

NCBI chr13:100,633,012...100,689,226
Ensembl chr13:100,633,015...100,689,226

G

olfactory receptor 100

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OLFR100 mRNA

G

opsin 1 (cone pigments), medium-wave-sensitive (color blindness, deutan)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPN1MW mRNA

NCBI chr X:73,171,072...73,194,362
Ensembl chr X:73,171,070...73,194,366

G

opioid receptor, delta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPRD1 mRNA

NCBI chr 4:131,834,980...131,872,042
Ensembl chr 4:131,838,037...131,871,797

G

opioid receptor, kappa 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OPRK1 mRNA

NCBI chr 1:5,658,673...5,676,357
Ensembl chr 1:5,658,689...5,676,354

G

olfactory receptor family 10 subfamily AD member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AD1 mRNA

NCBI chr15:98,100,192...98,118,937
Ensembl chr15:98,104,852...98,118,937

G

olfactory receptor family 10 subfamily AG member 57

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10AG57 mRNA

NCBI chr 2:87,218,051...87,219,031
Ensembl chr 2:87,216,193...87,222,274

G

olfactory receptor family 10 subfamily AL member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AL6 mRNA

NCBI chr17:38,079,533...38,083,511
Ensembl chr17:38,079,498...38,084,640

G

olfactory receptor family 10 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10B1 mRNA

NCBI chr10:78,334,017...78,357,117
Ensembl chr10:78,353,262...78,356,400

G

olfactory receptor family 10 subfamily D member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10D5 mRNA

NCBI chr 9:39,861,133...39,862,065
Ensembl chr 9:39,859,427...39,863,342

G

olfactory receptor family 10 subfamily H member 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10H28 mRNA

NCBI chr17:33,487,700...33,488,650
Ensembl chr17:33,483,650...33,494,618

G

olfactory receptor family 10 subfamily J member 3B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10J3 mRNA

NCBI chr 1:173,030,925...173,031,866
Ensembl chr 1:173,025,375...173,033,903

G

olfactory receptor family 10 subfamily V member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10V5 mRNA

NCBI chr19:11,805,441...11,806,388
Ensembl chr19:11,804,167...11,816,583

G

olfactory receptor family 11 subfamily A member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11A4 mRNA

NCBI chr17:37,535,982...37,537,032
Ensembl chr17:37,531,037...37,537,564

G

olfactory receptor family 11 subfamily G member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11G7 mRNA

NCBI chr14:50,690,511...50,693,135
Ensembl chr14:50,683,002...50,694,390

G

olfactory receptor family 11 subfamily M member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR11M3 mRNA

NCBI chr15:98,390,281...98,397,312
Ensembl chr15:98,390,283...98,400,518

G

olfactory receptor family 11 subfamily N member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11N2 mRNA

NCBI chr X:48,974,346...48,975,278
Ensembl chr X:48,971,868...48,980,360

G

olfactory receptor family 12 subfamily J member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR12J3 mRNA

NCBI chr 7:139,952,598...139,953,521
Ensembl chr 7:139,951,785...139,956,244

G

olfactory receptor family 12 subfamily K member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR12K5 mRNA

NCBI chr 2:36,894,632...36,895,624
Ensembl chr 2:36,892,175...36,899,347

G

olfactory receptor family 12 subfamily K member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR12K7 mRNA

NCBI chr 2:36,958,319...36,959,272
Ensembl chr 2:36,955,758...36,959,663

G

olfactory receptor family 13 subfamily A member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13A17 mRNA

NCBI chr 7:140,270,797...140,271,832
Ensembl chr 7:140,261,864...140,276,758

G

olfactory receptor family 13 subfamily A member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13A18 mRNA

NCBI chr 7:140,181,253...140,191,037
Ensembl chr 7:140,181,182...140,197,591

G

olfactory receptor family 13 subfamily A member 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13A20 mRNA

NCBI chr 7:140,226,365...140,232,832
Ensembl chr 7:140,226,365...140,232,998

G

olfactory receptor family 13 subfamily A member 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR13A24 mRNA

NCBI chr 7:140,154,068...140,155,000
Ensembl chr 7:140,147,799...140,155,706

G

olfactory receptor family 13 subfamily C member 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13C25 mRNA

NCBI chr 4:52,910,833...52,911,792
Ensembl chr 4:52,910,207...52,919,178

G

olfactory receptor family 13 subfamily L member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR13L2 mRNA

NCBI chr 3:97,317,533...97,318,495
Ensembl chr 3:97,314,766...97,329,336

G

olfactory receptor family 13 subfamily P member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR13P3 mRNA

NCBI chr 4:118,566,606...118,567,544
Ensembl chr 4:118,560,720...118,570,635

G

olfactory receptor family 13 subfamily P member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR13P5 mRNA

NCBI chr 4:118,591,728...118,592,675
Ensembl chr 4:118,589,372...118,594,103

G

olfactory receptor family 14 subfamily J member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR14J10 mRNA

NCBI chr17:37,934,559...37,935,524
Ensembl chr17:37,931,468...37,938,090

G

olfactory receptor family 14 subfamily J member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR14J7 mRNA

NCBI chr17:38,234,459...38,235,385
Ensembl chr17:38,231,439...38,237,692

G

olfactory receptor family 1 subfamily AD member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1AD1 mRNA

NCBI chr11:50,875,530...50,876,453
Ensembl chr11:50,872,794...50,877,420

G

olfactory receptor family 1 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1B1 mRNA

NCBI chr 2:36,994,707...36,995,660
Ensembl chr 2:36,991,718...37,007,922

G

olfactory receptor family 1 subfamily E member 1F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1E1F mRNA

NCBI chr11:73,855,436...73,856,383
Ensembl chr11:73,851,643...73,858,638

G

olfactory receptor family 1 subfamily E member 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1E26 mRNA

NCBI chr11:73,479,624...73,480,562
Ensembl chr11:73,479,128...73,483,834

G

olfactory receptor family 1 subfamily F member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1F19 mRNA

NCBI chr16:3,410,262...3,411,203
Ensembl chr16:3,408,906...3,417,187

G

olfactory receptor family 1 subfamily J member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1J10 mRNA

NCBI chr 2:36,266,790...36,267,710
Ensembl chr 2:36,263,531...36,272,445

G

olfactory receptor family 1 subfamily J member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1J13 mRNA

NCBI chr 2:36,369,199...36,370,140
Ensembl chr 2:36,363,733...36,372,480

G

olfactory receptor family 1 subfamily J member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1J15 mRNA

NCBI chr 2:36,458,612...36,459,541
Ensembl chr 2:36,456,674...36,466,190

G

olfactory receptor family 1 subfamily M member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1M1 mRNA

NCBI chr 9:18,665,988...18,666,929
Ensembl chr 9:18,662,803...18,675,292

G

olfactory receptor family 1 subfamily O member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1O2 mRNA

NCBI chr17:37,542,327...37,543,259
Ensembl chr17:37,541,854...37,548,221

G

olfactory receptor family 1 subfamily Q member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1Q1 mRNA

NCBI chr 2:36,886,824...36,887,750
Ensembl chr 2:36,883,839...36,891,859

G

olfactory receptor family 1 subfamily JRmember 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR1R1 mRNA

NCBI chr11:73,874,488...73,875,432
Ensembl chr11:73,870,793...73,881,233

G

olfactory receptor family 1 subfamily S member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR1S2 mRNA

NCBI chr19:13,757,912...13,758,978
Ensembl chr19:13,755,242...13,760,284

G

olfactory receptor family 2 subfamily A member 54

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2A54 mRNA

NCBI chr 6:43,092,678...43,093,610
Ensembl chr 6:43,083,303...43,094,737

G

olfactory receptor family 2 subfamily A member 57

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2A57 mRNA

NCBI chr 6:43,212,544...43,213,509
Ensembl chr 6:43,208,463...43,213,893

G

olfactory receptor family 2 subfamily AD member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AD1 mRNA

NCBI chr13:21,326,281...21,327,225
Ensembl chr13:21,326,052...21,330,037

G

olfactory receptor family 2 subfamily AG member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AG17 mRNA

NCBI chr 7:106,389,256...106,390,206
Ensembl chr 7:106,387,170...106,392,405

G

olfactory receptor family 2 subfamily AG member 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AG2 mRNA

NCBI chr 7:106,413,336...106,419,916
Ensembl chr 7:106,413,336...106,420,679

G

olfactory receptor family 2 subfamily AJ member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2AJ5 mRNA

NCBI chr16:19,424,475...19,425,416
Ensembl chr16:19,424,446...19,430,632

G

olfactory receptor family 2 subfamily AK member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR2AK4 mRNA

NCBI chr11:58,642,356...58,650,292
Ensembl chr11:58,643,560...58,650,497

G

olfactory receptor family 2 subfamily AV member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2AV9 mRNA

NCBI chr11:58,380,545...58,383,325
Ensembl chr11:58,378,776...58,383,381

G

olfactory receptor family 2 subfamily B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2B4 mRNA

NCBI chr17:38,115,960...38,117,081
Ensembl chr17:38,110,779...38,119,508

G

olfactory receptor family 2 subfamily B member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2B7 mRNA

NCBI chr13:21,739,210...21,740,190
Ensembl chr13:21,738,064...21,744,063

G

olfactory receptor family 2 subfamily D member 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR2D2B mRNA

NCBI chr 7:106,705,119...106,706,066
Ensembl chr 7:106,702,955...106,709,576

G

olfactory receptor family 2 subfamily D member 3B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2D3B mRNA

NCBI chr 7:106,507,332...106,514,330
Ensembl chr 7:106,507,208...106,515,472

G

olfactory receptor family 2 subfamily F member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2F2 mRNA

NCBI chr 6:42,766,975...42,767,928
Ensembl chr 6:42,762,027...42,768,553

G

olfactory receptor family 2 subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2G1 mRNA

NCBI chr17:38,106,337...38,107,266
Ensembl chr17:38,104,420...38,109,025

G

olfactory receptor family 2 subfamily L member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2L13 mRNA

NCBI chr16:19,305,590...19,306,528
Ensembl chr16:19,302,444...19,308,632

G

olfactory receptor family 2 subfamily L member 13B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2L13B mRNA

NCBI chr16:19,348,730...19,349,668
Ensembl chr16:19,348,024...19,354,305

G

olfactory receptor family 2 subfamily O member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2O1 mRNA

NCBI chr11:49,050,843...49,051,781
Ensembl chr11:49,045,204...49,053,681

G

olfactory receptor family 2 subfamily R member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2R11 mRNA

NCBI chr 6:42,437,010...42,437,951
Ensembl chr 6:42,436,913...42,442,130

G

olfactory receptor family 2 subfamily R member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2R3 mRNA

NCBI chr 6:42,448,169...42,449,110
Ensembl chr 6:42,444,949...42,453,269

G

olfactory receptor family 2 subfamily T member 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2T26 mRNA

NCBI chr11:49,039,086...49,040,039
Ensembl chr11:49,033,101...49,041,280

G

olfactory receptor family 2 subfamily T member 43

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2T43 mRNA

NCBI chr11:58,456,682...58,461,394
Ensembl chr11:58,456,682...58,461,379

G

olfactory receptor family 2 subfamily T member 48

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2T48 mRNA

NCBI chr11:58,419,755...58,425,651
Ensembl chr11:58,418,012...58,425,662

G

olfactory receptor family 2 subfamily V member 1

increases expression

Dextran Sulfate results in increased expression of OR2V1 mRNA

NCBI chr11:49,025,000...49,026,214
Ensembl chr11:48,941,560...49,026,214

G

olfactory receptor family 2 subfamily V member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2V2 mRNA

NCBI chr11:49,003,604...49,004,584
Ensembl chr11:49,000,809...49,005,701

G

olfactory receptor family 2 subfamily W member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2W4 mRNA

NCBI chr13:21,795,190...21,796,174
Ensembl chr13:21,795,148...21,798,192

G

olfactory receptor family 2 subfamily Y member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Y14 mRNA

NCBI chr11:49,404,445...49,405,478
Ensembl chr11:49,397,551...49,408,172

G

olfactory receptor family 2 subfamily Y member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Y15 mRNA

NCBI chr11:49,350,508...49,351,443
Ensembl chr11:49,346,170...49,354,828

G

olfactory receptor family 2 subfamily Y member 1G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2Y1G mRNA

NCBI chr11:49,154,700...49,183,186
Ensembl chr11:49,169,131...49,173,596

G

olfactory receptor family 2 subfamily Z member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2Z8 mRNA

NCBI chr 8:72,811,504...72,812,519
Ensembl chr 8:72,795,062...72,814,474

G

olfactory receptor family 2 subfamily Z member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Z9 mRNA

NCBI chr 8:72,853,606...72,854,550
Ensembl chr 8:72,837,021...72,856,928

G

olfactory receptor family 3 subfamily A member 1D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR3A1D mRNA

NCBI chr11:74,237,450...74,238,498
Ensembl chr11:74,235,955...74,243,476

G

olfactory receptor family 3 subfamily A member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR3A4 mRNA

NCBI chr11:73,944,602...73,945,604
Ensembl chr11:73,943,953...73,947,441

G

olfactory receptor family 4 subfamily B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4B1B mRNA

NCBI chr 2:90,111,991...90,112,917
Ensembl chr 2:90,110,607...90,123,185

G

olfactory receptor family 4 subfamily B member 1D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4B1D mRNA

NCBI chr 2:89,968,425...89,980,334
Ensembl chr 2:89,966,617...89,972,640

G

olfactory receptor family 4 subfamily C member 10B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C10B mRNA

NCBI chr 2:89,709,708...89,712,147
Ensembl chr 2:89,708,781...89,713,370

G

olfactory receptor family 4 subfamily C member 112

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C112 mRNA

NCBI chr 2:88,853,339...88,854,443
Ensembl chr 2:88,851,680...88,862,409

G

olfactory receptor family 4 subfamily C member 113

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C113 mRNA

NCBI chr 2:88,884,833...88,885,768
Ensembl chr 2:88,882,640...88,891,531

G

olfactory receptor family 4 subfamily C member 117

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C117 mRNA

NCBI chr 2:88,955,138...88,956,073
Ensembl chr 2:88,953,229...88,963,398

G

olfactory receptor family 4 subfamily C member 121

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR4C121 mRNA

NCBI chr 2:89,023,444...89,024,376
Ensembl chr 2:89,019,183...89,030,392

G

olfactory receptor family 4 subfamily C member 123

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C123 mRNA

NCBI chr 2:89,126,695...89,127,612
Ensembl chr 2:89,126,695...89,127,612

G

olfactory receptor family 4 subfamily C member 124

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C124 mRNA

NCBI chr 2:89,155,587...89,156,522
Ensembl chr 2:89,155,333...89,160,019

G

olfactory receptor family 4 subfamily C member 127

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C127 mRNA

NCBI chr 2:89,832,752...89,833,666
Ensembl chr 2:89,830,489...89,838,635

G

olfactory receptor family 4 subfamily C member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C15 mRNA

NCBI chr 2:88,759,722...88,764,870
Ensembl chr 2:88,757,220...88,768,455

G

olfactory receptor family 4 subfamily C member 58

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C58 mRNA

NCBI chr 2:89,674,410...89,675,315
Ensembl chr 2:89,672,137...89,678,549

G

olfactory receptor family 4 subfamily E member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4E2 mRNA

NCBI chr14:52,687,850...52,688,859
Ensembl chr14:52,680,447...52,690,031

G

olfactory receptor family 4 subfamily E member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR4E5 mRNA

NCBI chr14:52,727,392...52,733,152
Ensembl chr14:52,726,248...52,733,206

G

olfactory receptor family 4 subfamily F member 14D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F14D mRNA

NCBI chr 2:111,960,216...111,961,160
Ensembl chr 2:111,957,341...111,965,322

G

olfactory receptor family 4 subfamily F member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F15 mRNA

NCBI chr 2:111,813,479...111,814,441
Ensembl chr 2:111,810,202...111,820,626

G

olfactory receptor family 4 subfamily F member 58

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F58 mRNA

NCBI chr 2:111,851,259...111,852,197
Ensembl chr 2:111,850,001...111,854,757

G

olfactory receptor family 4 subfamily G member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4G17 mRNA

NCBI chr 2:111,209,347...111,210,282
Ensembl chr 2:111,205,867...111,210,958

G

olfactory receptor family 4 subfamily K member 36

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4K36 mRNA

NCBI chr 2:111,144,295...111,204,476
Ensembl chr 2:111,144,362...111,156,348

G

olfactory receptor family 4 subfamily K member 44

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4K44 mRNA

NCBI chr 2:111,367,694...111,368,632
Ensembl chr 2:111,366,875...111,370,636

G

olfactory receptor family 4 subfamily N member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4N5 mRNA

NCBI chr14:50,131,715...50,139,398
Ensembl chr14:50,131,715...50,139,456

G

olfactory receptor family 4 subfamily P member 22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4P22 mRNA

NCBI chr 2:88,317,078...88,318,013
Ensembl chr 2:88,313,942...88,319,628

G

olfactory receptor family 4 subfamily Q member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4Q3 mRNA

NCBI chr14:50,582,833...50,583,897
Ensembl chr14:50,580,069...50,586,329

G

olfactory receptor family 4 subfamily Z member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4Z4 mRNA

NCBI chr19:12,076,066...12,077,001
Ensembl chr19:12,075,370...12,080,698

G

olfactory receptor family 51 subfamily A member 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51A25 mRNA

NCBI chr 7:102,372,739...102,373,695
Ensembl chr 7:102,372,414...102,376,698

G

olfactory receptor family 51 subfamily A member 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR51A39 mRNA

NCBI chr 7:102,362,662...102,363,618
Ensembl chr 7:102,361,358...102,368,277

G

olfactory receptor family 51 subfamily A member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A7 mRNA

NCBI chr 7:102,614,309...102,615,247
Ensembl chr 7:102,611,867...102,624,367

G

olfactory receptor family 51 subfamily A member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A8 mRNA

NCBI chr 7:102,549,549...102,550,593
Ensembl chr 7:102,543,784...102,550,917

G

olfactory receptor family 51 subfamily AA member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51AA2 mRNA

NCBI chr 7:103,187,468...103,188,439
Ensembl chr 7:103,186,429...103,191,924

G

olfactory receptor family 51 subfamily AA member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51AA5 mRNA

NCBI chr 7:103,166,618...103,167,589
Ensembl chr 7:103,165,672...103,170,053

G

olfactory receptor family 51 subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51B6 mRNA

NCBI chr 7:103,555,549...103,556,654
Ensembl chr 7:103,552,694...103,557,857

G

olfactory receptor family 51 subfamily D member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51D1 mRNA

NCBI chr 7:102,347,423...102,348,479
Ensembl chr 7:102,345,117...102,349,914

G

olfactory receptor family 51 subfamily E member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51E2 mRNA

NCBI chr 7:102,389,928...102,408,678
Ensembl chr 7:102,387,718...102,408,678

G

olfactory receptor family 51 subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51G1 mRNA

NCBI chr 7:102,633,428...102,634,369
Ensembl chr 7:102,630,815...102,638,531

G

olfactory receptor family 51 subfamily G member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51G2 mRNA

NCBI chr 7:102,622,259...102,623,197
Ensembl chr 7:102,620,387...102,625,150

G

olfactory receptor family 51 subfamily M member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51M1 mRNA

NCBI chr 7:103,564,269...103,579,873
Ensembl chr 7:103,578,032...103,578,991

G

olfactory receptor family 51 subfamily Q member 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51Q1C mRNA

NCBI chr 7:103,652,466...103,653,431
Ensembl chr 7:103,647,953...103,653,564

G

olfactory receptor family 51 subfamily V member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51V14 mRNA

NCBI chr 7:103,260,617...103,261,558
Ensembl chr 7:103,254,102...103,261,741

G

olfactory receptor family 52 subfamily AE member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR52AE7 mRNA

NCBI chr 7:103,119,248...103,120,198
Ensembl chr 7:103,119,084...103,120,565

G

olfactory receptor family 52 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR52B1 mRNA

NCBI chr 7:104,978,424...104,979,485
Ensembl chr 7:104,977,432...104,983,311

G

olfactory receptor family 52 subfamily E member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR52E8 mRNA

NCBI chr 7:104,621,683...104,625,202
Ensembl chr 7:104,622,103...104,628,333

G

olfactory receptor family 52 subfamily X member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR52X1 mRNA

NCBI chr 7:104,852,595...104,853,548
Ensembl chr 7:104,851,065...104,856,692

G

olfactory receptor family 5 subfamily AC member 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OLFR209 mRNA

NCBI chr16:59,181,587...59,182,603
Ensembl chr16:59,181,523...59,184,356

G

olfactory receptor family 5 subfamily AF member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5AF1 mRNA

NCBI chr11:58,721,982...58,722,908
Ensembl chr11:58,720,063...58,725,606

G

olfactory receptor family 5 subfamily AQ member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5AQ6 mRNA

NCBI chr 2:86,922,801...86,930,230
Ensembl chr 2:86,921,539...86,926,352

G

olfactory receptor family 5 subfamily AQ member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5AQ7 mRNA

NCBI chr 2:86,937,791...86,938,729
Ensembl chr 2:86,934,922...86,944,911

G

olfactory receptor family 5 subfamily B member 112

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5B112 mRNA

NCBI chr19:13,319,124...13,321,692
Ensembl chr19:13,316,226...13,320,936

G

olfactory receptor family 5 subfamily B member 123

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5B123 mRNA

NCBI chr19:13,596,528...13,597,475
Ensembl chr19:13,594,739...13,600,436

G

olfactory receptor family 5 subfamily B member 12B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5B12B mRNA

NCBI chr19:12,861,247...12,862,191
Ensembl chr19:12,861,219...12,862,219

G

olfactory receptor family 5 subfamily B member 94

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5B94 mRNA

NCBI chr19:12,651,543...12,652,607
Ensembl chr19:12,647,803...12,654,641

G

olfactory receptor family 5 subfamily C member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5C1 mRNA

NCBI chr 2:37,221,761...37,222,744
Ensembl chr 2:37,216,527...37,222,784

G

olfactory receptor family 5 subfamily D member 36

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5D36 mRNA

NCBI chr 2:87,900,709...87,901,751
Ensembl chr 2:87,900,161...87,902,174

G

olfactory receptor family 5 subfamily D member 41

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5D41 mRNA

NCBI chr 2:88,054,424...88,055,374
Ensembl chr 2:88,052,442...88,058,678

G

olfactory receptor family 5 subfamily D member 47

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5D47 mRNA

NCBI chr 2:87,804,051...87,805,007
Ensembl chr 2:87,804,051...87,805,007

G

olfactory receptor family 5 subfamily E member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5E1 mRNA

NCBI chr 7:108,354,065...108,354,994
Ensembl chr 7:108,350,180...108,356,007

G

olfactory receptor family 5 subfamily G member 27

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5G27 mRNA

NCBI chr 2:85,409,559...85,410,626
Ensembl chr 2:85,409,559...85,410,626

G

olfactory receptor family 5 subfamily H member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5H19 mRNA

NCBI chr16:58,856,143...58,860,112
Ensembl chr16:58,855,926...58,860,130

G

olfactory receptor family 5 subfamily H member 22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR5H22 mRNA

NCBI chr16:58,894,518...58,895,441
Ensembl chr16:58,887,503...58,898,368

G

olfactory receptor family 5 subfamily H member 26

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5H26 mRNA

NCBI chr16:58,987,575...58,992,475
Ensembl chr16:58,987,010...58,990,817

G

olfactory receptor family 5 subfamily H member 27, pseudogene 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OLFR197 mRNA

NCBI chr16:59,005,919...59,006,844
Ensembl chr16:59,005,582...59,010,291

G

olfactory receptor family 5 subfamily K member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5K3 mRNA

NCBI chr16:58,969,215...58,970,141
Ensembl chr16:58,967,409...58,971,140

G

olfactory receptor family 5 subfamily M member 13B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5M13B mRNA

NCBI chr 2:85,753,614...85,754,537
Ensembl chr 2:85,751,902...85,754,967

G

olfactory receptor family 5 subfamily M member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5M5 mRNA

NCBI chr 2:85,809,656...85,815,142
Ensembl chr 2:85,809,620...85,818,638

G

olfactory receptor family 5 subfamily P member 51

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P51 mRNA

NCBI chr 7:107,443,994...107,444,938
Ensembl chr 7:107,442,112...107,446,697

G

olfactory receptor family 5 subfamily P member 56

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5P56 mRNA

NCBI chr 7:107,589,574...107,590,506
Ensembl chr 7:107,585,900...107,591,930

G

olfactory receptor family 5 subfamily P member 58

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5P58 mRNA

NCBI chr 7:107,693,804...107,694,775
Ensembl chr 7:107,692,206...107,696,793

G

olfactory receptor family 5 subfamily P member 59

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5P59 mRNA

NCBI chr 7:107,702,518...107,703,465
Ensembl chr 7:107,700,056...107,705,151

G

olfactory receptor family 5 subfamily P member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P6 mRNA

NCBI chr 7:107,630,502...107,633,174
Ensembl chr 7:107,629,172...107,633,196

G

olfactory receptor family 5 subfamily P member 60

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5P60 mRNA

NCBI chr 7:107,723,503...107,724,468
Ensembl chr 7:107,719,898...107,726,656

G

olfactory receptor family 5 subfamily P member 76

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P76 mRNA

NCBI chr 7:108,122,211...108,123,155
Ensembl chr 7:108,120,032...108,124,272

G

olfactory receptor family 5 subfamily W member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5W11 mRNA

NCBI chr 2:87,458,809...87,459,738
Ensembl chr 2:87,457,448...87,460,547

G

olfactory receptor family 5 subfamily W member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5W18 mRNA

NCBI chr 2:87,632,735...87,633,679
Ensembl chr 2:87,630,936...87,634,618

G

olfactory receptor family 5 subfamily W member 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5W20 mRNA

NCBI chr 2:87,726,521...87,727,477
Ensembl chr 2:87,725,306...87,728,654

G

olfactory receptor family 5 subfamily W member 22

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5W22 mRNA

NCBI chr 2:87,362,379...87,363,302
Ensembl chr 2:87,362,140...87,363,397

G

olfactory receptor family 6 subfamily B member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6B13 mRNA

NCBI chr 7:139,781,299...139,785,192
Ensembl chr 7:139,778,412...139,785,877

G

olfactory receptor family 6 subfamily B member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6B3 mRNA

NCBI chr 1:92,438,770...92,446,237
Ensembl chr 1:92,434,088...92,446,383

G

olfactory receptor family 6 subfamily B member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6B9 mRNA

NCBI chr 7:106,555,191...106,556,141
Ensembl chr 7:106,552,458...106,563,144

G

olfactory receptor family 6 subfamily C member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C1B mRNA

NCBI chr10:129,272,683...129,273,621
Ensembl chr10:129,263,175...129,274,949

G

olfactory receptor family 6 subfamily C member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C2 mRNA

NCBI chr10:129,362,098...129,363,036
Ensembl chr10:129,357,661...129,364,222

G

olfactory receptor family 6 subfamily C member 211

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C211 mRNA

NCBI chr10:129,505,430...129,506,386
Ensembl chr10:129,502,858...129,509,734

G

olfactory receptor family 6 subfamily C member 216

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C216 mRNA

NCBI chr10:129,677,977...129,678,909
Ensembl chr10:129,677,287...129,681,963

G

olfactory receptor family 6 subfamily C member 217

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C217 mRNA

NCBI chr10:129,737,645...129,738,595
Ensembl chr10:129,736,439...129,741,736

G

olfactory receptor family 6 subfamily C member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C3 mRNA

NCBI chr10:129,308,563...129,309,498
Ensembl chr10:129,306,867...129,312,487

G

olfactory receptor family 6 subfamily C member 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C66 mRNA

NCBI chr10:129,460,993...129,461,928
Ensembl chr10:129,458,484...129,463,803

G

olfactory receptor family 6 subfamily C member 68

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR6C68 mRNA

NCBI chr10:129,157,494...129,158,432
Ensembl chr10:129,153,986...129,160,010

G

olfactory receptor family 6 subfamily C member 74

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C74 mRNA

NCBI chr10:129,869,497...129,870,429
Ensembl chr10:129,866,217...129,870,940

G

olfactory receptor family 6 subfamily C member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C8 mRNA

NCBI chr10:128,914,901...128,915,830
Ensembl chr10:128,910,694...128,918,779

G

olfactory receptor family 6 subfamily F member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6F2 mRNA

NCBI chr 7:139,756,017...139,756,970
Ensembl chr 7:139,753,130...139,758,671

G

olfactory receptor family 6 subfamily K member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6K4 mRNA

NCBI chr 1:173,964,312...173,965,259
Ensembl chr 1:173,959,083...173,965,823

G

olfactory receptor family 6 subfamily K member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6K6 mRNA

NCBI chr 1:173,944,657...173,945,580
Ensembl chr 1:173,940,777...173,948,728

G

olfactory receptor family 6 subfamily N member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6N2 mRNA

NCBI chr 1:173,896,866...173,897,819
Ensembl chr 1:173,894,171...173,899,839

G

olfactory receptor family 7 subfamily E member 174

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR7E174 mRNA

NCBI chr 9:20,009,922...20,012,986
Ensembl chr 9:20,009,922...20,016,050

G

olfactory receptor family 7 subfamily E member 178

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7E178 mRNA

NCBI chr 9:20,223,391...20,247,389
Ensembl chr 9:20,223,448...20,247,390

G

olfactory receptor family 7 subfamily G member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7G18 mRNA

NCBI chr 9:18,786,256...18,787,572
Ensembl chr 9:18,785,989...18,789,665

G

olfactory receptor family 7 subfamily G member 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7G25 mRNA

NCBI chr 9:19,159,653...19,160,759
Ensembl chr 9:19,154,252...19,163,283

G

olfactory receptor family 7 subfamily G member 29

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR7G29 mRNA

NCBI chr 9:19,286,237...19,287,175
Ensembl chr 9:19,284,964...19,289,965

G

olfactory receptor family 8 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8B1 mRNA

NCBI chr 9:38,399,327...38,400,262
Ensembl chr 9:38,398,381...38,402,856

G

olfactory receptor family 8 subfamily B member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR8B12 mRNA

NCBI chr 9:37,656,596...37,658,402
Ensembl chr 9:37,656,402...37,659,890

G

olfactory receptor family 8 subfamily B member 12B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8B12B mRNA

NCBI chr 9:37,683,933...37,684,936
Ensembl chr 9:37,683,153...37,685,755

G

olfactory receptor family 8 subfamily B member 12I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8B12I mRNA

NCBI chr 9:20,081,930...20,082,865
Ensembl chr 9:20,079,829...20,085,353

G

olfactory receptor family 8 subfamily B member 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8B1C mRNA

NCBI chr 9:38,384,045...38,384,977
Ensembl chr 9:38,382,403...38,388,309

G

olfactory receptor family 8 subfamily B member 42

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8B42 mRNA

NCBI chr 9:38,341,580...38,342,515
Ensembl chr 9:38,340,751...38,343,978

G

olfactory receptor family 8 subfamily B member 44

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8B44 mRNA

NCBI chr 9:38,409,967...38,410,899
Ensembl chr 9:38,407,097...38,411,178

G

olfactory receptor family 8 subfamily B member 46

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8B46 mRNA

NCBI chr 9:38,449,178...38,451,125
Ensembl chr 9:38,449,145...38,452,116

G

olfactory receptor family 8 subfamily B member 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8B50 mRNA

NCBI chr 9:38,517,763...38,518,713
Ensembl chr 9:38,516,398...38,522,274

G

olfactory receptor family 8 subfamily D member 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8D23 mRNA

NCBI chr 9:38,841,469...38,842,395
Ensembl chr 9:38,841,105...38,842,692

G

olfactory receptor family 8 subfamily D member 2D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8D2B mRNA

NCBI chr 9:38,788,474...38,789,400
Ensembl chr 9:38,788,422...38,789,472

G

olfactory receptor family 8 subfamily G member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G18 mRNA

NCBI chr 9:39,148,783...39,149,727
Ensembl chr 9:39,145,708...39,161,290

G

olfactory receptor family 8 subfamily G member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G2 mRNA

NCBI chr 9:39,821,101...39,822,024
Ensembl chr 9:39,818,632...39,824,028

G

olfactory receptor family 8 subfamily G member 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR8G28 mRNA

NCBI chr 9:39,169,016...39,169,975
Ensembl chr 9:39,168,165...39,188,114

G

olfactory receptor family 8 subfamily G member 30

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8G30 mRNA

NCBI chr 9:39,229,943...39,230,908
Ensembl chr 9:39,227,008...39,237,341

G

olfactory receptor family 8 subfamily G member 32

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G32 mRNA

NCBI chr 9:39,305,089...39,306,033
Ensembl chr 9:39,298,706...39,306,929

G

olfactory receptor family 8 subfamily G member 34

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G34 mRNA

NCBI chr 9:39,372,729...39,373,673
Ensembl chr 9:39,367,997...39,375,921

G

olfactory receptor family 8 subfamily G member 50

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G50 mRNA

NCBI chr 9:39,648,113...39,649,051
Ensembl chr 9:39,642,274...39,649,752

G

olfactory receptor family 8 subfamily G member 54

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G54 mRNA

NCBI chr 9:39,706,673...39,707,608
Ensembl chr 9:39,702,241...39,707,931

G

olfactory receptor family 8 subfamily K member 17

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8K17 mRNA

NCBI chr 2:86,066,215...86,067,177
Ensembl chr 2:86,064,295...86,070,633

G

olfactory receptor family 8 subfamily K member 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR8K28 mRNA

NCBI chr 2:86,285,672...86,286,613
Ensembl chr 2:86,285,672...86,286,613

G

olfactory receptor family 9 subfamily A member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR9A4 mRNA

NCBI chr 6:40,546,086...40,549,438
Ensembl chr 6:40,546,421...40,551,277

G

olfactory receptor family 9 subfamily G member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9G4 mRNA

NCBI chr 2:85,504,555...85,509,085
Ensembl chr 2:85,504,001...85,509,111

G

olfactory receptor family 9 subfamily I member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9I1B mRNA

NCBI chr19:13,896,386...13,897,336
Ensembl chr19:13,890,894...13,899,230

G

olfactory receptor family 9 subfamily S member 13

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR9S13 mRNA

NCBI chr 1:92,547,603...92,548,723
Ensembl chr 1:92,545,510...92,551,134

G

olfactory receptor family 9 subfamily S member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9S14 mRNA

NCBI chr 1:92,535,561...92,536,529
Ensembl chr 1:92,533,504...92,542,528

G

oncostatin M

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSM mRNA

NCBI chr11:4,186,831...4,191,027
Ensembl chr11:4,186,420...4,191,026

G

oncostatin M receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSMR mRNA

NCBI chr15:6,843,049...6,904,434
Ensembl chr15:6,843,058...6,904,450

G

oviductal glycoprotein 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of OVGP1 protein

NCBI chr 3:105,881,118...105,894,739
Ensembl chr 3:105,881,027...105,894,739

G

oxytocin receptor

decreases expression

Dextran Sulfate results in decreased expression of OXTR mRNA

NCBI chr 6:112,450,646...112,467,800
Ensembl chr 6:112,450,644...112,466,904

G

purinergic receptor P2X, ligand-gated ion channel, 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX5 mRNA

NCBI chr11:73,029,164...73,063,509
Ensembl chr11:73,051,247...73,063,511

G

purinergic receptor P2X, ligand-gated ion channel, 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX7 mRNA

NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495

G

pyrimidinergic receptor P2Y, G-protein coupled, 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of P2RY4 mRNA

NCBI chr X:99,631,964...99,638,533
Ensembl chr X:99,633,760...99,638,475

G

pyrimidinergic receptor P2Y, G-protein coupled, 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RY6 mRNA

NCBI chr 7:100,586,837...100,628,528
Ensembl chr 7:100,586,837...100,623,856

G

prolyl 3-hydroxylase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P3H3 mRNA

NCBI chr 6:124,818,052...124,834,680
Ensembl chr 6:124,818,052...124,834,715

G

prolyl 4-hydroxylase, beta polypeptide

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P4HB mRNA
Dextran Sulfate results in decreased expression of P4HB protein

PMID:29950665 PMID:35999755

NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079

G

poly(A) binding protein, nuclear 1

increases expression

Dextran Sulfate results in increased expression of PABPN1 mRNA

NCBI chr14:55,131,600...55,136,384
Ensembl chr14:55,129,957...55,135,626

G

phosphoprotein associated with glycosphingolipid microdomains 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAG1 mRNA

NCBI chr 3:9,752,539...9,898,744
Ensembl chr 3:9,752,539...9,898,739

G

p21 (RAC1) activated kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAK4 mRNA

NCBI chr 7:28,258,244...28,297,609
Ensembl chr 7:28,258,244...28,297,610

G

pantothenate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of PANK1 mRNA

NCBI chr19:34,784,335...34,862,420
Ensembl chr19:34,784,340...34,856,855

G

polyamine oxidase (exo-N4-amino)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAOX mRNA

NCBI chr 7:139,693,182...139,714,249
Ensembl chr 7:139,695,712...139,717,137

G

pregnancy-associated plasma protein A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAPPA mRNA

NCBI chr 4:65,041,993...65,276,776
Ensembl chr 4:65,042,411...65,275,746

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAPSS2 mRNA

NCBI chr19:32,573,072...32,644,587
Ensembl chr19:32,573,190...32,644,587

G

poly (ADP-ribose) polymerase family, member 1

increases cleavage
multiple interactions

Dextran Sulfate results in increased cleavage of PARP1 protein
[Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [Plant Extracts co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of PARP1 protein]

PMID:21989142 PMID:25449198

NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819

G

parvin, beta

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PARVB protein
Dextran Sulfate results in decreased expression of PARVB protein

NCBI chr15:84,116,244...84,199,890
Ensembl chr15:84,116,244...84,199,889

G

PRKC, apoptosis, WT1, regulator

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PAWR protein]

NCBI chr10:108,168,050...108,250,708
Ensembl chr10:108,167,982...108,250,101

G

paired box 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX4 mRNA

NCBI chr 6:28,442,333...28,449,339
Ensembl chr 6:28,442,333...28,449,352

G

paired box 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX6 mRNA

NCBI chr 2:105,499,241...105,528,755
Ensembl chr 2:105,499,245...105,527,709

G

propionyl Coenzyme A carboxylase, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCCB mRNA

NCBI chr 9:100,864,085...100,916,993
Ensembl chr 9:100,864,085...100,916,951

G

protocadherin gamma subfamily B, 1

decreases expression

Dextran Sulfate results in decreased expression of PCDHGB1 mRNA

NCBI chr18:37,813,325...37,974,923
Ensembl chr18:37,813,286...37,974,923

G

proliferating cell nuclear antigen

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]

PMID:17438113 PMID:19028472 PMID:34964214

NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234

G

PEST proteolytic signal containing nuclear protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PCNP protein]

NCBI chr16:55,835,870...55,851,590
Ensembl chr16:55,827,608...55,850,102

G

procollagen C-endopeptidase enhancer protein

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PCOLCE mRNA
Dextran Sulfate results in decreased expression of PCOLCE mRNA

PMID:29950665 PMID:35093514

NCBI chr 5:137,603,369...137,609,666
Ensembl chr 5:137,603,365...137,612,046

G

Purkinje cell protein 4-like 1

decreases expression

Dextran Sulfate results in decreased expression of PCP4L1 mRNA

NCBI chr 1:171,000,833...171,023,837
Ensembl chr 1:171,000,831...171,023,837

G

PDGFA associated protein 1

increases expression

Dextran Sulfate results in increased expression of PDAP1 mRNA

NCBI chr 5:145,065,580...145,076,835
Ensembl chr 5:145,065,579...145,077,048

G

programmed cell death 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDCD4 protein]

NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291

G

phosphodiesterase 10A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE10A mRNA

NCBI chr17:8,742,719...9,205,480
Ensembl chr17:8,744,204...9,205,480

G

phosphodiesterase 1A, calmodulin-dependent

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE1A mRNA

NCBI chr 2:79,664,797...80,026,862
Ensembl chr 2:79,664,797...79,959,802

G

phosphodiesterase 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE1C mRNA

NCBI chr 6:56,046,783...56,629,590
Ensembl chr 6:56,046,789...56,629,472

G

phosphodiesterase 2A, cGMP-stimulated

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE2A mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PDE2A protein]

PMID:29950665 PMID:32272095

NCBI chr 7:101,070,905...101,162,026
Ensembl chr 7:101,060,093...101,162,026
Ensembl chr 7:101,060,093...101,162,026

G

phosphodiesterase 3A, cGMP inhibited

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE3A mRNA

NCBI chr 6:141,194,995...141,452,588
Ensembl chr 6:141,194,995...141,453,174

G

phosphodiesterase 4A, cAMP specific

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4A mRNA

NCBI chr 9:21,076,998...21,124,544
Ensembl chr 9:21,073,005...21,124,544

G

phosphodiesterase 4B, cAMP specific

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4B mRNA; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]

PMID:29950665 PMID:30188895

NCBI chr 4:101,944,529...102,464,459
Ensembl chr 4:101,944,740...102,464,456

G

phosphodiesterase 7A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE7A mRNA

NCBI chr 3:19,277,272...19,365,486
Ensembl chr 3:19,277,272...19,365,486

G

phosphodiesterase 7B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE7B mRNA

NCBI chr10:20,272,798...20,600,824
Ensembl chr10:20,273,750...20,600,824

G

platelet derived growth factor, B polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFB mRNA

NCBI chr15:79,880,066...79,899,178
Ensembl chr15:79,880,075...79,899,178

G

platelet derived growth factor receptor, alpha polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRA mRNA

NCBI chr 5:75,311,988...75,358,867
Ensembl chr 5:75,312,953...75,358,876

G

platelet derived growth factor receptor, beta polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRB mRNA

NCBI chr18:61,178,194...61,218,139
Ensembl chr18:61,178,222...61,218,133

G

protein disulfide isomerase associated 3

decreases expression

Dextran Sulfate results in decreased expression of PDIA3 protein

NCBI chr 2:121,244,383...121,269,168
Ensembl chr 2:121,244,256...121,269,168

G

prodynorphin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDYN mRNA

NCBI chr 2:129,528,469...129,541,858
Ensembl chr 2:129,528,485...129,541,764

G

PDZK1 interacting protein 1

increases expression

Dextran Sulfate results in increased expression of PDZK1IP1 mRNA

NCBI chr 4:114,945,905...114,951,091
Ensembl chr 4:114,945,905...114,951,096

G

platelet/endothelial cell adhesion molecule 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PECAM1 protein

NCBI chr11:106,545,039...106,606,107
Ensembl chr11:106,545,043...106,641,454

G

platelet factor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PF4 mRNA

NCBI chr 5:90,920,362...90,921,242
Ensembl chr 5:90,920,294...90,921,242

G

profilin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PFN1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PFN1 protein

NCBI chr11:70,542,670...70,547,625
Ensembl chr11:70,542,676...70,545,470

G

profilin 3

increases expression

Dextran Sulfate results in increased expression of PFN3 mRNA

NCBI chr13:55,562,501...55,563,045
Ensembl chr13:55,562,501...55,563,045

G

phosphoglycerate mutase 1

decreases expression

Dextran Sulfate results in decreased expression of PGAM1 protein

NCBI chr19:41,900,310...41,907,104
Ensembl chr19:41,900,362...41,907,099

G

phosphoglycerate mutase 2

decreases expression

Dextran Sulfate results in decreased expression of PGAM2 protein

NCBI chr11:5,751,637...5,753,796
Ensembl chr11:5,751,640...5,753,733

G

placental growth factor

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PGF mRNA
Oligosaccharides inhibits the reaction [Dextran Sulfate results in decreased expression of PGF mRNA]

NCBI chr12:85,213,413...85,224,087
Ensembl chr12:85,213,409...85,224,564

G

phosphoglycerate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of PGK1 protein

NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305

G

6-phosphogluconolactonase

decreases expression

Dextran Sulfate results in decreased expression of PGLS protein

NCBI chr 8:72,044,828...72,048,911
Ensembl chr 8:72,044,820...72,053,736

G

phosphoglucomutase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM1 mRNA

NCBI chr 4:99,786,648...99,844,491
Ensembl chr 4:99,786,611...99,844,491

G

phosphoglucomutase 2

decreases expression

Dextran Sulfate results in decreased expression of PGM2 protein

NCBI chr 5:64,250,258...64,285,698
Ensembl chr 5:64,250,293...64,285,694

G

phosphoglucomutase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM3 mRNA

NCBI chr 9:86,423,997...86,453,927
Ensembl chr 9:86,436,430...86,453,895

G

phosphoglycolate phosphatase

increases expression

Dextran Sulfate results in increased expression of PGP mRNA

NCBI chr17:24,689,400...24,692,084
Ensembl chr17:24,689,366...24,692,084

G

phosphate regulating endopeptidase homolog, X-linked

increases expression

Dextran Sulfate results in increased expression of PHEX protein

NCBI chr X:155,945,071...156,198,282
Ensembl chr X:155,945,071...156,198,308

G

phosphorylase kinase alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKA1 mRNA

NCBI chr X:101,557,581...101,687,907
Ensembl chr X:101,557,581...101,687,852

G

phosphorylase kinase beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKB mRNA

NCBI chr 8:86,567,489...86,790,883
Ensembl chr 8:86,567,588...86,788,005

G

phosphoinositide-3-kinase adaptor protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PIK3AP1 mRNA

NCBI chr19:41,260,980...41,373,541
Ensembl chr19:41,260,816...41,373,541

G

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PIK3CA mRNA

NCBI chr 3:32,451,203...32,520,256
Ensembl chr 3:32,451,820...32,522,635

G

phosphoinositide-3-kinase regulatory subunit 5

increases expression

Dextran Sulfate results in increased expression of PIK3R5 protein

NCBI chr11:68,322,951...68,388,675
Ensembl chr11:68,322,947...68,388,675

G

protein kinase domain containing, cytoplasmic

decreases expression

Dextran Sulfate results in decreased expression of PKDCC mRNA

NCBI chr17:83,522,708...83,532,496
Ensembl chr17:83,522,721...83,532,499

G

pyruvate kinase liver and red blood cell

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PKLR mRNA

NCBI chr 3:89,043,429...89,054,122
Ensembl chr 3:89,043,449...89,054,091

G

plakophilin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PKP2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PKP2 protein]

NCBI chr16:16,031,209...16,090,576
Ensembl chr16:16,031,182...16,090,576

G

phospholipase A2, group X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G10 mRNA

NCBI chr16:13,532,921...13,548,863
Ensembl chr16:13,532,921...13,548,847

G

phospholipase A2, group XIIA

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G12A mRNA

NCBI chr 3:129,672,255...129,689,474
Ensembl chr 3:129,672,255...129,689,474

G

phospholipase A2, group XIIB

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G12B mRNA

NCBI chr10:59,239,242...59,257,798
Ensembl chr10:59,239,482...59,257,798

G

phospholipase A2, group IIA (platelets, synovial fluid)

increases expression

Dextran Sulfate results in increased expression of PLA2G2A mRNA

NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497

G

phospholipase A2, group IIC

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G2C mRNA

NCBI chr 4:138,452,636...138,471,886
Ensembl chr 4:138,452,103...138,473,443

G

phospholipase A2, group IIE

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2E mRNA

NCBI chr 4:138,605,253...138,610,125
Ensembl chr 4:138,605,253...138,610,128

G

phospholipase A2, group IIF

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2F mRNA

NCBI chr 4:138,477,842...138,484,932
Ensembl chr 4:138,477,844...138,484,937

G

phospholipase A2, group IVA (cytosolic, calcium-dependent)

multiple interactions
increases phosphorylation

tussilagone inhibits the reaction [Dextran Sulfate results in increased phosphorylation of PLA2G4A protein]

NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041

G

phospholipase A2, group IVC (cytosolic, calcium-independent)

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PLA2G4C protein]

NCBI chr 7:13,045,432...13,094,597
Ensembl chr 7:13,058,580...13,094,597

G

phospholipase A2, group IVF

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G4F mRNA

NCBI chr 2:120,130,433...120,144,646
Ensembl chr 2:120,130,438...120,144,646

G

plasminogen activator, tissue

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAT mRNA

NCBI chr 8:23,247,655...23,272,864
Ensembl chr 8:23,247,743...23,272,860

G

plasminogen activator, urokinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAU mRNA

NCBI chr14:20,886,730...20,893,456
Ensembl chr14:20,886,728...20,893,453

G

plasminogen activator, urokinase receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAUR mRNA

NCBI chr 7:24,161,857...24,175,393
Ensembl chr 7:24,161,909...24,175,393

G

phospholipase C, beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLCB2 mRNA

NCBI chr 2:118,535,484...118,559,140
Ensembl chr 2:118,537,998...118,558,919

G

phospholipase C, beta 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCB4 mRNA

NCBI chr 2:135,500,523...135,856,522
Ensembl chr 2:135,500,931...135,856,513

G

phospholipase C, epsilon 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCE1 mRNA

NCBI chr19:38,469,438...38,773,549
Ensembl chr19:38,469,557...38,773,474

G

phospholipase D family member 3

decreases expression

Dextran Sulfate results in decreased expression of PLD3 mRNA

NCBI chr 7:27,231,090...27,252,511
Ensembl chr 7:27,231,425...27,252,643

G

pleckstrin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLEK mRNA

NCBI chr11:16,921,206...16,958,718
Ensembl chr11:16,921,206...17,002,381

G

plasminogen

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLG mRNA

NCBI chr17:12,597,496...12,638,271
Ensembl chr17:12,597,495...12,638,272

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA

NCBI chr 9:92,421,828...92,490,481
Ensembl chr 9:92,424,276...92,490,481

G

plastin 1 (I-isoform)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PLS1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PLS1 protein

NCBI chr 9:95,634,695...95,727,359
Ensembl chr 9:95,634,695...95,727,364

G

phospholipid transfer protein

decreases expression

Dextran Sulfate results in decreased expression of PLTP mRNA

NCBI chr 2:164,681,441...164,699,564
Ensembl chr 2:164,681,438...164,699,631

G

plexin A1

decreases expression

Dextran Sulfate results in decreased expression of PLXNA1 mRNA

NCBI chr 6:89,293,295...89,339,595
Ensembl chr 6:89,293,296...89,339,602

G

plexin C1

decreases expression

Dextran Sulfate results in decreased expression of PLXNC1 mRNA

NCBI chr10:94,626,728...94,780,875
Ensembl chr10:94,626,728...94,780,697

G

plexin D1

decreases expression

Dextran Sulfate results in decreased expression of PLXND1 mRNA

NCBI chr 6:115,931,772...115,972,300
Ensembl chr 6:115,931,772...115,971,966

G

premelanosome protein

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PMEL protein

NCBI chr10:128,531,757...128,555,993
Ensembl chr10:128,540,064...128,556,107

G

phosphomannomutase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PMM2 mRNA

NCBI chr16:8,455,467...8,475,472
Ensembl chr16:8,455,538...8,480,331

G

pancreatic lipase related protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PNLIPRP1 mRNA

NCBI chr19:58,717,319...58,732,601
Ensembl chr19:58,717,319...58,732,601

G

purine-nucleoside phosphorylase 2

decreases expression

Dextran Sulfate results in decreased expression of PNP2 mRNA

NCBI chr14:51,193,598...51,202,206
Ensembl chr14:51,193,449...51,202,206

G

polyribonucleotide nucleotidyltransferase 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PNPT1 protein]

NCBI chr11:29,080,236...29,112,010
Ensembl chr11:29,080,744...29,111,828

G

podocalyxin-like

decreases expression

Dextran Sulfate results in decreased expression of PODXL mRNA

NCBI chr 6:31,496,428...31,540,872
Ensembl chr 6:31,496,423...31,540,916

G

paraoxonase 3

decreases expression

Dextran Sulfate results in decreased expression of PON3 mRNA

NCBI chr 6:5,216,253...5,256,236
Ensembl chr 6:5,220,852...5,256,286

G

periostin, osteoblast specific factor

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of POSTN protein]

NCBI chr 3:54,266,688...54,298,462
Ensembl chr 3:54,268,530...54,298,458

G

peroxisome proliferator activated receptor alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARA mRNA

NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020

G

peroxisome proliferator activator receptor delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARD mRNA

NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448

G

peroxisome proliferator activated receptor gamma

increases expression
multiple interactions
affects localization

Dextran Sulfate results in increased expression of PPARG protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARG mRNA; ligustilide inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]; Mesalamine inhibits the reaction [Dextran Sulfate affects the localization of PPARG protein]

PMID:23261717 PMID:29950665 PMID:33130971

NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360

G

peroxisome proliferative activated receptor, gamma, coactivator 1 alpha

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of PPARGC1A protein
Hesperidin inhibits the reaction [Dextran Sulfate results in decreased expression of PPARGC1A protein]

NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068

G

peptidylprolyl isomerase A

decreases expression

Dextran Sulfate results in decreased expression of PPIA protein

NCBI chr11:6,365,867...6,369,817
Ensembl chr11:6,365,443...6,369,817

G

peptidyl prolyl isomerase H

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPIH protein]

NCBI chr 4:119,157,207...119,177,720
Ensembl chr 4:119,157,207...119,177,743

G

protein phosphatase 1 catalytic subunit gamma

increases expression

Dextran Sulfate results in increased expression of PPP1CC mRNA

NCBI chr 5:122,296,338...122,313,336
Ensembl chr 5:122,296,341...122,313,336

G

protein phosphatase 1 catalytic subunit gamma B

decreases expression

Dextran Sulfate results in decreased expression of PPP1CCB mRNA

NCBI chr 7:119,339,133...119,341,467
Ensembl chr 7:119,339,351...119,340,322
Ensembl chr 7:119,339,351...119,340,322

G

protein phosphatase 1, regulatory inhibitor subunit 14A

increases expression
multiple interactions

Dextran Sulfate results in increased expression of PPP1R14A protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of PPP1R14A protein]

NCBI chr 7:28,988,732...28,992,817
Ensembl chr 7:28,988,733...28,993,226

G

protein phosphatase 1, regulatory inhibitor subunit 1B

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PPP1R1B protein]

NCBI chr11:98,239,232...98,248,622
Ensembl chr11:98,239,230...98,248,622

G

protein phosphatase 3, catalytic subunit, gamma isoform

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPP3CC mRNA

NCBI chr14:70,455,314...70,526,979
Ensembl chr14:70,455,314...70,526,920

G

pancreatic polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPY mRNA

NCBI chr11:101,990,757...101,992,145
Ensembl chr11:101,990,756...101,992,145

G

peroxiredoxin 1

decreases expression

Dextran Sulfate results in decreased expression of PRDX1 protein

NCBI chr 4:116,542,796...116,557,196
Ensembl chr 4:116,542,741...116,558,019

G

protein kinase, cAMP dependent, catalytic, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKACB mRNA

NCBI chr 3:146,435,334...146,518,691
Ensembl chr 3:146,435,329...146,518,745

G

protein kinase, AMP-activated, gamma 2 non-catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKAG2 mRNA

NCBI chr 5:25,067,733...25,311,576
Ensembl chr 5:25,067,742...25,305,640

G

protein kinase C, alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKCA mRNA

NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754

G

protein kinase C, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCB mRNA

NCBI chr 7:121,888,327...122,233,625
Ensembl chr 7:121,887,974...122,233,625

G

protein kinase C, theta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCQ mRNA

NCBI chr 2:11,176,922...11,306,033
Ensembl chr 2:11,176,919...11,306,033

G

protein kinase, cGMP-dependent, type II

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKG2 mRNA

NCBI chr 5:99,077,632...99,185,042
Ensembl chr 5:99,077,632...99,185,210

G

prolactin family 2, subfamily c, member 3

increases expression

Dextran Sulfate results in increased expression of PRL2C3 protein

NCBI chr13:12,805,705...12,814,982
Ensembl chr13:12,805,705...12,814,968

G

prolactin family 3, subfamily b, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRL3B1 mRNA

NCBI chr13:27,426,413...27,433,666
Ensembl chr13:27,425,830...27,433,666

G

prolactin family 3, subfamily d, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRL3D1 mRNA

NCBI chr13:27,278,172...27,284,243
Ensembl chr13:27,278,173...27,284,241

G

prolactin family 6, subfamily a, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRL6A1 mRNA

NCBI chr13:27,496,598...27,503,237
Ensembl chr13:27,496,610...27,503,235

G

prolactin receptor

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRLR mRNA
Dextran Sulfate results in decreased expression of PRLR mRNA

PMID:29950665 PMID:35093514

NCBI chr15:10,177,324...10,349,276
Ensembl chr15:10,177,324...10,349,266

G

protamine 3

increases expression

Dextran Sulfate results in increased expression of PRM3 mRNA

NCBI chr16:10,608,372...10,608,778
Ensembl chr16:10,608,369...10,608,778

G

protein C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PROC mRNA

NCBI chr18:32,256,179...32,272,623
Ensembl chr18:32,256,179...32,272,623

G

protein S (alpha)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PROS1 mRNA

NCBI chr16:62,674,670...62,749,709
Ensembl chr16:62,674,670...62,749,709

G

prospero homeobox 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PROX1 mRNA

NCBI chr 1:189,850,232...189,903,024
Ensembl chr 1:189,850,232...189,902,911

G

PRP38 pre-mRNA processing factor 38 (yeast) domain containing B

increases expression

Dextran Sulfate results in increased expression of PRPF38B mRNA

NCBI chr 3:108,810,121...108,819,055
Ensembl chr 3:108,810,121...108,819,043

G

proline-rich coiled-coil 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of PRRC1 protein]

NCBI chr18:57,487,805...57,526,028
Ensembl chr18:57,487,813...57,526,028

G

proline-rich coiled-coil 2C

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of PRRC2C mRNA

NCBI chr 1:162,499,354...162,568,125
Ensembl chr 1:162,498,294...162,568,125

G

serine protease 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS2 mRNA

NCBI chr 6:41,498,710...41,502,013
Ensembl chr 6:41,498,721...41,502,013

G

peroxiredoxin like 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRXL2B mRNA

NCBI chr 4:154,980,884...154,983,522
Ensembl chr 4:154,979,961...154,983,592

G

presenilin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PSEN1 mRNA

NCBI chr12:83,734,926...83,781,869
Ensembl chr12:83,734,926...83,781,973

G

proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)

increases expression

Dextran Sulfate results in increased expression of PSMB8 mRNA

NCBI chr17:34,417,169...34,420,428
Ensembl chr17:34,416,695...34,420,428

G

proline-serine-threonine phosphatase-interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PSTPIP1 mRNA

NCBI chr 9:55,985,729...56,036,174
Ensembl chr 9:55,997,246...56,036,172

G

platelet-activating factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTAFR mRNA

NCBI chr 4:132,291,378...132,309,994
Ensembl chr 4:132,291,378...132,309,994

G

phosphatase and tensin homolog

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]

NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560

G

prostaglandin D2 receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDR2 mRNA

NCBI chr19:10,901,883...10,919,875
Ensembl chr19:10,914,524...10,919,875

G

prostaglandin D2 synthase (brain)

multiple interactions
decreases expression
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDS mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGDS protein]
Dextran Sulfate results in decreased expression of PTGDS protein

PMID:29950665 PMID:30489199 PMID:35999755

NCBI chr 2:25,356,723...25,360,080
Ensembl chr 2:25,356,721...25,360,058

G

prostaglandin E receptor 2 (subtype EP2)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER2 mRNA

NCBI chr14:45,225,568...45,241,277
Ensembl chr14:45,225,652...45,241,277

G

prostaglandin E receptor 3 (subtype EP3)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGER3 mRNA

NCBI chr 3:157,272,459...157,350,392
Ensembl chr 3:157,272,529...157,351,525

G

prostaglandin E receptor 4 (subtype EP4)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER4 mRNA

NCBI chr15:5,262,880...5,273,668
Ensembl chr15:5,236,142...5,273,668

G

prostaglandin E synthase

multiple interactions
increases expression

resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGES mRNA; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGES protein]

PMID:19228061 PMID:20132809 PMID:29950665 PMID:30489199 PMID:36543318

NCBI chr 2:30,779,483...30,793,309
Ensembl chr 2:30,779,483...30,819,875

G

prostaglandin E synthase 3

decreases expression

Dextran Sulfate results in decreased expression of PTGES3 protein

NCBI chr10:127,894,851...127,913,123
Ensembl chr10:127,894,823...127,913,141

G

prostaglandin F receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGFR mRNA

NCBI chr 3:151,504,247...151,543,165
Ensembl chr 3:151,502,139...151,543,267

G

prostaglandin I receptor (IP)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIR mRNA

NCBI chr 7:16,640,442...16,644,828
Ensembl chr 7:16,640,415...16,644,830

G

prostaglandin I2 (prostacyclin) synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIS mRNA

NCBI chr 2:167,045,114...167,095,069
Ensembl chr 2:167,033,725...167,082,524

G

prostaglandin reductase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGR1 mRNA

NCBI chr 4:58,965,590...58,987,131
Ensembl chr 4:58,965,439...58,987,119

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGS2 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein]; monotropein inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; NFE2L2 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]
resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]
Dextran Sulfate results in increased expression of PTGS2 mRNA; Dextran Sulfate results in increased expression of PTGS2 protein

PMID:15459021 PMID:15652231 PMID:16049979 PMID:17438113 PMID:19228061 More...

NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978

G

parathyroid hormone 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTH1R mRNA

NCBI chr 9:110,551,132...110,576,213
Ensembl chr 9:110,551,153...110,576,213

G

parathyroid hormone-like peptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTHLH mRNA

NCBI chr 6:147,153,607...147,165,511
Ensembl chr 6:147,153,599...147,165,681

G

pleiotrophin

decreases expression

Dextran Sulfate results in decreased expression of PTN mRNA

NCBI chr 6:36,691,863...36,787,114
Ensembl chr 6:36,691,864...36,787,155

G

protein tyrosine phosphatase receptor type C

increases expression

Dextran Sulfate results in increased expression of PTPRC mRNA

NCBI chr 1:137,990,601...138,103,491
Ensembl chr 1:137,990,599...138,103,446

G

protein tyrosine phosphatase receptor type H

decreases expression

Dextran Sulfate results in decreased expression of PTPRH mRNA

NCBI chr 7:4,551,607...4,607,040
Ensembl chr 7:4,551,611...4,607,040

G

protein tyrosine phosphatase receptor type M

decreases expression

Dextran Sulfate results in decreased expression of PTPRM protein

NCBI chr17:66,973,843...67,661,486
Ensembl chr17:66,973,942...67,661,452

G

protein tyrosine phosphatase receptor type U

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTPRU mRNA

NCBI chr 4:131,495,768...131,565,617
Ensembl chr 4:131,495,768...131,565,599

G

protein tyrosine phosphatase receptor type V

decreases expression

Dextran Sulfate results in decreased expression of PTPRV mRNA

NCBI chr 1:135,036,236...135,060,313
Ensembl chr 1:135,036,235...135,060,332

G

PYD and CARD domain containing

increases expression
multiple interactions

Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein; [Streptozocin co-treated with Dextran Sulfate] results in increased expression of PYCARD protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of PYCARD protein]

PMID:30270565 PMID:34964214

NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039

G

brain glycogen phosphorylase

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of PYGB protein
Dextran Sulfate results in decreased expression of PYGB protein

NCBI chr 2:150,628,716...150,673,668
Ensembl chr 2:150,628,655...150,673,678

G

liver glycogen phosphorylase

decreases expression

Dextran Sulfate results in decreased expression of PYGL protein

NCBI chr12:70,237,589...70,274,457
Ensembl chr12:70,237,585...70,278,262

G

peptide YY

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PYY mRNA

NCBI chr11:101,997,502...101,998,658
Ensembl chr11:101,997,502...101,998,658

G

R3H domain and coiled-coil containing 1

increases expression

Dextran Sulfate results in increased expression of R3HCC1 mRNA

NCBI chr14:69,934,753...69,952,258
Ensembl chr14:69,934,756...69,945,033

G

RAB11B, member RAS oncogene family

decreases expression

Dextran Sulfate results in decreased expression of RAB11B protein

NCBI chr17:33,961,458...33,979,460
Ensembl chr17:33,961,458...33,979,504

G

RAB1B, member RAS oncogene family

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB1B protein]

NCBI chr19:5,149,235...5,157,024
Ensembl chr19:5,149,233...5,157,100

G

RAB21, member RAS oncogene family

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB21 protein

NCBI chr10:115,125,767...115,151,540
Ensembl chr10:115,122,989...115,151,499

G

RAB27A, member RAS oncogene family

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RAB27A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RAB27A protein]

NCBI chr 9:72,952,092...73,004,905
Ensembl chr 9:72,952,136...73,004,911

G

RAB27B, member RAS oncogene family

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB27B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RAB27B mRNA
Dextran Sulfate results in decreased expression of RAB27B protein

PMID:29950665 PMID:35999755

NCBI chr18:70,112,202...70,274,704
Ensembl chr18:70,112,202...70,274,676

G

RAB39B, member RAS oncogene family

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RAB39B protein

NCBI chr X:74,615,651...74,621,837
Ensembl chr X:74,615,652...74,621,837

G

Rac family small GTPase 3

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA]

NCBI chr11:120,612,294...120,614,795
Ensembl chr11:120,612,296...120,614,795

G

receptor (calcitonin) activity modifying protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP1 mRNA

NCBI chr 1:91,107,544...91,152,918
Ensembl chr 1:91,107,544...91,152,918

G

receptor (calcitonin) activity modifying protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP2 mRNA

NCBI chr11:101,137,160...101,139,076
Ensembl chr11:101,136,854...101,150,372

G

receptor (calcitonin) activity modifying protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP3 mRNA

NCBI chr11:6,608,507...6,627,478
Ensembl chr11:6,608,521...6,627,475

G

RAS related protein 1b

decreases expression

Dextran Sulfate results in decreased expression of RAP1B protein

NCBI chr10:117,650,502...117,681,879
Ensembl chr10:117,649,776...117,681,940

G

Rap guanine nucleotide exchange factor (GEF) 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAPGEF4 mRNA

NCBI chr 2:71,811,559...72,087,818
Ensembl chr 2:71,811,584...72,087,818

G

retinoic acid receptor, gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RARG mRNA

NCBI chr15:102,143,373...102,165,891
Ensembl chr15:102,143,373...102,165,952

G

retinoic acid receptor responder (tazarotene induced) 1

decreases expression

Dextran Sulfate results in decreased expression of RARRES1 mRNA

NCBI chr 3:67,386,219...67,422,856
Ensembl chr 3:67,386,305...67,422,856

G

RAS, guanyl releasing protein 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RASGRP3 mRNA

NCBI chr17:75,742,849...75,836,049
Ensembl chr17:75,742,891...75,836,049

G

Ras association (RalGDS/AF-6) domain family member 1

increases response to substance
multiple interactions

RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased activity of MPO protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of IL6 protein

NCBI chr 9:107,428,752...107,439,460
Ensembl chr 9:107,428,754...107,439,466

G

RNA binding motif protein 12 B2

decreases expression

Dextran Sulfate results in decreased expression of RBM12B2 mRNA

NCBI chr 4:12,089,370...12,105,618
Ensembl chr 4:12,089,439...12,096,243

G

retinol binding protein 4, plasma

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of RBP4 protein

NCBI chr19:38,105,068...38,113,769
Ensembl chr19:38,105,077...38,113,729

G

regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2

increases expression

Dextran Sulfate results in increased expression of RCBTB2 mRNA

NCBI chr14:73,376,185...73,421,495
Ensembl chr14:73,360,477...73,445,283

G

radixin

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RDX protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RDX protein]

NCBI chr 9:51,958,450...52,000,038
Ensembl chr 9:51,958,473...52,011,763

G

regenerating islet-derived 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of REG1 protein

NCBI chr 6:78,402,966...78,405,651
Ensembl chr 6:78,399,694...78,405,650

G

regenerating islet-derived 3 beta

increases expression

Dextran Sulfate results in increased expression of REG3B mRNA

NCBI chr 6:78,347,868...78,350,449
Ensembl chr 6:78,347,640...78,350,449

G

regenerating islet-derived 3 gamma

increases expression

Dextran Sulfate results in increased expression of REG3G mRNA

NCBI chr 6:78,443,252...78,445,857
Ensembl chr 6:78,443,252...78,445,855

G

v-rel reticuloendotheliosis viral oncogene homolog A (avian)

multiple interactions
increases activity
affects localization
increases phosphorylation
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; [Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RELA protein; [Streptozocin co-treated with Dextran Sulfate] results in increased phosphorylation of RELA protein; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein; Dextran Sulfate results in increased expression of and affects the localization of RELA protein; Dextran Sulfate results in increased phosphorylation of and affects the localization of RELA protein; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of and results in increased phosphorylation of RELA protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of and results in increased activity of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of and affects the localization of RELA protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; monotropein inhibits the reaction [Dextran Sulfate affects the localization of RELA protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein modified form]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased phosphorylation of RELA protein]; RELA protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of RELA protein]
Dextran Sulfate results in increased expression of RELA protein; Dextran Sulfate results in increased expression of RELA protein modified form

PMID:21724996 PMID:23261679 PMID:24038091 PMID:25449198 PMID:25472953 More...

NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158

G

renin binding protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RENBP mRNA

NCBI chr X:72,965,727...72,974,408
Ensembl chr X:72,965,727...72,974,456

G

resistin like beta

increases expression

Dextran Sulfate results in increased expression of RETNLB mRNA

NCBI chr16:48,637,219...48,639,255
Ensembl chr16:48,637,219...48,639,255

G

resistin like gamma

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of RETNLG protein

NCBI chr16:48,692,971...48,694,861
Ensembl chr16:48,692,984...48,694,859

G

retinol saturase (all trans retinol 13,14 reductase)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RETSAT mRNA

NCBI chr 6:72,575,585...72,584,471
Ensembl chr 6:72,575,458...72,585,408

G

retinal G protein coupled receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGR mRNA

NCBI chr14:36,756,866...36,770,971
Ensembl chr14:36,756,866...36,770,921

G

regulator of G-protein signaling 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS19 mRNA

NCBI chr 2:181,330,212...181,336,330
Ensembl chr 2:181,330,212...181,335,770

G

regulator of G protein signaling 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS7 mRNA

NCBI chr 1:174,886,642...175,320,287
Ensembl chr 1:174,886,653...175,320,066

G

Rhesus blood group-associated B glycoprotein

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RHBG mRNA
Dextran Sulfate results in decreased expression of RHBG mRNA

PMID:29950665 PMID:35093514

NCBI chr 3:88,150,181...88,162,046
Ensembl chr 3:88,150,181...88,162,016

G

ras homolog family member J

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RHOJ mRNA

NCBI chr12:75,355,087...75,448,229
Ensembl chr12:75,355,096...75,448,230

G

reactive intermediate imine deaminase A homolog

decreases expression

Dextran Sulfate results in decreased expression of RIDA protein

NCBI chr15:34,484,168...34,495,392
Ensembl chr15:34,484,167...34,495,401

G

receptor (TNFRSF)-interacting serine-threonine kinase 1

multiple interactions
increases expression

dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK1 protein]

NCBI chr13:34,181,072...34,219,153
Ensembl chr13:34,186,346...34,221,130

G

receptor-interacting serine-threonine kinase 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of RIPK3 protein
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of RIPK3 protein]

NCBI chr14:56,022,452...56,026,314
Ensembl chr14:56,022,452...56,026,322

G

ring finger protein 213

decreases expression

Dextran Sulfate results in decreased expression of RNF213 mRNA

NCBI chr11:119,280,778...119,378,245
Ensembl chr11:119,283,926...119,378,244

G

RAR-related orphan receptor gamma

increases expression
multiple interactions

Dextran Sulfate results in increased expression of RORC mRNA; Dextran Sulfate results in increased expression of RORC mRNA alternative form
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA alternative form]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of RORC mRNA]

PMID:31737179 PMID:31807802

NCBI chr 3:94,280,106...94,305,583
Ensembl chr 3:94,280,101...94,305,583

G

ribosomal protein L39-like

increases expression

Dextran Sulfate results in increased expression of RPL39L mRNA

NCBI chr16:9,988,061...9,992,775
Ensembl chr16:9,988,090...9,992,775

G

ribosomal protein L41

increases expression

Dextran Sulfate results in increased expression of RPL41 mRNA

NCBI chr10:128,383,979...128,385,037
Ensembl chr10:128,383,983...128,385,174

G

ribosomal protein S14

increases expression

Dextran Sulfate results in increased expression of RPS14 mRNA

NCBI chr18:60,907,668...60,911,618
Ensembl chr18:60,880,170...60,911,618

G

ribosomal protein S15

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RPS15 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15 protein]

NCBI chr10:80,128,265...80,129,948
Ensembl chr10:80,128,287...80,129,948

G

ribosomal protein S15A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RPS15A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RPS15A protein]

NCBI chr 7:117,703,597...117,715,370
Ensembl chr 7:117,703,595...117,715,411

G

ribosomal protein S29

increases expression

Dextran Sulfate results in increased expression of RPS29 mRNA

NCBI chr12:69,204,495...69,205,891
Ensembl chr12:69,204,496...69,205,960

G

ribosomal protein S6

multiple interactions
increases phosphorylation

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of RPS6 protein; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6 protein]

PMID:19931517 PMID:31676321

NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649

G

ribosomal protein S6 kinase, polypeptide 1

multiple interactions
increases phosphorylation
decreases phosphorylation

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr11:86,389,695...86,435,711
Ensembl chr11:86,389,697...86,435,631

G

related RAS viral (r-ras) oncogene 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of RRAS2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of RRAS2 protein]

NCBI chr 7:113,646,017...113,717,016
Ensembl chr 7:113,646,017...113,717,016

G

ribosome binding protein 1

increases expression

Dextran Sulfate results in increased expression of RRBP1 mRNA

NCBI chr 2:143,789,315...143,853,216
Ensembl chr 2:143,789,315...143,853,183

G

ribosomal RNA processing 1

increases expression

Dextran Sulfate results in increased expression of RRP1 mRNA

NCBI chr10:78,236,196...78,248,877
Ensembl chr10:78,236,218...78,248,877

G

radial spoke head 1 homolog (Chlamydomonas)

increases expression

Dextran Sulfate results in increased expression of RSPH1 mRNA

NCBI chr17:31,473,993...31,496,270
Ensembl chr17:31,473,993...31,496,357

G

Ras suppressor protein 1

decreases expression

Dextran Sulfate results in decreased expression of RSU1 protein

NCBI chr 2:13,081,778...13,276,116
Ensembl chr 2:13,081,632...13,276,226

G

relaxin/insulin-like family peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP1 mRNA

NCBI chr 3:79,548,910...79,645,258
Ensembl chr 3:79,548,918...79,645,187

G

relaxin family peptide receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP4 mRNA

NCBI chr 3:88,559,081...88,560,489
Ensembl chr 3:88,559,205...88,560,449

G

retinoid X receptor alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RXRA mRNA

NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969

G

ryanodine receptor 1, skeletal muscle

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RYR1 mRNA

NCBI chr 7:28,702,765...28,824,599
Ensembl chr 7:28,702,769...28,824,604

G

S100 calcium binding protein A11

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of S100A11 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of S100A11 protein]

NCBI chr 3:93,427,803...93,433,595
Ensembl chr 3:93,427,795...93,433,594

G

S100 calcium binding protein A4

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A4 protein]

NCBI chr 3:90,511,077...90,513,349
Ensembl chr 3:90,511,078...90,513,352

G

S100 calcium binding protein A8 (calgranulin A)

increases expression

Dextran Sulfate results in increased expression of S100A8 mRNA

NCBI chr 3:90,576,378...90,577,341
Ensembl chr 3:90,576,285...90,577,342

G

S100 calcium binding protein A9 (calgranulin B)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of S100A9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of S100A9 protein]

NCBI chr 3:90,599,937...90,603,028
Ensembl chr 3:90,599,939...90,603,028

G

S100 calcium binding protein G

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of S100G mRNA

NCBI chr X:161,744,988...161,747,595
Ensembl chr X:161,744,988...161,747,595

G

sphingosine-1-phosphate receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of S1PR2 mRNA

NCBI chr 9:20,877,248...20,888,089
Ensembl chr 9:20,873,657...20,888,077

G

serum amyloid A 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SAA1 mRNA

NCBI chr 7:46,389,921...46,392,404
Ensembl chr 7:46,389,921...46,392,404

G

serum amyloid A 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SAA2 mRNA

NCBI chr 7:46,401,257...46,403,737
Ensembl chr 7:46,401,214...46,403,737

G

serum amyloid A 3

increases expression

Dextran Sulfate results in increased expression of SAA3 mRNA

NCBI chr 7:46,361,422...46,365,100
Ensembl chr 7:46,361,422...46,365,124

G

scaffold attachment factor B

increases expression

Dextran Sulfate results in increased expression of SAFB mRNA

NCBI chr17:56,891,982...56,913,294
Ensembl chr17:56,891,825...56,913,294

G

scaffold attachment factor B2

increases expression

Dextran Sulfate results in increased expression of SAFB2 mRNA

NCBI chr17:56,867,971...56,891,673
Ensembl chr17:56,867,965...56,891,585

G

sin3 associated polypeptide

increases expression

Dextran Sulfate results in increased expression of SAP30 mRNA

NCBI chr 8:57,935,740...57,940,874
Ensembl chr 8:57,935,741...57,940,894

G

sarcosine dehydrogenase

decreases expression

Dextran Sulfate results in decreased expression of SARDH mRNA

NCBI chr 2:27,078,405...27,138,344
Ensembl chr 2:27,078,405...27,138,349

G

SAP domain containing ribonucleoprotein

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SARNP protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SARNP protein]

NCBI chr10:128,657,633...128,713,507
Ensembl chr10:128,653,202...128,713,498

G

squamous cell carcinoma antigen recognized by T cells 1

increases expression

Dextran Sulfate results in increased expression of SART1 mRNA

NCBI chr19:5,427,551...5,438,731
Ensembl chr19:5,427,551...5,438,731

G

sterol-C5-desaturase

decreases expression

Dextran Sulfate results in decreased expression of SC5D mRNA

NCBI chr 9:42,162,888...42,175,607
Ensembl chr 9:42,162,891...42,175,552

G

secretory carrier membrane protein 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SCAMP1 protein]

NCBI chr13:94,337,818...94,422,339
Ensembl chr13:94,337,818...94,422,365

G

stearoyl-Coenzyme A desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of SCD1 mRNA

NCBI chr19:44,382,889...44,396,148
Ensembl chr19:44,382,894...44,396,318

G

stearoyl-Coenzyme A desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of SCD2 mRNA

NCBI chr19:44,282,115...44,295,303
Ensembl chr19:44,282,113...44,295,303

G

secretoglobin, family 1A, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SCGB1A1 mRNA

NCBI chr19:9,061,006...9,065,320
Ensembl chr19:9,061,000...9,065,322

G

secretoglobin, family 3A, member 1

increases expression

Dextran Sulfate results in increased expression of SCGB3A1 mRNA

NCBI chr11:49,554,422...49,555,945
Ensembl chr11:49,554,437...49,555,945

G

scinderin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCIN mRNA

NCBI chr12:40,109,768...40,184,227
Ensembl chr12:40,109,768...40,184,227

G

sodium channel, nonvoltage-gated 1 alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1A mRNA

NCBI chr 6:125,286,657...125,321,906
Ensembl chr 6:125,297,622...125,321,906

G

sodium channel, nonvoltage-gated 1 beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1B mRNA

NCBI chr 7:121,464,261...121,517,951
Ensembl chr 7:121,464,261...121,517,737

G

secretin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCT mRNA

NCBI chr 7:140,858,243...140,859,082
Ensembl chr 7:140,858,243...140,859,046

G

syndecan 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SDC3 mRNA

NCBI chr 4:130,519,855...130,553,629
Ensembl chr 4:130,519,848...130,553,630

G

SEC62 homolog, preprotein translocation

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SEC62 protein]

NCBI chr 3:30,847,025...30,875,412
Ensembl chr 3:30,847,024...30,875,412

G

selectin, platelet

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SELP mRNA

NCBI chr 1:163,942,833...163,977,595
Ensembl chr 1:163,942,833...163,977,595

G

serine (or cysteine) preptidase inhibitor, clade A, member 1B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of SERPINA1B protein

NCBI chr12:103,694,415...103,704,448
Ensembl chr12:103,694,415...103,796,632

G

serine (or cysteine) peptidase inhibitor, clade A, member 1E

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of SERPINA1E protein
Dextran Sulfate results in increased expression of SERPINA1E protein

NCBI chr12:103,913,190...103,923,156
Ensembl chr12:103,913,190...103,925,234

G

serine (or cysteine) peptidase inhibitor, clade A, member 3F

increases expression

Dextran Sulfate results in increased expression of SERPINA3F mRNA

NCBI chr12:104,180,803...104,187,388
Ensembl chr12:104,180,803...104,187,388

G

serine (or cysteine) peptidase inhibitor, clade A, member 3N

increases expression

Dextran Sulfate results in increased expression of SERPINA3N mRNA

PMID:23894361 PMID:35093514

NCBI chr12:104,372,967...104,380,588
Ensembl chr12:104,372,988...104,380,588

G

serine (or cysteine) peptidase inhibitor, clade A, member 5

multiple interactions

Dextran Sulfate affects the reaction [SEMG2 protein binds to SERPINA5 protein]

NCBI chr12:104,065,572...104,072,397
Ensembl chr12:104,067,372...104,072,396

G

serine (or cysteine) peptidase inhibitor, clade B, member 1a

decreases expression

Dextran Sulfate results in decreased expression of SERPINB1A protein

NCBI chr13:33,026,075...33,037,189
Ensembl chr13:33,026,075...33,035,168

G

serine (or cysteine) peptidase inhibitor, clade E, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPINE1 mRNA

NCBI chr 5:137,090,358...137,101,126
Ensembl chr 5:137,090,358...137,101,122

G

serine (or cysteine) peptidase inhibitor, clade G, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPING1 mRNA

NCBI chr 2:84,595,704...84,605,748
Ensembl chr 2:84,595,731...84,605,788

G

splicing factor 3a, subunit 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SF3A2 protein]

NCBI chr10:80,634,569...80,640,756
Ensembl chr10:80,634,032...80,640,758

G

serum/glucocorticoid regulated kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SGK2 mRNA

NCBI chr 2:162,829,249...162,856,059
Ensembl chr 2:162,829,250...162,856,047

G

sphingomyelin synthase 2

increases expression

Dextran Sulfate results in increased expression of SGMS2 mRNA

NCBI chr 3:131,112,634...131,197,204
Ensembl chr 3:131,112,634...131,197,172

G

sphingosine-1-phosphate phosphatase 2

multiple interactions
increases expression

Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SGPP2 mRNA]

NCBI chr 1:78,286,186...78,396,926
Ensembl chr 1:78,286,982...78,396,926

G

SH3-binding domain glutamic acid-rich protein like

decreases expression

Dextran Sulfate results in decreased expression of SH3BGRL protein

NCBI chr X:108,139,013...108,206,073
Ensembl chr X:108,138,971...108,241,479

G

SH3 domain binding glutamic acid-rich protein-like 3

decreases expression

Dextran Sulfate results in decreased expression of SH3BGRL3 protein

NCBI chr 4:133,854,717...133,856,044
Ensembl chr 4:133,854,717...133,856,100

G

SH3-domain GRB2-like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SH3GL2 mRNA

NCBI chr 4:85,123,663...85,307,617
Ensembl chr 4:85,123,363...85,557,432

G

SH3-domain kinase binding protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SH3KBP1 mRNA

NCBI chr X:158,409,888...158,758,916
Ensembl chr X:158,410,268...158,761,065

G

serine hydroxymethyltransferase 1 (soluble)

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SHMT1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SHMT1 protein]

NCBI chr11:60,679,723...60,702,062
Ensembl chr11:60,678,930...60,702,544

G

sialic acid acetylesterase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SIAE protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SIAE protein]

NCBI chr 9:37,525,117...37,559,554
Ensembl chr 9:37,466,994...37,560,951

G

signal-induced proliferation associated gene 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SIPA1 mRNA

NCBI chr19:5,701,211...5,713,758
Ensembl chr19:5,701,213...5,713,735

G

sirtuin 1

multiple interactions
decreases expression

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of SIRT1 protein]
Dextran Sulfate results in decreased expression of SIRT1 mRNA; Dextran Sulfate results in decreased expression of SIRT1 protein

PMID:19940103 PMID:24548422

NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 1

decreases expression

Dextran Sulfate results in decreased expression of SLC10A1 mRNA; Dextran Sulfate results in decreased expression of SLC10A1 protein

NCBI chr12:80,999,959...81,015,479
Ensembl chr12:80,999,957...81,015,479

G

solute carrier family 10, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC10A2 mRNA

NCBI chr 8:5,133,219...5,155,287
Ensembl chr 8:5,133,219...5,155,351

G

solute carrier family 10 (sodium/bile acid cotransporter family), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC10A6 mRNA

NCBI chr 5:103,753,583...103,777,152
Ensembl chr 5:103,753,577...103,777,269

G

solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC11A1 mRNA

NCBI chr 1:74,414,318...74,429,974
Ensembl chr 1:74,414,354...74,425,221

G

solute carrier family 12, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC12A4 mRNA

NCBI chr 8:106,670,222...106,692,781
Ensembl chr 8:106,670,222...106,692,729

G

solute carrier family 12, member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC12A7 mRNA

NCBI chr13:73,881,172...73,964,873
Ensembl chr13:73,881,213...73,964,873

G

solute carrier family 13 (sodium/sulfate symporters), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A1 mRNA

NCBI chr 6:24,088,282...24,168,118
Ensembl chr 6:24,088,282...24,168,091

G

solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A2 mRNA

NCBI chr11:78,288,102...78,313,107
Ensembl chr11:78,287,913...78,313,043

G

solute carrier family 13 (sodium-dependent citrate transporter), member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A5 mRNA

NCBI chr11:72,132,816...72,158,092
Ensembl chr11:72,132,815...72,158,048

G

solute carrier family 15 (oligopeptide transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC15A1 mRNA

NCBI chr14:121,697,033...121,742,666
Ensembl chr14:121,697,033...121,742,664

G

solute carrier family 15, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC15A4 mRNA

NCBI chr 5:127,668,795...127,710,356
Ensembl chr 5:127,672,728...127,709,961

G

solute carrier family 16 (monocarboxylic acid transporters), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A3 mRNA

NCBI chr11:120,839,310...120,849,826
Ensembl chr11:120,839,306...120,851,694

G

solute carrier family 16 (monocarboxylic acid transporters), member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A8 mRNA

NCBI chr15:79,135,216...79,139,619
Ensembl chr15:79,135,214...79,138,961

G

solute carrier family 17 (anion/sugar transporter), member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A5 mRNA

NCBI chr 9:78,443,769...78,495,346
Ensembl chr 9:78,443,770...78,495,323

G

solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC17A6 mRNA

NCBI chr 7:51,271,578...51,320,874
Ensembl chr 7:51,271,754...51,320,867

G

solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A8 mRNA

NCBI chr10:89,409,882...89,457,111
Ensembl chr10:89,409,882...89,457,115

G

solute carrier family 18 (vesicular monoamine), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC18A1 mRNA

NCBI chr 8:69,490,360...69,547,951
Ensembl chr 8:69,490,363...69,541,887

G

solute carrier family 1 (glial high affinity glutamate transporter), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A2 mRNA

NCBI chr 2:102,488,584...102,621,129
Ensembl chr 2:102,489,004...102,621,129

G

solute carrier family 1 (neutral amino acid transporter), member 5

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SLC1A5 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SLC1A5 protein]

NCBI chr 7:16,515,259...16,532,199
Ensembl chr 7:16,515,265...16,532,199

G

solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A6 mRNA

NCBI chr10:78,615,923...78,650,659
Ensembl chr10:78,616,330...78,650,599

G

solute carrier family 1 (glutamate transporter), member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A7 mRNA

NCBI chr 4:107,825,603...107,870,726
Ensembl chr 4:107,825,529...107,870,729

G

solute carrier family 22 (organic cation transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A1 mRNA

NCBI chr17:12,867,761...12,894,725
Ensembl chr17:12,867,756...12,894,716

G

solute carrier family 22 (organic cation transporter), member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A18 mRNA

NCBI chr 7:143,027,502...143,053,071
Ensembl chr 7:143,027,473...143,053,071

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A21 mRNA

NCBI chr11:53,840,780...53,871,159
Ensembl chr11:53,840,791...53,871,158

G

solute carrier family 22 (organic cation transporter), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A3 mRNA

NCBI chr17:12,638,859...12,726,591
Ensembl chr17:12,637,847...12,726,591

G

solute carrier family 22 (organic cation transporter), member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC22A4 mRNA

NCBI chr11:53,873,941...53,920,866
Ensembl chr11:53,873,949...53,918,916

G

solute carrier family 22 (organic cation transporter), member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A5 mRNA

NCBI chr11:53,755,368...53,782,609
Ensembl chr11:53,755,368...53,782,486

G

solute carrier family 22 (organic anion transporter), member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A8 mRNA

NCBI chr19:8,568,576...8,589,199
Ensembl chr19:8,568,618...8,589,199

G

solute carrier family 25 (mitochondrial carrier, dicarboxylate transporter), member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC25A10 mRNA

NCBI chr11:120,382,663...120,391,987
Ensembl chr11:120,382,666...120,390,013

G

solute carrier family 25, member 28

increases expression

Dextran Sulfate results in increased expression of SLC25A28 mRNA

NCBI chr19:43,652,240...43,663,320
Ensembl chr19:43,652,240...43,663,320

G

solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC25A4 mRNA

NCBI chr 8:46,660,205...46,664,099
Ensembl chr 8:46,659,834...46,664,321

G

solute carrier family 26 (sulfate transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A1 mRNA

NCBI chr 5:108,817,744...108,826,246
Ensembl chr 5:108,817,744...108,823,435

G

solute carrier family 26 (sulfate transporter), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A2 mRNA

NCBI chr18:61,329,926...61,344,668
Ensembl chr18:61,325,991...61,344,684

G

solute carrier family 26, member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A3 mRNA

NCBI chr12:31,483,141...31,523,921
Ensembl chr12:31,440,870...31,523,916

G

solute carrier family 26, member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A7 mRNA

NCBI chr 4:14,502,430...14,621,946
Ensembl chr 4:14,502,430...14,621,805

G

solute carrier family 26, member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC26A9 mRNA

NCBI chr 1:131,671,760...131,699,242
Ensembl chr 1:131,671,760...131,699,242

G

solute carrier family 27 (fatty acid transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A1 mRNA

NCBI chr 8:72,021,372...72,039,951
Ensembl chr 8:72,021,526...72,039,946

G

solute carrier family 27 (fatty acid transporter), member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A4 mRNA

NCBI chr 2:29,692,646...29,707,534
Ensembl chr 2:29,692,646...29,707,534

G

solute carrier family 28 (sodium-coupled nucleoside transporter), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC28A3 mRNA

NCBI chr13:58,701,121...58,758,691
Ensembl chr13:58,693,213...58,758,691

G

solute carrier family 29 (nucleoside transporters), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC29A2 mRNA

NCBI chr19:5,069,085...5,082,000
Ensembl chr19:5,073,888...5,082,000

G

solute carrier family 2 (facilitated glucose transporter), member 1

increases expression

Dextran Sulfate results in increased expression of SLC2A1 protein

NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180

G

solute carrier family 2 (facilitated glucose transporter), member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A12 mRNA

NCBI chr10:22,488,821...22,579,779
Ensembl chr10:22,520,910...22,580,184

G

solute carrier family 2 (facilitated glucose transporter), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A3 mRNA

NCBI chr 6:122,704,783...122,779,149
Ensembl chr 6:122,704,768...122,778,599

G

solute carrier family 30 (zinc transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC30A1 mRNA

NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359

G

solute carrier family 30 (zinc transporter), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC30A2 mRNA

NCBI chr 4:134,070,357...134,081,795
Ensembl chr 4:134,070,492...134,081,795

G

solute carrier family 34 (sodium phosphate), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC34A2 mRNA

NCBI chr 5:53,206,695...53,229,006
Ensembl chr 5:53,195,423...53,229,006

G

solute carrier family 35 (CMP-sialic acid transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A1 mRNA

NCBI chr 4:34,663,257...34,688,113
Ensembl chr 4:34,663,257...34,687,438

G

solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A3 mRNA

NCBI chr 3:116,463,118...116,506,366
Ensembl chr 3:116,463,119...116,506,480

G

solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter), member D1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D1 mRNA

NCBI chr 4:103,027,846...103,078,208
Ensembl chr 4:103,027,846...103,072,361

G

solute carrier family 35, member D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D2 mRNA

NCBI chr13:64,244,122...64,277,195
Ensembl chr13:64,244,122...64,277,182

G

solute carrier family 36 (proton/amino acid symporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC36A1 mRNA

NCBI chr11:55,095,148...55,127,156
Ensembl chr11:55,095,176...55,127,156

G

solute carrier family 38, member 1

decreases expression

Dextran Sulfate results in decreased expression of SLC38A1 mRNA

NCBI chr15:96,469,299...96,541,396
Ensembl chr15:96,469,299...96,540,794

G

solute carrier family 38, member 2

increases expression

Dextran Sulfate results in increased expression of SLC38A2 mRNA

NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611

G

solute carrier family 39 (zinc transporter), member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A10 mRNA

NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012

G

solute carrier family 39 (zinc transporter), member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A14 mRNA

NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874

G

solute carrier family 39 (zinc transporter), member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A4 mRNA

NCBI chr15:76,496,583...76,501,579
Ensembl chr15:76,496,583...76,501,584

G

solute carrier family 39 (metal ion transporter), member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A5 mRNA

NCBI chr10:128,231,796...128,237,145
Ensembl chr10:128,231,800...128,237,098

G

solute carrier family 39 (metal ion transporter), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A6 mRNA

NCBI chr18:24,712,938...24,736,874
Ensembl chr18:24,712,938...24,736,874

G

solute carrier family 39 (metal ion transporter), member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A8 mRNA

NCBI chr 3:135,522,644...135,594,333
Ensembl chr 3:135,531,040...135,594,333

G

solute carrier family 3, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC3A1 mRNA

NCBI chr17:85,335,775...85,371,669
Ensembl chr17:85,335,804...85,371,664

G

solute carrier family 40 (iron-regulated transporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC40A1 mRNA

NCBI chr 1:45,947,230...45,965,690
Ensembl chr 1:45,947,228...45,965,683

G

solute carrier family 44, member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A3 mRNA

NCBI chr 3:121,253,177...121,325,993
Ensembl chr 3:121,253,177...121,326,053

G

solute carrier family 44, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A4 mRNA

NCBI chr17:35,133,200...35,149,412
Ensembl chr17:35,133,442...35,149,412

G

solute carrier family 46, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC46A1 mRNA

NCBI chr11:78,356,527...78,362,771
Ensembl chr11:78,356,523...78,362,885

G

solute carrier family 47, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A1 mRNA

NCBI chr11:61,234,226...61,269,668
Ensembl chr11:61,234,227...61,269,171

G

solute carrier family 47, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A2 mRNA

NCBI chr11:61,192,453...61,233,686
Ensembl chr11:61,192,457...61,233,686

G

solute carrier family 4 (anion exchanger), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A1 mRNA

NCBI chr11:102,239,646...102,256,107
Ensembl chr11:102,239,650...102,257,029

G

solute carrier family 4 (anion exchanger), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A2 mRNA

NCBI chr 5:24,628,834...24,645,945
Ensembl chr 5:24,628,835...24,645,948

G

solute carrier family 4, sodium bicarbonate cotransporter, member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A7 mRNA

NCBI chr14:7,669,819...7,766,808
Ensembl chr14:7,669,823...7,767,484

G

solute carrier family 51, alpha subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51A mRNA

NCBI chr16:32,294,396...32,306,697
Ensembl chr16:32,293,322...32,306,697

G

solute carrier family 51, beta subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51B mRNA

NCBI chr 9:65,320,035...65,330,055
Ensembl chr 9:65,319,996...65,330,237

G

solute carrier protein 52, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC52A2 mRNA

NCBI chr15:76,422,994...76,432,078
Ensembl chr15:76,423,032...76,428,808

G

solute carrier family 5 (sodium/glucose cotransporter), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A1 mRNA

NCBI chr 5:33,261,563...33,320,043
Ensembl chr 5:33,261,563...33,320,214

G

solute carrier family 5 (sodium/glucose cotransporter), member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A11 mRNA

NCBI chr 7:122,813,817...122,873,612
Ensembl chr 7:122,814,003...122,872,476

G

solute carrier family 5 (inositol transporters), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC5A3 mRNA

NCBI chr16:91,855,210...91,884,361
Ensembl chr16:91,855,210...91,884,361

G

solute carrier family 5 (iodide transporter), member 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A8 mRNA

NCBI chr10:88,721,854...88,765,377
Ensembl chr10:88,721,854...88,765,377

G

solute carrier family 5 (sodium/glucose cotransporter), member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A9 mRNA

NCBI chr 4:111,732,571...111,759,993
Ensembl chr 4:111,732,572...111,760,115

G

solute carrier family 6 (neurotransmitter transporter, GABA), member 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A11 mRNA

NCBI chr 6:114,108,202...114,226,847
Ensembl chr 6:114,108,202...114,226,913

G

solute carrier family 6 (neurotransmitter transporter, betaine/GABA), member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A12 mRNA

NCBI chr 6:121,319,533...121,342,732
Ensembl chr 6:121,320,035...121,342,734

G

solute carrier family 6 (neurotransmitter transporter), member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A14 mRNA

NCBI chr X:21,581,139...21,608,597
Ensembl chr X:21,581,135...21,608,594

G

solute carrier family 6 (neurotransmitter transporter), member 19

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A19 mRNA

NCBI chr13:73,827,864...73,848,899
Ensembl chr13:73,827,864...73,852,984

G

solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A2 mRNA

NCBI chr 8:93,687,100...93,728,295
Ensembl chr 8:93,686,707...93,728,295

G

solute carrier family 6 (neurotransmitter transporter, dopamine), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A3 mRNA

NCBI chr13:73,684,270...73,726,791
Ensembl chr13:73,684,866...73,726,791

G

solute carrier family 6 (neurotransmitter transporter, taurine), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A6 mRNA

NCBI chr 6:91,661,031...91,736,044
Ensembl chr 6:91,661,034...91,736,047

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A5 mRNA

NCBI chr 8:122,607,885...122,634,425
Ensembl chr 8:122,607,889...122,634,433

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC7A6 mRNA

NCBI chr 8:106,894,718...106,925,346
Ensembl chr 8:106,895,489...106,925,338

G

solute carrier family 7 (cationic amino acid transporter, y+ system), member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A9 mRNA

NCBI chr 7:35,148,152...35,165,459
Ensembl chr 7:35,148,221...35,165,461

G

solute carrier family 8 (sodium/calcium exchanger), member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A1 mRNA

NCBI chr17:81,680,534...82,045,816
Ensembl chr17:81,680,534...82,045,806

G

solute carrier family 8 (sodium/calcium exchanger), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A3 mRNA

NCBI chr12:81,244,686...81,380,506
Ensembl chr12:81,244,689...81,379,954

G

solute carrier family 9 (sodium/hydrogen exchanger), member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A2 mRNA

NCBI chr 1:40,720,872...40,808,045
Ensembl chr 1:40,719,734...40,808,433

G

solute carrier family 9 (sodium/hydrogen exchanger), member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A3 mRNA

NCBI chr13:74,234,374...74,317,561
Ensembl chr13:74,269,576...74,317,561

G

solute carrier family 9 (sodium/hydrogen exchanger), member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC9A7 mRNA

NCBI chr X:19,965,090...20,158,274
Ensembl chr X:19,971,993...20,158,046

G

solute carrier organic anion transporter family, member 1a1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLCO1A1 mRNA

NCBI chr 6:141,853,007...141,892,688
Ensembl chr 6:141,853,008...141,892,688

G

solute carrier organic anion transporter family, member 1a4

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO1A4 mRNA
Dextran Sulfate results in decreased expression of SLCO1A4 mRNA

PMID:29950665 PMID:35093514

NCBI chr 6:141,751,164...141,802,011
Ensembl chr 6:141,751,166...141,801,925

G

solute carrier organic anion transporter family, member 1a6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO1A6 mRNA

NCBI chr 6:142,031,487...142,131,903
Ensembl chr 6:142,031,487...142,154,247

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO2B1 mRNA

NCBI chr 7:99,307,011...99,360,547
Ensembl chr 7:99,307,011...99,360,547

G

solute carrier organic anion transporter family, member 3a1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLCO3A1 mRNA

NCBI chr 7:73,925,166...74,204,528
Ensembl chr 7:73,925,167...74,204,528

G

smoothened, frizzled class receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMO mRNA

NCBI chr 6:29,735,480...29,761,359
Ensembl chr 6:29,735,502...29,761,364

G

spermine oxidase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMOX mRNA

NCBI chr 2:131,333,624...131,367,103
Ensembl chr 2:131,333,416...131,367,842

G

sphingomyelin phosphodiesterase 2, neutral

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SMPD2 mRNA
Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD2 mRNA]

NCBI chr10:41,363,168...41,366,410
Ensembl chr10:41,361,638...41,366,365

G

sphingomyelin phosphodiesterase 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SMPD4 mRNA
Fenofibrate promotes the reaction [Dextran Sulfate results in decreased expression of SMPD4 mRNA]

NCBI chr16:17,437,218...17,462,694
Ensembl chr16:17,437,218...17,462,692

G

snail family zinc finger 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SNAI1 protein

NCBI chr 2:167,380,115...167,384,734
Ensembl chr 2:167,380,115...167,384,734

G

small nucleolar RNA, C/D box 118

increases expression

Dextran Sulfate results in increased expression of SNORD118 mRNA

NCBI chr11:68,964,252...68,964,388
Ensembl chr11:68,964,253...68,964,387

G

sorting nexin 9

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SNX9 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SNX9 protein]

NCBI chr17:5,891,599...5,982,231
Ensembl chr17:5,891,604...5,982,229

G

SRY (sex determining region Y)-box 4

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of SOX4 mRNA

NCBI chr13:29,132,902...29,137,682
Ensembl chr13:29,132,902...29,137,696

G

SRY (sex determining region Y)-box 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SOX9 mRNA

NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586

G

secreted acidic cysteine rich glycoprotein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA

NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009

G

sphingosine kinase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPHK1 mRNA
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of SPHK1 protein]

PMID:29950665 PMID:30811821

NCBI chr11:116,421,662...116,427,502
Ensembl chr11:116,421,751...116,427,501

G

sialophorin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPN mRNA

NCBI chr 7:126,731,404...126,743,785
Ensembl chr 7:126,731,404...126,736,995

G

secreted phosphoprotein 1

multiple interactions
increases expression
decreases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of SPP1 mRNA]
Dextran Sulfate results in decreased expression of SPP1 protein

PMID:32033881 PMID:35999755

NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916

G

small proline-rich protein 1A

increases expression

Dextran Sulfate results in increased expression of SPRR1A mRNA

NCBI chr 3:92,391,261...92,393,188
Ensembl chr 3:92,391,259...92,393,202

G

spectrin beta, non-erythrocytic 1

decreases expression

Dextran Sulfate results in decreased expression of SPTBN1 protein

NCBI chr11:30,049,395...30,218,384
Ensembl chr11:30,049,395...30,218,175

G

sequestosome 1

multiple interactions
decreases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in decreased expression of SQSTM1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in decreased expression of SQSTM1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654

G

steroid 5 alpha-reductase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SRD5A2 mRNA

NCBI chr17:74,321,886...74,354,855
Ensembl chr17:74,323,950...74,354,911

G

SLIT-ROBO Rho GTPase activating protein 3

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SRGAP3 mRNA
Dextran Sulfate results in decreased expression of SRGAP3 mRNA

PMID:29950665 PMID:35093514

NCBI chr 6:112,694,932...112,924,466
Ensembl chr 6:112,694,932...112,924,227

G

signal recognition particle 9

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of SRP9 protein]

NCBI chr 1:181,952,302...181,959,980
Ensembl chr 1:181,952,302...181,959,972

G

serine and arginine-rich splicing factor 4

increases expression

Dextran Sulfate results in increased expression of SRSF4 mRNA

NCBI chr 4:131,600,841...131,629,036
Ensembl chr 4:131,600,928...131,629,017

G

somatostatin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SSTR1 mRNA

NCBI chr12:58,258,524...58,262,822
Ensembl chr12:58,258,558...58,260,673

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ST3GAL3 mRNA

NCBI chr 4:117,789,349...117,992,169
Ensembl chr 4:117,789,351...117,992,111

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ST3GAL6 mRNA

NCBI chr16:58,290,105...58,344,614
Ensembl chr16:58,288,488...58,344,606

G

steroidogenic acute regulatory protein

decreases expression

Dextran Sulfate results in decreased expression of STAR mRNA

NCBI chr 8:26,298,502...26,306,010
Ensembl chr 8:26,296,583...26,306,010

G

StAR related lipid transfer domain containing 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STARD5 mRNA

NCBI chr 7:83,281,225...83,291,536
Ensembl chr 7:83,281,167...83,302,335

G

signal transducer and activator of transcription 1

multiple interactions
increases phosphorylation

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT1 protein]

NCBI chr 1:52,158,588...52,201,024
Ensembl chr 1:52,158,599...52,201,024

G

signal transducer and activator of transcription 3

multiple interactions
increases expression
increases phosphorylation

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein]
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein]; Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of STAT3 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased phosphorylation of and results in increased activity of STAT3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]

PMID:19028472 PMID:20155626 PMID:22334590 PMID:25026504 PMID:26074695 More...

NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366

G

six transmembrane epithelial antigen of the prostate 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP1 mRNA

NCBI chr 5:5,786,322...5,799,317
Ensembl chr 5:5,786,317...5,799,326

G

six transmembrane epithelial antigen of prostate 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP2 mRNA

NCBI chr 5:5,714,829...5,744,649
Ensembl chr 5:5,714,829...5,744,578

G

stromal interaction molecule 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STIM1 mRNA

NCBI chr 7:101,909,279...102,086,525
Ensembl chr 7:101,917,013...102,086,526

G

stress-induced phosphoprotein 1

decreases expression

Dextran Sulfate results in decreased expression of STIP1 protein

NCBI chr19:6,998,064...7,017,394
Ensembl chr19:6,998,070...7,017,335

G

serine/threonine kinase 4

multiple interactions

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in decreased activity of STK4 protein

NCBI chr 2:163,916,033...163,997,444
Ensembl chr 2:163,912,242...163,997,444

G

stimulated by retinoic acid gene 8

increases expression

Dextran Sulfate results in increased expression of STRA8 mRNA

NCBI chr 6:34,897,098...34,916,279
Ensembl chr 6:34,897,098...34,916,279

G

syntaxin 1A (brain)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STX1A mRNA

NCBI chr 5:135,051,473...135,079,954
Ensembl chr 5:135,052,336...135,079,954

G

SUB1 homolog, transcriptional regulator

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUB1 protein]

NCBI chr15:11,981,422...11,996,091
Ensembl chr15:11,981,425...11,997,069

G

succinate-Coenzyme A ligase, GDP-forming, beta subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SUCLG2 mRNA

NCBI chr 6:95,449,992...95,695,799
Ensembl chr 6:95,449,990...95,695,781

G

sulfotransferase family 1B, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1B1 mRNA

NCBI chr 5:87,661,186...87,686,054
Ensembl chr 5:87,661,198...87,686,054

G

sulfotransferase family, cytosolic, 1C, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1C2 mRNA

NCBI chr17:54,136,665...54,152,986
Ensembl chr17:54,136,665...54,153,367

G

sulfotransferase family 1E, member 1

decreases expression

Dextran Sulfate results in decreased expression of SULT1E1 mRNA

NCBI chr 5:87,723,827...87,739,470
Ensembl chr 5:87,723,828...87,739,453

G

sulfotransferase family 5A, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1A1 mRNA

NCBI chr 8:123,869,582...123,885,170
Ensembl chr 8:123,866,931...123,885,054

G

sulfite oxidase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of SUOX protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of SUOX protein]

NCBI chr10:128,505,756...128,509,787
Ensembl chr10:128,505,763...128,509,942

G

suppressor of variegation 3-9 1

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in increased expression of SUV39H1 protein]

NCBI chr X:7,927,401...7,940,994
Ensembl chr X:7,927,410...7,940,999

G

supervillin

decreases expression

Dextran Sulfate results in decreased expression of SVIL mRNA

NCBI chr18:4,920,497...5,119,290
Ensembl chr18:4,920,540...5,119,299

G

trace amine-associated receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAAR4 mRNA

NCBI chr10:23,836,392...23,837,435
Ensembl chr10:23,836,392...23,837,435

G

trace amine-associated receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAAR5 mRNA

NCBI chr10:23,846,604...23,847,617
Ensembl chr10:23,846,604...23,847,617

G

trace amine-associated receptor 7B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAAR7B mRNA

NCBI chr10:23,875,837...23,876,913
Ensembl chr10:23,875,837...23,876,913

G

trace amine-associated receptor 7F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAAR7F mRNA

NCBI chr10:23,925,408...23,926,484
Ensembl chr10:23,925,408...23,926,484

G

tachykinin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAC1 mRNA

NCBI chr 6:7,555,061...7,562,978
Ensembl chr 6:7,554,879...7,565,834

G

tachykinin receptor 1

affects response to substance
multiple interactions

TACR1 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TACR1 mRNA

PMID:20889569 PMID:29950665

NCBI chr 6:82,378,990...82,537,085
Ensembl chr 6:82,379,315...82,537,085

G

tachykinin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TACR2 mRNA

NCBI chr10:62,088,217...62,101,769
Ensembl chr10:62,088,217...62,101,769

G

TATA-box binding protein associated factor 15

increases expression

Dextran Sulfate results in increased expression of TAF15 mRNA

NCBI chr11:83,363,897...83,397,569
Ensembl chr11:83,363,912...83,397,569

G

T cell activation Rho GTPase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAGAP mRNA

NCBI chr17:8,144,832...8,153,729
Ensembl chr17:8,144,832...8,153,729

G

transgelin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN protein

NCBI chr 9:45,840,926...45,847,356
Ensembl chr 9:45,840,917...45,847,356

G

transgelin 2

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of TAGLN2 protein
Dextran Sulfate results in decreased expression of TAGLN2 protein

NCBI chr 1:172,327,813...172,334,942
Ensembl chr 1:172,327,614...172,334,947

G

transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TAP1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAP1 mRNA

PMID:23894361 PMID:29950665

NCBI chr17:34,406,530...34,416,199
Ensembl chr17:34,406,527...34,416,199

G

taste receptor, type 1, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TAS1R2 mRNA

NCBI chr 4:139,380,849...139,397,591
Ensembl chr 4:139,380,849...139,397,591

G

taste receptor, type 1, member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS1R3 mRNA

NCBI chr 4:155,943,725...155,947,810
Ensembl chr 4:155,943,725...155,947,819

G

taste receptor, type 2, member 103

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R103 mRNA

NCBI chr 6:133,013,126...133,014,064
Ensembl chr 6:133,013,126...133,014,064

G

taste receptor, type 2, member 109

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS2R109 mRNA

NCBI chr 6:132,956,978...132,957,928
Ensembl chr 6:132,956,978...132,957,928

G

taste receptor, type 2, member 118

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R118 mRNA

NCBI chr 6:23,969,160...23,970,059
Ensembl chr 6:23,969,160...23,970,059

G

taste receptor, type 2, member 131

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS2R131 mRNA

NCBI chr 6:132,933,875...132,934,807
Ensembl chr 6:132,933,847...132,934,882

G

taste receptor, type 2, member 137

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R137 mRNA

NCBI chr 6:40,468,172...40,469,173
Ensembl chr 6:40,468,167...40,469,239

G

TBC1 domain family, member 15

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TBC1D15 protein]

NCBI chr10:115,031,459...115,087,343
Ensembl chr10:115,033,777...115,087,372

G

tubulin-specific chaperone C

increases expression

Dextran Sulfate results in increased expression of TBCC mRNA

NCBI chr17:47,201,547...47,203,389
Ensembl chr17:47,201,610...47,202,773

G

T-box 21

multiple interactions
increases expression

Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TBX21 mRNA]

NCBI chr11:96,988,833...97,006,157
Ensembl chr11:96,988,897...97,006,157

G

thromboxane A synthase 1, platelet

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TBXAS1 mRNA
Dextran Sulfate results in increased expression of TBXAS1 protein

PMID:29950665 PMID:30489199

NCBI chr 6:38,817,897...39,061,524
Ensembl chr 6:38,852,338...39,061,519

G

TRPM8 channel-associated factor 1

decreases expression

Dextran Sulfate results in decreased expression of TCAF1 mRNA

NCBI chr 6:42,644,933...42,687,065
Ensembl chr 6:42,644,936...42,687,022

G

TRPM8 channel-associated factor 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TCAF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TCAF2 protein]

NCBI chr 6:42,599,950...42,622,134
Ensembl chr 6:42,599,950...42,622,188

G

titin-cap

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TCAP mRNA

NCBI chr11:98,274,637...98,275,779
Ensembl chr11:98,274,637...98,275,779

G

transcription factor 7, T cell specific

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA]

NCBI chr11:52,137,347...52,174,211
Ensembl chr11:52,143,198...52,174,158

G

trichoplein, keratin filament binding

increases expression

Dextran Sulfate results in increased expression of TCHP mRNA

NCBI chr 5:114,845,813...114,860,388
Ensembl chr 5:114,845,821...114,860,388

G

trefoil factor 3, intestinal

increases expression

Dextran Sulfate results in increased expression of TFF3 mRNA

NCBI chr17:31,344,280...31,348,585
Ensembl chr17:31,344,280...31,348,620

G

transferrin receptor

increases expression

Dextran Sulfate results in increased expression of TFRC protein

NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612

G

transforming growth factor, beta 1

multiple interactions
increases expression
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TGFB1 protein]
Dextran Sulfate results in increased expression of TGFB1 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of TGFB1 mRNA]

PMID:20881082 PMID:25026504 PMID:26074695 PMID:35439472

NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502

G

transforming growth factor, beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TGFB3 mRNA

NCBI chr12:86,103,517...86,125,815
Ensembl chr12:86,103,519...86,125,815

G

T cell specific GTPase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TGTP1 mRNA; Dextran Sulfate results in increased expression of TGTP1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TGTP1 protein]

PMID:23894361 PMID:32272095

NCBI chr11:48,876,156...48,883,073
Ensembl chr11:48,876,154...48,884,999

G

thrombomodulin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBD mRNA
Dextran Sulfate results in decreased expression of THBD mRNA

PMID:29950665 PMID:35093514

NCBI chr 2:148,246,391...148,250,108
Ensembl chr 2:148,246,386...148,250,108

G

thrombospondin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS1 mRNA

NCBI chr 2:117,942,357...117,957,614
Ensembl chr 2:117,942,357...117,957,614

G

thrombospondin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS4 mRNA

NCBI chr13:92,888,094...92,931,326
Ensembl chr13:92,888,098...92,931,326

G

thymus cell antigen 1, theta

increases expression
multiple interactions

Dextran Sulfate results in increased expression of THY1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of THY1 protein]

NCBI chr 9:43,954,681...43,959,876
Ensembl chr 9:43,954,681...43,959,876

G

tissue inhibitor of metalloproteinase 1

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP1 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TIMP1 mRNA]

PMID:29950665 PMID:32033881

NCBI chr X:20,736,524...20,740,972
Ensembl chr X:20,736,405...20,740,974

G

tissue inhibitor of metalloproteinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP2 mRNA

NCBI chr11:118,191,887...118,246,237
Ensembl chr11:118,191,887...118,246,566

G

tissue inhibitor of metalloproteinase 3

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP3 mRNA; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; Resveratrol inhibits the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]

PMID:24548422 PMID:29950665

NCBI chr10:86,136,276...86,185,369
Ensembl chr10:86,136,236...86,185,370

G

tight junction protein 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of TJP1 mRNA; Dextran Sulfate results in decreased expression of TJP1 protein
[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 protein]; HU 211 inhibits the reaction [Dextran Sulfate results in decreased expression of TJP1 mRNA]; obeticholic acid promotes the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TJP1 protein]

PMID:27995407 PMID:35439472 PMID:35670535 PMID:36281492 PMID:37209277 More...

NCBI chr 7:64,945,913...65,177,629
Ensembl chr 7:64,945,913...65,177,529

G

thymidine kinase 1

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA; alfacalcidol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA]

NCBI chr11:117,706,345...117,716,913
Ensembl chr11:117,706,352...117,716,918

G

transketolase

decreases expression

Dextran Sulfate results in decreased expression of TKT mRNA

NCBI chr14:30,271,088...30,296,681
Ensembl chr14:30,270,316...30,296,677

G

tolloid-like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLL1 mRNA

NCBI chr 8:64,466,132...64,659,043
Ensembl chr 8:64,467,965...64,659,305

G

talin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLN1 mRNA

NCBI chr 4:43,531,513...43,562,583
Ensembl chr 4:43,531,519...43,562,691

G

toll-like receptor 4

multiple interactions
increases expression
affects response to substance

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; [Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR4 mRNA; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of IL6 protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Lipopolysaccharides inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in increased expression of TLR4 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TLR4 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]
TLR4 protein affects the susceptibility to Dextran Sulfate

PMID:21359540 PMID:27995407 PMID:29950665 PMID:31442584 PMID:32272095 More...

NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521

G

toll-like receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR7 mRNA

NCBI chr X:166,086,376...166,113,570
Ensembl chr X:166,087,925...166,113,554

G

transmembrane protein 109

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TMEM109 protein]

NCBI chr19:10,848,021...10,859,107
Ensembl chr19:10,848,024...10,859,365

G

transmembrane protein 164

decreases expression

Dextran Sulfate results in decreased expression of TMEM164 mRNA

NCBI chr X:141,463,343...141,626,490
Ensembl chr X:141,464,402...141,626,490

G

transmembrane protein 191

increases expression

Dextran Sulfate results in increased expression of TMEM191C mRNA

NCBI chr16:17,094,164...17,096,525
Ensembl chr16:17,093,941...17,101,093

G

transmembrane protein 252

increases expression

Dextran Sulfate results in increased expression of TMEM252 mRNA

NCBI chr19:24,651,372...24,657,025
Ensembl chr19:24,651,372...24,659,597

G

thymosin, beta 4, X chromosome

decreases expression

Dextran Sulfate results in decreased expression of TMSB4X protein

NCBI chr X:165,990,089...165,996,475
Ensembl chr X:165,990,089...165,992,311

G

thiol methyltransferase 1B

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TMT1B protein]

NCBI chr10:128,794,146...128,796,857
Ensembl chr10:128,794,143...128,796,857

G

tumor necrosis factor

multiple interactions
increases secretion
increases expression
affects expression

(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of TNF protein; [IL17A protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; apigenin-6,8-di-C-glycopyranoside inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; asperuloside inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; bisphenol A promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]]; Butylated Hydroxytoluene inhibits the reaction [Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]]; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; Chlorpyrifos promotes the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Cholecalciferol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Coumarins inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Dextran Sulfate affects the reaction [TLR4 protein affects the expression of TNF protein]; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein]; Dextran Sulfate inhibits the reaction [Polymyxin B results in decreased expression of TNF protein]; Dextran Sulfate promotes the reaction [Ascorbic Acid promotes the reaction [Quartz results in increased secretion of TNF protein]]; Dextran Sulfate promotes the reaction [Quartz results in increased secretion of TNF protein]; Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein; dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Fenofibrate promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; geraniol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerenone A inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein]; isovitexin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Lipopolysaccharides promotes the reaction [Dextran Sulfate results in increased expression of TNF protein]; mangiferin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; MIF protein affects the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Minocycline inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; NFE2L2 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; NFE2L2 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; Nicotine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]; Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of TNF protein]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]]; TLR4 protein affects the reaction [HU 211 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]; tussilagone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA]
[2,2-bis(4-glycidyloxyphenyl)propane co-treated with Dextran Sulfate co-treated with Rosiglitazone] results in increased expression of TNF protein; [2,2-bis(4-glycidyloxyphenyl)propane co-treated with Dextran Sulfate] results in increased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; celastrol inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; celastrol promotes the reaction [N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Olmesartan Medoxomil inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]
Dextran Sulfate results in increased expression of TNF mRNA; Dextran Sulfate results in increased expression of TNF protein

PMID:12105854 PMID:16774945 PMID:17438113 PMID:19028472 PMID:19285099 More...

NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983

G

tumor necrosis factor receptor superfamily, member 11a, NFKB activator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFRSF11A mRNA

NCBI chr 1:105,708,443...105,777,172
Ensembl chr 1:105,708,443...105,775,709

G

tumor necrosis factor receptor superfamily, member 12a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF12A mRNA

NCBI chr17:23,894,419...23,896,423
Ensembl chr17:23,894,419...23,896,442

G

tumor necrosis factor receptor superfamily, member 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF18 mRNA

NCBI chr 4:156,110,779...156,113,351
Ensembl chr 4:156,110,621...156,113,352

G

tumor necrosis factor receptor superfamily, member 1a

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF1A mRNA

NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447

G

tumor necrosis factor receptor superfamily, member 1b

increases expression

Dextran Sulfate results in increased expression of TNFRSF1B mRNA

NCBI chr 4:144,938,938...144,973,453
Ensembl chr 4:144,940,033...144,973,440

G

tumor necrosis factor receptor superfamily, member 8

affects response to substance
multiple interactions

TNFRSF8 protein affects the susceptibility to Dextran Sulfate
[TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFRSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein

NCBI chr 4:144,993,702...145,041,734
Ensembl chr 4:144,993,707...145,041,734

G

tumor necrosis factor (ligand) superfamily, member 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF12 mRNA

NCBI chr11:69,577,066...69,586,924
Ensembl chr11:69,577,076...69,586,675

G

tumor necrosis factor (ligand) superfamily, member 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF14 mRNA

NCBI chr17:57,496,437...57,501,182
Ensembl chr17:57,496,492...57,501,177

G

tumor necrosis factor (ligand) superfamily, member 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFSF15 mRNA

NCBI chr 4:63,642,837...63,663,296
Ensembl chr 4:63,642,840...63,663,350

G

tumor necrosis factor (ligand) superfamily, member 8

affects response to substance
increases expression
multiple interactions

TNFSF8 protein affects the susceptibility to Dextran Sulfate
Dextran Sulfate results in increased expression of TNFSF8 protein
[TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL1B protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of IL6 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the expression of TNF protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IFNG protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL10 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL17A protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL2 protein; [TNFSF8 protein affects the susceptibility to Dextran Sulfate] which affects the secretion of IL4 protein

NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584

G

tumor necrosis factor (ligand) superfamily, member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF9 mRNA

NCBI chr17:57,412,113...57,414,757
Ensembl chr17:57,412,325...57,414,757

G

troponin C, cardiac/slow skeletal

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC1 mRNA

NCBI chr14:30,930,274...30,933,671
Ensembl chr14:30,930,269...30,933,686

G

troponin C2, fast

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC2 mRNA

NCBI chr 2:164,619,081...164,621,654
Ensembl chr 2:164,619,081...164,621,887

G

troponin I, skeletal, slow 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNNI1 mRNA

NCBI chr 1:135,709,252...135,738,727
Ensembl chr 1:135,707,172...135,738,727

G

troponin I, skeletal, fast 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNI2 mRNA

NCBI chr 7:141,995,553...141,998,147
Ensembl chr 7:141,995,545...141,998,147

G

troponin T3, skeletal, fast

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNT3 mRNA

NCBI chr 7:142,052,530...142,069,746
Ensembl chr 7:142,052,573...142,069,746

G

toll interacting protein

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in decreased expression of TOLLIP protein]

NCBI chr 7:141,435,317...141,456,198
Ensembl chr 7:141,428,550...141,472,244

G

translocase of outer mitochondrial membrane 7

increases expression

Dextran Sulfate results in increased expression of TOMM7 mRNA

NCBI chr 5:24,043,942...24,049,143
Ensembl chr 5:24,043,942...24,049,159

G

two pore channel 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPCN1 mRNA

NCBI chr 5:120,672,222...120,726,731
Ensembl chr 5:120,672,218...120,726,738

G

tryptophan hydroxylase 1

multiple interactions
increases expression

Granisetron inhibits the reaction [Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of TPH1 protein]

NCBI chr 7:46,294,065...46,321,961
Ensembl chr 7:46,294,065...46,321,961

G

triosephosphate isomerase 1

increases expression
decreases expression

Dextran Sulfate results in increased expression of TPI1 mRNA
Dextran Sulfate results in decreased expression of TPI1 protein

PMID:35093514 PMID:35999755

NCBI chr 6:124,787,549...124,791,121
Ensembl chr 6:124,787,549...124,791,259

G

tropomyosin 2, beta

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of TPM2 mRNA
Dextran Sulfate results in decreased expression of TPM2 protein

PMID:26271895 PMID:35999755

NCBI chr 4:43,513,726...43,523,583
Ensembl chr 4:43,514,711...43,523,765

G

tropomyosin 3, gamma

decreases expression

Dextran Sulfate results in decreased expression of TPM3 protein

NCBI chr 3:89,979,958...90,008,209
Ensembl chr 3:89,979,956...90,008,209

G

tropomyosin 4

decreases expression

Dextran Sulfate results in decreased expression of TPM4 protein

NCBI chr 8:72,889,132...72,906,986
Ensembl chr 8:72,884,018...72,906,986

G

thiopurine methyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPMT mRNA

NCBI chr13:47,175,463...47,196,833
Ensembl chr13:47,175,958...47,198,213

G

tryptase beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TPSB2 mRNA

NCBI chr17:25,585,282...25,587,070
Ensembl chr17:25,585,170...25,588,079

G

tumor protein, translationally-controlled 1

decreases expression

Dextran Sulfate results in decreased expression of TPT1 protein

NCBI chr14:76,082,771...76,085,743
Ensembl chr14:76,082,533...76,085,965

G

TRAF3 interacting protein 1

increases expression

Dextran Sulfate results in increased expression of TRAF3IP1 mRNA

NCBI chr 1:91,422,311...91,457,029
Ensembl chr 1:91,422,369...91,457,029

G

TNF receptor-associated factor 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TRAF6 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of TRAF6 protein]

NCBI chr 2:101,508,765...101,532,013
Ensembl chr 2:101,508,774...101,532,014

G

tetratricopeptide repeat and ankyrin repeat containing 1

decreases expression

Dextran Sulfate results in decreased expression of TRANK1 mRNA

NCBI chr 9:111,140,351...111,224,843
Ensembl chr 9:111,140,807...111,224,843

G

triggering receptor expressed on myeloid cells 2

multiple interactions
increases expression

huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TREM2 protein]

NCBI chr17:48,653,429...48,659,304
Ensembl chr17:48,653,429...48,661,175

G

transferrin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRF mRNA

NCBI chr 9:103,086,075...103,107,485
Ensembl chr 9:103,081,200...103,107,643

G

thyrotropin releasing hormone

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRH mRNA

NCBI chr 6:92,219,042...92,221,631
Ensembl chr 6:92,219,042...92,221,631

G

tribbles pseudokinase 2

decreases expression

Dextran Sulfate results in decreased expression of TRIB2 mRNA

NCBI chr12:15,841,726...15,866,963
Ensembl chr12:15,841,728...15,866,923

G

tripartite motif-containing 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRIM25 mRNA

NCBI chr11:88,890,194...88,911,119
Ensembl chr11:88,890,202...88,911,119

G

tripartite motif-containing 41

increases expression

Dextran Sulfate results in increased expression of TRIM41 mRNA

NCBI chr11:48,697,230...48,709,026
Ensembl chr11:48,697,231...48,708,180

G

telomerase RNA component interacting RNase

increases expression

Dextran Sulfate results in increased expression of TRIR mRNA

NCBI chr 8:85,753,440...85,756,920
Ensembl chr 8:85,753,452...85,756,915

G

transformation related protein 53

increases expression

Dextran Sulfate results in increased expression of TRP53 protein

NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC3 mRNA

NCBI chr 3:36,674,626...36,744,276
Ensembl chr 3:36,674,631...36,744,316

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC6 mRNA

NCBI chr 9:8,543,868...8,680,753
Ensembl chr 9:8,544,143...8,680,742

G

transient receptor potential cation channel, subfamily C, member 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPC7 mRNA

NCBI chr13:56,920,911...57,043,778
Ensembl chr13:56,920,926...57,043,806

G

transient receptor potential cation channel, subfamily M, member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRPM1 mRNA

NCBI chr 7:63,803,583...63,923,630
Ensembl chr 7:63,803,583...63,919,523

G

transient receptor potential cation channel, subfamily M, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM4 mRNA

NCBI chr 7:44,952,579...44,983,495
Ensembl chr 7:44,952,056...44,983,204

G

transient receptor potential cation channel, subfamily M, member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM6 mRNA

NCBI chr19:18,707,566...18,869,885
Ensembl chr19:18,727,347...18,869,875

G

transient receptor potential cation channel, subfamily M, member 8

increases expression

Dextran Sulfate results in increased expression of TRPM8 mRNA

NCBI chr 1:88,234,457...88,318,909
Ensembl chr 1:88,205,383...88,317,015

G

transient receptor potential cation channel, subfamily V, member 1

affects expression
multiple interactions

Dextran Sulfate affects the expression of TRPV1 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV1 mRNA

PMID:18687398 PMID:29950665

NCBI chr11:73,124,975...73,152,148
Ensembl chr11:73,125,118...73,152,068

G

transient receptor potential cation channel, subfamily V, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV2 mRNA

NCBI chr11:62,465,312...62,491,131
Ensembl chr11:62,465,312...62,491,341

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV4 mRNA

NCBI chr 5:114,760,213...114,796,497
Ensembl chr 5:114,760,213...114,796,482

G

transient receptor potential cation channel, subfamily V, member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV6 mRNA

NCBI chr 6:41,597,553...41,613,339
Ensembl chr 6:41,597,558...41,613,339

G

trypsin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS3 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY4 mRNA

NCBI chr 6:41,279,206...41,282,467
Ensembl chr 6:41,279,203...41,282,466

G

trypsin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY5 mRNA

NCBI chr 6:41,288,166...41,291,644
Ensembl chr 6:41,288,167...41,293,775

G

TSC complex subunit 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of TSC2 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]]; alpinetin inhibits the reaction [Dextran Sulfate results in decreased expression of TSC2 protein]

NCBI chr17:24,814,788...24,851,607
Ensembl chr17:24,814,790...24,851,604

G

TSC22 domain family, member 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TSC22D3 mRNA

NCBI chr X:139,440,277...139,501,257
Ensembl chr X:139,440,277...139,501,408

G

testis-specific serine kinase substrate

increases expression

Dextran Sulfate results in increased expression of TSKS mRNA

NCBI chr 7:44,579,044...44,607,465
Ensembl chr 7:44,592,628...44,607,459

G

translin-associated factor X

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of TSNAX protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of TSNAX protein]

NCBI chr 8:125,739,780...125,760,947
Ensembl chr 8:125,739,736...125,760,931

G

thiosulfate sulfurtransferase, mitochondrial

multiple interactions
decreases expression

Dextran Sulfate affects the activity of and results in decreased expression of TST protein
Dextran Sulfate results in decreased expression of TST mRNA

NCBI chr15:78,283,756...78,290,065
Ensembl chr15:78,283,756...78,290,107

G

titin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTN mRNA

NCBI chr 2:76,534,324...76,812,901
Ensembl chr 2:76,534,324...76,812,891

G

transthyretin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTR mRNA

NCBI chr18:20,797,266...20,807,383
Ensembl chr18:20,798,337...20,807,378

G

tubulin, alpha 1A

decreases expression

Dextran Sulfate results in decreased expression of TUBA1A protein

NCBI chr15:98,847,728...98,851,382
Ensembl chr15:98,847,718...98,851,584

G

tubulin, alpha 4A

decreases expression

Dextran Sulfate results in decreased expression of TUBA4A protein

NCBI chr 1:75,190,867...75,197,905
Ensembl chr 1:75,190,872...75,196,509

G

tubulin, beta 1 class VI

decreases expression

Dextran Sulfate results in decreased expression of TUBB1 protein

NCBI chr 2:174,292,388...174,300,173
Ensembl chr 2:174,292,488...174,299,675

G

tubulin, beta 6 class V

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TUBB6 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of TUBB6 protein]

NCBI chr18:67,523,801...67,535,819
Ensembl chr18:67,523,787...67,535,819

G

thymidylate synthase

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA

NCBI chr 5:30,243,544...30,279,261
Ensembl chr 5:30,263,200...30,278,615

G

TYRO protein tyrosine kinase binding protein

increases expression
multiple interactions

Dextran Sulfate results in increased expression of TYROBP mRNA; Dextran Sulfate results in increased expression of TYROBP protein
huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP mRNA]; huanglian-jie-du decoction inhibits the reaction [Dextran Sulfate results in increased expression of TYROBP protein]

NCBI chr 7:30,113,207...30,117,007
Ensembl chr 7:30,113,185...30,117,010

G

UDP-N-acteylglucosamine pyrophosphorylase 1-like 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of UAP1L1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of UAP1L1 protein]

NCBI chr 2:25,251,501...25,255,695
Ensembl chr 2:25,249,901...25,255,694

G

ubiquitin-like modifier activating enzyme 1

decreases expression

Dextran Sulfate results in decreased expression of UBA1 protein

NCBI chr X:20,524,660...20,549,420
Ensembl chr X:20,524,565...20,549,418

G

ubiquitin-like modifier activating enzyme 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UBA7 mRNA

NCBI chr 9:107,852,766...107,861,255
Ensembl chr 9:107,852,704...107,861,259

G

ubiquilin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of UBQLN1 protein]

NCBI chr13:58,323,970...58,363,467
Ensembl chr13:58,323,970...58,363,467

G

uridine-cytidine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UCK2 mRNA

NCBI chr 1:167,050,464...167,112,657
Ensembl chr 1:167,050,452...167,112,889

G

UDP-glucose dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGDH mRNA

NCBI chr 5:65,570,550...65,593,185
Ensembl chr 5:65,570,564...65,593,292

G

UDP glycosyltransferase 1 family, polypeptide A10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A10 mRNA

NCBI chr 1:87,983,133...88,147,724
Ensembl chr 1:87,983,110...88,146,726

G

UDP glucuronosyltransferase 1 family, polypeptide A6A

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A6A mRNA
Dextran Sulfate results in decreased expression of UGT1A6A mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:88,062,531...88,147,724
Ensembl chr 1:88,062,531...88,146,719

G

UDP glucuronosyltransferase 1 family, polypeptide A6B

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A6B mRNA
Dextran Sulfate results in decreased expression of UGT1A6B mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:88,030,979...88,146,720
Ensembl chr 1:88,030,974...88,146,725

G

UDP glucuronosyltransferase 1 family, polypeptide A7C

decreases expression

Dextran Sulfate results in decreased expression of UGT1A7C mRNA

NCBI chr 1:88,022,723...88,147,724
Ensembl chr 1:88,022,784...88,147,724

G

UDP glucuronosyltransferase 2 family, polypeptide A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2A1 mRNA

NCBI chr 5:87,607,349...87,638,730
Ensembl chr 5:87,607,349...87,638,730

G

UDP glucuronosyltransferase 2 family, polypeptide B34

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B34 mRNA

NCBI chr 5:87,037,613...87,054,805
Ensembl chr 5:87,037,626...87,054,796

G

UDP glucuronosyltransferase 2 family, polypeptide B37

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B37 mRNA

NCBI chr 5:87,388,351...87,402,647
Ensembl chr 5:87,388,352...87,402,663

G

UDP glucuronosyltransferase 2 family, polypeptide B38

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B38 mRNA

NCBI chr 5:87,557,798...87,572,062
Ensembl chr 5:87,557,801...87,572,062

G

unc-80, NALCN activator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UNC80 mRNA

NCBI chr 1:66,507,093...66,738,309
Ensembl chr 1:66,507,526...66,738,307

G

ureidopropionase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPB1 mRNA

NCBI chr10:75,242,745...75,277,513
Ensembl chr10:75,236,949...75,277,513

G

UPF3 regulator of nonsense transcripts homolog A (yeast)

increases expression

Dextran Sulfate results in increased expression of UPF3A mRNA

NCBI chr 8:13,834,636...13,848,723
Ensembl chr 8:13,835,615...13,849,193

G

uridine phosphorylase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPP2 mRNA

NCBI chr 2:58,456,329...58,685,858
Ensembl chr 2:58,457,310...58,682,983

G

ubiquinol-cytochrome c reductase, complex III subunit VII

increases expression

Dextran Sulfate results in increased expression of UQCRQ mRNA

NCBI chr11:53,318,749...53,321,658
Ensembl chr11:53,318,749...53,321,658

G

vomeronasal 1 receptor, A8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of V1RA8 mRNA

NCBI chr 6:90,179,799...90,180,638
Ensembl chr 6:90,179,768...90,182,848

G

vav 1 oncogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV1 mRNA

NCBI chr17:57,586,080...57,636,236
Ensembl chr17:57,586,100...57,635,031

G

vav 3 oncogene

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV3 mRNA

NCBI chr 3:109,247,757...109,593,010
Ensembl chr 3:109,247,969...109,593,014

G

vascular cell adhesion molecule 1

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; Dexamethasone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; fraxinellone inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA]

PMID:21724996 PMID:25448682

NCBI chr 3:115,903,669...115,923,337
Ensembl chr 3:115,903,598...115,923,337

G

versican

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA

NCBI chr13:89,803,429...89,891,146
Ensembl chr13:89,803,431...89,890,628

G

vinculin

decreases expression

Dextran Sulfate results in decreased expression of VCL protein

NCBI chr14:20,979,436...21,083,744
Ensembl chr14:20,979,466...21,083,744

G

vitamin D (1,25-dihydroxyvitamin D3) receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VDR mRNA

NCBI chr15:97,752,308...97,806,177
Ensembl chr15:97,752,306...97,808,511

G

vascular endothelial growth factor A

increases expression

Dextran Sulfate results in increased expression of VEGFA mRNA; Dextran Sulfate results in increased expression of VEGFA protein

PMID:20025956 PMID:35093514

NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295

G

vascular endothelial growth factor C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFC mRNA

NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131

G

vascular endothelial growth factor D

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFD mRNA

NCBI chr X:163,156,282...163,185,643
Ensembl chr X:163,156,374...163,185,646

G

vimentin

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of VIM protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIM protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VIM mRNA

PMID:29950665 PMID:34273909 PMID:36543318

NCBI chr 2:13,579,122...13,587,637
Ensembl chr 2:13,578,738...13,587,637

G

vasoactive intestinal peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIPR1 mRNA

NCBI chr 9:121,471,782...121,502,020
Ensembl chr 9:121,471,782...121,502,020

G

vomeronasal 1 receptor 42

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R42 mRNA

NCBI chr 6:89,821,500...89,822,597
Ensembl chr 6:89,819,555...89,853,395

G

vomeronasal 1 receptor 43

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R43 mRNA

NCBI chr 6:89,846,443...89,847,511
Ensembl chr 6:89,835,916...89,853,395

G

vomeronasal 1 receptor 47

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R47 mRNA

NCBI chr 6:89,998,870...89,999,802
Ensembl chr 6:89,993,129...90,004,459

G

vomeronasal 1 receptor 56

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R56 mRNA

NCBI chr 7:5,197,915...5,199,746
Ensembl chr 7:5,197,915...5,199,746

G

vomeronasal 1 receptor 62

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R62 mRNA

NCBI chr 7:5,677,603...5,679,598
Ensembl chr 7:5,676,630...5,679,662

G

vomeronasal 1 receptor 63

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VMN1R63 mRNA

NCBI chr 7:5,805,344...5,829,228
Ensembl chr 7:5,805,344...5,808,444

G

WD repeat domain 1

decreases expression

Dextran Sulfate results in decreased expression of WDR1 protein

NCBI chr 5:38,684,149...38,720,265
Ensembl chr 5:38,684,156...38,720,564

G

WAP four-disulfide core domain 17

increases expression

Dextran Sulfate results in increased expression of WFDC17 mRNA

NCBI chr11:83,594,882...83,597,095
Ensembl chr11:83,594,817...83,597,094

G

WAP four-disulfide core domain 18

increases expression

Dextran Sulfate results in increased expression of WFDC18 mRNA

NCBI chr11:83,599,830...83,602,186
Ensembl chr11:83,599,841...83,602,174

G

Wnt inhibitory factor 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 mRNA; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WIF1 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA]

PMID:26271895 PMID:31715269

NCBI chr10:120,869,909...120,936,547
Ensembl chr10:120,869,865...120,936,555

G

WNK lysine deficient protein kinase 1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of WNK1 mRNA

NCBI chr 6:119,900,930...120,015,659
Ensembl chr 6:119,900,930...120,015,633

G

WNK lysine deficient protein kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNK4 mRNA

NCBI chr11:101,151,363...101,168,235
Ensembl chr11:101,151,393...101,168,235

G

wingless-type MMTV integration site family, member 10A

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA]

NCBI chr 1:74,831,178...74,843,335
Ensembl chr 1:74,830,675...74,843,338

G

wingless-type MMTV integration site family, member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of WNT2 mRNA

NCBI chr 6:17,988,939...18,032,771
Ensembl chr 6:17,988,939...18,030,584

G

wingless-type MMTV integration site family, member 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNT2B mRNA

NCBI chr 3:104,852,121...104,869,025
Ensembl chr 3:104,852,588...104,869,237

G

wingless-type MMTV integration site family, member 3

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA]

NCBI chr11:103,665,000...103,708,854
Ensembl chr11:103,664,976...103,708,783

G

wingless-type MMTV integration site family, member 6

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA]

NCBI chr 1:74,793,499...74,824,481
Ensembl chr 1:74,811,051...74,824,481

G

wingless-type MMTV integration site family, member 7B

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA]

NCBI chr15:85,419,638...85,466,022
Ensembl chr15:85,419,638...85,466,674

G

chemokine (C motif) ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCL1 mRNA

NCBI chr 1:164,759,216...164,763,094
Ensembl chr 1:164,759,213...164,763,096

G

chemokine (C motif) receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCR1 mRNA

NCBI chr 9:123,681,380...123,691,094
Ensembl chr 9:123,681,380...123,691,094

G

X-linked inhibitor of apoptosis

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]

NCBI chr X:41,148,483...41,198,541
Ensembl chr X:41,148,556...41,198,533

G

X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XPNPEP2 mRNA

NCBI chr X:47,195,790...47,225,859
Ensembl chr X:47,197,602...47,225,858

G

yes-associated protein 1

multiple interactions

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased phosphorylation of and affects the localization of YAP1 protein

NCBI chr 9:7,932,000...8,004,890
Ensembl chr 9:7,932,000...8,004,597

G

Y box protein 2

increases expression

Dextran Sulfate results in increased expression of YBX2 mRNA

NCBI chr11:69,826,652...69,832,430
Ensembl chr11:69,826,622...69,832,431

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptide

decreases expression

Dextran Sulfate results in decreased expression of YWHAE protein

NCBI chr11:75,620,121...75,656,667
Ensembl chr11:75,623,695...75,656,671

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide

decreases expression

Dextran Sulfate results in decreased expression of YWHAH protein

NCBI chr 5:33,176,160...33,185,310
Ensembl chr 5:33,176,160...33,185,310

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of YWHAQ protein

NCBI chr12:21,440,330...21,467,437
Ensembl chr12:21,440,072...21,467,638

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide

decreases expression

Dextran Sulfate results in decreased expression of YWHAZ protein

NCBI chr15:36,770,505...36,803,228
Ensembl chr15:36,771,014...36,797,173

G

Z-DNA binding protein 1

increases expression

Dextran Sulfate results in increased expression of ZBP1 mRNA

NCBI chr 2:173,048,405...173,060,715
Ensembl chr 2:173,048,405...173,060,716

G

zinc finger CCCH-type containing 18

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ZC3H18 protein]

NCBI chr 8:123,103,298...123,144,104
Ensembl chr 8:123,103,348...123,144,099

G

zinc finger protein 821

increases expression

Dextran Sulfate results in increased expression of ZFP821 mRNA

NCBI chr 8:110,421,884...110,451,564
Ensembl chr 8:110,432,178...110,451,564

G

zinc finger, FYVE domain containing 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ZFYVE9 mRNA

NCBI chr 4:108,494,663...108,642,514
Ensembl chr 4:108,494,663...108,637,995

G

zinc and ring finger 4

increases expression

Dextran Sulfate results in increased expression of ZNRF4 mRNA

NCBI chr17:56,818,248...56,819,483
Ensembl chr17:56,818,248...56,819,431

G

zona pellucida 3 receptor

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein

NCBI chr 1:130,474,847...130,557,371
Ensembl chr 1:130,504,450...130,557,358

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	22210
role	22195
biological role	22194
antimicrobial agent	19596
antiviral agent	11413
dextran sulfate	1890
Path 2
Term	Annotations
CHEBI ontology	22210
subatomic particle	22202
composite particle	22202
hadron	22202
baryon	22202
nucleon	22202
atomic nucleus	22202
atom	22202
main group element atom	22136
p-block element atom	22136
carbon group element atom	21936
carbon atom	21861
organic molecular entity	21861
heteroorganic entity	21517
organochalcogen compound	21005
organooxygen compound	20846
carbohydrates and carbohydrate derivatives	16042
carbohydrate	16042
polysaccharide	8712
homopolysaccharide	6270
glucan	5416
alpha-D-glucan	1891
(1->6)-alpha-D-glucan	1891
dextran sulfate	1890

paths to the root